Microneedle array patches (MAPS), systems, and methods for manufacturing and using same

Abstract

Dispensable formulations, microneedles, microarray patches (MAPs), and systems that can facilitate simple, substantially pain-free, and consistent delivery of a wide range of active pharmaceutical ingredients (APIs) and doses, as well as methods of manufacturing and using the same are described herein.

Description

MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME RELATED APPLICATIONSThis application claims priority to U.S. Provisional Patent Application No. 63 / 723,023 filed on November 20, 2024, U.S. Provisional Patent Application No. 63 / 712,367 filed on October 25, 2024, U.S. Provisional Patent Application No. 63 / 701,470 filed on September 30, 2024, U.S. Provisional Patent Application No. 63 / 683,233 filed on August 14, 2024, and U.S. Provisional Patent Application No. 63 / 623,084 filed on January 19, 2024, and is a continuation-in-part of International Application No. PCT / US2024 / 034901 filed on June 21, 2024, which claims priority to U.S. Provisional Patent Application No. 63 / 522,931 filed on June 23, 2023, the contents of which are incorporated herein by reference in their entirety. GOVERNMENT SUPPORTThis invention was made with government support under 1R43DK142429-01 awarded by the National Institute of Diabetes and Digestive and Kidney Diseases. The government has certain rights in the invention.BACKGROUNDConventional methods of administering active pharmaceutical ingredients (APIs) often involves painful injections, leading to discomfort and challenges with patient compliance and dosing errors. A promising alternative to these conventional methods is transdermal delivery of APIs using microarray patches (MAPs), which offer a more comfortable way to deliver APIs through the patient’s skin. However, there exists significant technical and commercial challenges to the clinical adoption of microneedles for API delivery, including dosage calibration, pharmacodynamics, biocompatibility, patient compliance, sterilization, mass production, and regulatory oversight.Current microneedles can be characterized by a limited dosing capacity, given that the microneedles’ size can restrict the total amount of API that they can carry. Current microneedles can also be characterized by inconsistent pharmacokinetics, due in part to factors related to the architecture of human skin which can impede microneedle insertion and lead to inconsistent API delivery. Safety concerns related to the selection of safe and biocompatible materials also remains an important yet challenging aspect of microneedle development. Moreover, large-scale manufacturing of microneedles remains costly due to expensive, but important, processing steps to ensure sterilization and batch consistency.There exists a need for improved microneedles and manufacturing processes that address the current technical and commercial challenges to the clinical adoption of microneedle array patches (MAPs) for API delivery. SUMMARYMicroneedles and microneedle array patches (MAPs) are promising alternatives to conventional methods of administering active pharmaceutical ingredients (APIs), but their clinical adoption for API delivery has been limited due to significant technical and commercial challenges related to, for example, loading capacity, dosing accuracy, pharmacodynamics, biocompatibility, patient compliance, sterilization, mass production, and regulatory oversight. The present disclosure relates to dispensable formulations, microneedles, microneedle array patches (MAPs), and systems for delivery of active pharmaceutical ingredients (APIs) that provide inter alia improved API delivery consistency and pharmacodynamics. The present disclosure is based, at least in part, on Applicant’s surprising discovery of specific combinations of water-soluble excipients that can, for example, effectively (1) enhance the stability of a high concentration of active pharmaceutical ingredients (API) for delivery of an effective dose of the API using a microneedle and / or a microarray patch (MAP) described herein; (2) enhance the fluid properties of a composition, such as a dispensable formulation, for manufacturing a microneedle and / or a microarray patch (MAP) described herein using, e.g., a liquid dispensing system; (3) enhance the consolidation of the API into the apex of the microneedle tip during manufacturing; (4) enhance the strength of the microneedle, e.g., to resist deformation during deployment; and / or (5) minimize, or eliminate, manufacturing defects, such as shell formation and microneedle tip dislodgement, that negatively affect microneedle morphology, strength, deployment efficiency, API delivery consistency, and pharmacodynamics.The present disclosure is further based, at least in part, on Applicant’s surprising discovery of a microneedle and / or a microarray patch (MAP) capable of effectively delivering a clinically relevant dose of an active pharmaceutical ingredient (API), such as a glucagon-like peptide-1 (GLP-1) receptor agonist (RA). GLP-1 receptor agonists (also referred to as “GLP-1 RA” or simply “GLP-1” herein), such as semaglutide, are important to Type 2 diabetes (T2D) and obesity treatments. GLP-1 works in the gastrointestinal system and in appetite centers of the brain to control glucose homeostasis, energy homeostasis, and satiety. However, the half-life of the GLP-1 polypeptide is relatively short at 1 to 2 minutes, making it difficult to use as a drug. Currently, some of the most effective T2D and obesity treatments, e.g., GLP-1 RAs, such as semaglutide, utilize a delivery strategy of attaching a half-life extending moiety (e.g., a fatty acid moiety), to the GLP-1 polypeptide that supports reversible binding to serum albumin and limits renal excretion and enzymatic degradation. While these modifications have reduced treatment frequency from daily to weekly, poor adherence linked to perceived treatment complexity and needle fear remains a general problem. These barriers highlight the need for new modes of GLP-1 RA delivery. The microneedles, microarray patches (MAPs), and systems described herein can be used to address several unmet needs associated with current delivery approaches for APIs, such as GLP-1 RAs, e.g., semaglutide, including, for example, treatment adherence and hesitancy associated with needle and syringe delivery and the low bioavailability associated with orally delivered APIs, such as GLP-1 RAs, e.g., semaglutide.Without wishing to be bound by theory, a higher dose of a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may be required to treat obesity relative to the dose required to treat Type 2 diabetes (T2D). For example, in some embodiments, approximately twice the dose of semaglutide is required for the treatment of obesity as compared to Type 2 diabetes (T2D). This is believed to be due, at least in part, to the need to achieve high concentrations and longer residence times of a glucagon-like peptide-1 (GLP-1) receptor agonist in the appetite centers of the brain. Accordingly, Applicant has developed compositions, including dispensable formulations comprising a water-soluble excipient, and methods for making a microneedle and / or a microarray patch (MAP), suitable for the treatment of, e.g., Type 2 diabetes (T2D) and / or obesity. In one aspect, the present disclosure provides a microneedle and / or a microarray patch (MAP) comprising a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide, and a water-soluble excipient. In some embodiments, the microneedle and / or the microarray patch (MAP) can include less than about 1 mg (e.g.,less than about 1000 µg) of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide, per microneedle and / or per consolidated microneedle tip. In some embodiments, the microneedle and / or the microarray patch (MAP) can include about 0.001 µg to about 1000 µg of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide, per microneedle and / or per consolidated microneedle tip. In some embodiments, the microneedle and / or the microarray patch (MAP) can include about 1 µg to about 20 µg of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide, per microneedle. In some embodiments, the microneedle and / or the microarray patch (MAP) can include about 1 µg to about 20 µg of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide, per consolidated microneedle tip. In some embodiments, the microarray patch (MAP) can include an array size of about 10 to about 1000 microneedles. In some embodiments, the microarray patch (MAP) can include an array size of about 10 to about 600 microneedles. In some embodiments, the microarray patch (MAP) can include an array size of about 10 to about 300 microneedles. In some embodiments, the microarray patch (MAP) can include an array size of about 200 to about 600 microneedles. In some embodiments, the microarray patch (MAP) can include a total dose of about 0.01 mg to about 10 mg of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide. In some embodiments, the microarray patch (MAP) can include a total dose of about 1 mg to about 10 mg of a glucagon-like peptide-1 (GLP-1) receptor agonist, e.g., semaglutide. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein may be referred to as being a part of the “MIMIX” platform or as being a “MIMIX” device. Accordingly, in one aspect, the present disclosure provides improved MIMIX microneedles, MIMIX microarray patches (MAPs), and MIMIX systems. Such improved microneedles, microarray patches (MAPs), and systems can be used to enhance the delivery of active pharmaceutical ingredients (APIs), including, e.g., therapeutic proteins, that may be characterized by unwanted immunogenicity, that is, the ability to provoke an unwanted immune response against itself. Such immunogenicity may be triggered by components that are intrinsic to an API, such as specific amino acid sequences present within a therapeutic protein; to host-cell proteins (HCPs) that may co-purify, or “hitchhike,” with an API produced in a biological expression system and which may be difficult to detect and remove during downstream processing (DSP); and / or to components, such as excipients (e.g., silk fibroin), that may be present in a pharmaceutical formulation. It is generally known in the art that unwanted immune responses to APIs, and the presence of anti-drug antibodies (ADAs), can pose problems for both clinical safety and efficacy of therapeutic products. For example, immunologically based adverse events, including, but not limited to, anaphylaxis, cytokine release syndrome, and cross-reactive neutralization of endogenous proteins, can cause a sponsor to terminate clinical development of what otherwise may have been an efficacious therapeutic product. Without wishing to be bound by theory, the immunogenicity of an API, and the detection of ADAs, can play an important role in the clinical development process, e.g., because the clinical effects of unwanted immune responses can affect the pharmacokinetics (PK), pharmacodynamics (PD), safety, and / or efficacy of the API. In addition, the route of administration, dose, and frequency can also affect immunogenicity. For example, in some instances, a lower dose administered intermittently may be more immunogenic than a larger dose administered without interruption. In general, a frequent or chronic dosage regimen may be considered to have a higher immunogenicity risk than a single dose regimen because multiple and / or chronic administration of APIs, may allow for the ‘prime and boost’ phenomenon often utilized in vaccine development. Accordingly, in one aspect, the present disclosure provides microneedles, microarray patches (MAPs), and systems that can address the problems associated with unwanted immunogenicity and / or repeated administration. In some embodiments, the present disclosure provides microneedles, microarray patches (MAPs), and systems that can reduce the clinical effects of unwanted immune responses and / or can improve the pharmacokinetics (PK), pharmacodynamics (PD), safety, and / or efficacy of an API, e.g., compared to a commercially approved formulation of the API.In one aspect, the present disclosure provides, a microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) an active pharmaceutical ingredient (API); and (ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 90% (w / v). In some embodiments, the dispensable formulation comprises an active pharmaceutical ingredient (API) at a concentration of greater than about 100 mg / mL. In some embodiments, the dispensable formulation comprises a water-soluble excipient at a concentration of about 0.01% (w / v) to about 30% (w / v). In some embodiments, the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof. In some embodiments, the dispensable formulation comprises a glucagon-like peptide-1 (GLP-1) receptor agonist. In one aspect, the present disclosure provides, a microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof. In one aspect, the present disclosure provides, a microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 10% (w / v). In some embodiments, the water-soluble excipient is selected from the group consisting of an amino acid, a surfactant, and combinations thereof. In some embodiments, the water-soluble excipient comprises an amino acid. In some embodiments, the water-soluble comprises a surfactant. In some embodiments, the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a povidone polymer, a polyvinyl alcohol (PVA) polymer, and combinations thereof. In some embodiments, the water-soluble excipient comprises a polymer selected from the group consisting of (i) a polyvinylpyrrolidone (PVP) polymer (povidone), optionally wherein the PVP polymer (povidone) is selected from the group consisting of Povidone K 12 (PVP K12), Povidone K 17 (PVP K17), Povidone K 30 (PVP K30), and combinations thereof; (ii) a polyvinyl alcohol (PVA) polymer, optionally wherein the PVA polymer comprises PVA 4-88; (iii) a vinylpyrrolidone-vinyl acetate (VP-VA) copolymer (copovidone), optionally wherein the VP-VA copolymer (copovidone) is selected from the group consisting of Kollidon® VA 64, Plasdone® S-630, and combinations thereof; (iv) a polyvinyl alcohol-poly-ethylene glycol (PEG-PVA) graft copolymer, optionally wherein the PEG-PVA graft polymer comprises Kollicoat® Protect; (v) a polysaccharide, optionally wherein the polysaccharide is selected from the group consisting of Pullulan, Dextran 40, Methyl Cellulose (MC), Hydroxypropyl Methylcellulose (HPMC), Carboxymethyl cellulose (CMC), and combinations thereof; (vi) a fibroin protein, optionally wherein the fibroin protein comprise a silk fibroin protein; and (vii) combinations thereof. In some embodiments, the water-soluble excipient is selected from the group consisting of (i) the polymer is selected from the group consisting of silk fibroin, Povidone K 12 (PVP K12), Povidone K 17 (PVP K17), Povidone K 30 (PVP K30), PVA 4-88, Kollidon® VA 64, Dextran 40, Methyl Cellulose (MC), Hydroxypropyl Methylcellulose (HPMC), Carboxymethyl cellulose (CMC), Plasdone® S-630, Pullulan, Kollicoat® Protect, and combinations thereof; (ii) the sugar is selected from the group consisting of sucrose, trehalose, lactose, and combinations thereof; (iii) the sugar alcohol is selected from the group consisting of mannitol, xylitol, sorbitol, glyercol, and combinations thereof; (iv) the amino acid is selected from the group consisting of arginine-HCl, proline, histidine, methionine, aspartic acid, glutamic acid, and combinations thereof; (v) the antioxidant is selected from the group consisting of sodium metabisulfite, sodium pyruvate, sodium ascorbate, and combinations thereof; (v) the buffer is selected from the group consisting of Tris-HCl, PBS, TE, MOPS, Phosphate, Bis-tris, HEPES, and combinations thereof; (vi) the surfactant is selected from the group consisting of Kolliphor® EL, Kolliphor® HS 15, Pluronic® F-127 (Poloxamer 407), Pluronic® F-68 (Poloxamer 188), Tween® 20 (polysorbate 20), Tween® 80 (polysorbate 80), Soluplus®, P124, CHAPS, and combinations thereof; and / or (vii) the salt is selected from the group consisting of NaCl, CaCl2, ZnCl2, MgCl2, urea, and combinations thereof. In some embodiments, of any one of the microneedles described herein, wherein: the silk fibroin is present in the printable tip formulation at about 0% w / v to about 2% w / v; the PVP K12 is present in the printable tip formulation at about 0% w / v to about 70% w / v; the PVP K17 is present in the printable tip formulation at about 0% w / v to about 70% w / v; the PVP K30 is present in the printable tip formulation at about 0% w / v to about 50% w / v; the PVA 4-88 is present in the printable tip formulation at about 0% w / v to about 20% w / v; the Kollidon® VA 64 is present in the printable tip formulation at about 0% w / v to about 70% w / v; the Dextran 40 is present in the printable tip formulation at about 0% w / v to about 30% w / v; the Methyl Cellulose is present in the printable tip formulation at about 0% w / v to about 8% w / v; the Hydroxypropyl Methylcellulose is present in the printable tip formulation at about 0% w / v to about 14% w / v; the Carboxymethyl cellulose is present in the printable tip formulation at about 0% w / v to about 4% w / v; the Plasdone® S-630 is present in the printable tip formulation at about 0% w / v to about 70% w / v; the Pullulan is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Kollicoat® Protect is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Sucrose is present in the printable tip formulation at about 0% w / v to about 60% w / v; the Trehalose is present in the printable tip formulation at about 0% w / v to about 20% w / v; the Lactose is present in the printable tip formulation at about 0% w / v to about 20% w / v; the Mannitol is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Xylitol is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Sorbitol is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Glyercol is present in the printable tip formulation at about 0% w / v to about 10% w / v; the Arginine-HCl is present in the printable tip formulation at about 0% w / v to about 20% w / v; the Proline is present in the printable tip formulation at about 0% w / v to about 6% w / v; the Histidine is present in the printable tip formulation at about 0% w / v to about 6% w / v; the Methionine is present in the printable tip formulation at about 0% w / v to about 6% w / v; the Aspartic Acid is present in the printable tip formulation at about 0% w / v to about 6% w / v; the Glutamic Acid is present in the printable tip formulation at about 0% w / v to about 6% w / v; the Sodium metabisulfite is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Sodium pyruvate is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Sodium ascorbate is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Tris-HCl is present in the printable tip formulation at about 0 mM to about 350 mM; the PBS is present in the printable tip formulation at about 0X to about 2X; the TE is present in the printable tip formulation at about 0X to about 2X; the MOPS is present in the printable tip formulation at about 0 mM to about 350 mM; the Phosphate is present in the printable tip formulation at about 0 mM to about 350 mM; the Bis-tris is present in the printable tip formulation at about 0 mM to about 350 mM; the HEPES is present in the printable tip formulation at about 0 mM to about 350 mM; the Kolliphor® EL is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Kolliphor® HS 15 is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Pluronic® F-127 (Poloxamer 407) is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Pluronic® F-68 (Poloxamer 188) is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Tween® 20 (polysorbate 20) is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Tween® 80 (polysorbate 80) is present in the printable tip formulation at about 0% w / v to about 2% w / v; the Soluplus® is present in the printable tip formulation at about 0% w / v to about 10% w / v; the P124 is present in the printable tip formulation at about 0% w / v to about 2% w / v; the CHAPS is present in the printable tip formulation at about 0% w / v to about 2% w / v; the NaCl is present in the printable tip formulation at about 0% w / v to about 2% w / v; the CaCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v; the ZnCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v; the MgCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v; and / or the Urea is present in the printable tip formulation at about 0% w / v to about 2% w / v. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 180 mg / mL. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is selected from the group consisting of semaglutide; dulaglutide; exenatide; liraglutide; lixisenatide; tirzepatide; albiglutide; taspoglutide; pharmaceutically acceptable salts thereof; derivatives thereof; and combinations thereof. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the microneedle further comprises an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof. In some embodiments, of any one of the microneedles described herein, wherein: (i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%; (iii) the surfactant is present in the printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v); (iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (v) the dispensable formulation further comprises a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (vi) the dispensable formulation further comprises a fibroin protein present at a concentration of about 0.1% (w / v) to about 2% (w / v); (vii) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); (viii) the dispensable formulation further comprises a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); and / or (ix) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM. In some embodiments, the consolidated tip comprises a proline amino acid, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a Polysorbate 80 surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyvinyl alcohol (PVA) 4-88 polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a silk fibroin protein, or a derivative thereof. In some embodiments, the consolidated tip comprises a NaCl salt. In some embodiments, the consolidated tip comprises a sucrose sugar. In some embodiments, the consolidated tip comprises a Tris-HCl buffer. In some embodiments, of any one of the microneedles described herein, further comprising a microneedle base formed from a dispensable formulation, optionally wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 10% (w / v) to about 70% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 20% (w / v); (iii) a water-soluble excipient comprising a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); (iv) a water-soluble excipient comprising a surfactant present at a concentration of about 0.01% (w / v) to about 1% (w / v); (v) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and (vi) combinations thereof. In some embodiments, the microneedle base comprises: (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; and (iii) a 1x TE buffer. In some embodiments, the microneedle base comprises: (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a sucrose sugar; and (iv) a Tris buffer. In some embodiments, of any one of the microneedle described herein, wherein: the PVP K12 is present in the printable base formulation at about 0% w / v to about 90% w / v; the PVP K17 is present in the printable base formulation at about 0% w / v to about 90% w / v; the Kollidon® VA 64 is present in the printable base formulation at about 0% w / v to about 90% w / v; the Dextran is present in the printable base formulation at about 0% w / v to about 90% w / v; the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 40% w / v; the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Tris-HCl is present in the printable base formulation at about 0% w / v to about 40 mM% w / v; the MOPS is present in the printable base formulation at about 0 mM to about 50 mM; the Tris-EDTA is present in the printable base formulation at about 0X to about 2X; the Kolliphor EL is present in the printable base formulation at about 0% w / v to about 2% w / v; the Pluronic® F-68 (Poloxamer 188) is present in the printable base formulation at about 0% w / v to about 2% w / v; the Kolliphor® HS 15 is present in the printable base formulation at about 0% w / v to about 2% w / v; the F-127 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Tween® 20 (polysorbate 20) is present in the printable base formulation at about 0% w / v to about 2% w / v; the Triton-X-100 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Sucrose is present in the printable base formulation at about 0% w / v to about 60% w / v; the Trehalose is present in the printable base formulation at about 0% w / v to about 40% w / v; the Glycerol is present in the printable base formulation at about 0% w / v to about 8% w / v; the Carboxymethylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; the Methyl Cellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; and / or the Hydroxypropyl Methylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v. In some embodiments, the active pharmaceutical ingredient (API) comprises at least one selected from the group consisting of a small molecule, a biological molecule, a nucleotide, an oligonucleotide, a nucleic acid, a DNA, an RNA, an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), an amino acid, a peptide, a polypeptide, a protein, a hormone, an antigen, a vaccine, a virus-like particle (VLP), a mimetic, an agonist, an antagonist, an inhibitor, a biologic, an antibody or antigen-binding fragment thereof, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. In some embodiments, the active pharmaceutical ingredient (API) comprises an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), or combinations thereof. In one aspect, the present disclosure provides, a microarray patch (MAP), comprising a plurality of microneedles, optionally wherein each of the plurality of microneedles comprises a consolidated microneedle tip and a microneedle base, wherein the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation, and wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin. In one aspect, the present disclosure provides, a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) an active pharmaceutical ingredient (API); and (ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 90% (w / v). In some embodiments, the dispensable formulation comprises an active pharmaceutical ingredient (API) at a concentration of greater than about 100 mg / mL. In some embodiments, the dispensable formulation comprises a water-soluble excipient at a concentration of about 0.01% (w / v) to about 30% (w / v). In some embodiments, the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof. In some embodiments, the dispensable formulation comprises a glucagon-like peptide-1 (GLP-1) receptor agonist.In one aspect, the present disclosure provides, a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof. In one aspect, the present disclosure provides, a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present at a concentration of about 180 mg / mL. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the microarray patch (MAP) further comprises an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof. In some embodiments, of any one of the microarray patches (MAPs) described herein, wherein: (i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%; (iii) the surfactant is present in the printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v); (iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (v) the dispensable formulation further comprises a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (vi) the dispensable formulation further comprises a fibroin protein present at a concentration of about 0.1% (w / v) to about 2% (w / v); (vii) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); (viii) the dispensable formulation further comprises a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); and / or (ix) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM. In some embodiments, the consolidated tip comprises a proline amino acid, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a Polysorbate 80 surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyvinyl alcohol (PVA) 4-88 polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a silk fibroin protein, or a derivative thereof. In some embodiments, the consolidated tip comprises a NaCl salt. In some embodiments, the consolidated tip comprises a sucrose sugar. In some embodiments, the consolidated tip comprises a Tris-HCl buffer. In some embodiments, the microarray patch (MAP), further comprises a microneedle base formed from a dispensable formulation, optionally wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 10% (w / v) to about 70% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 20% (w / v); (iii) a water-soluble excipient comprising a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); (iv) a water-soluble excipient comprising a surfactant present at a concentration of about 0.01% (w / v) to about 1% (w / v); (v) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and (vi) combinations thereof. In some embodiments, the microneedle base comprises: (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; and (iii) a 1x TE buffer. In some embodiments, the microneedle base comprises: (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a sucrose sugar; and (iv) a Tris buffer. In some embodiments, of any one of the microarray patches (MAPs) described herein, wherein: the PVP K12 is present in the printable base formulation at about 0% w / v to about 90% w / v; the PVP K17 is present in the printable base formulation at about 0% w / v to about 90% w / v; the Kollidon® VA 64 is present in the printable base formulation at about 0% w / v to about 90% w / v; the Dextran is present in the printable base formulation at about 0% w / v to about 90% w / v; the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 40% w / v; the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Tris-HCl is present in the printable base formulation at about 0% w / v to about 40 mM% w / v; the MOPS is present in the printable base formulation at about 0 mM to about 50 mM; the Tris-EDTA is present in the printable base formulation at about 0X to about 2X; the Kolliphor EL is present in the printable base formulation at about 0% w / v to about 2% w / v; the Pluronic® F-68 (Poloxamer 188) is present in the printable base formulation at about 0% w / v to about 2% w / v; the Kolliphor® HS 15 is present in the printable base formulation at about 0% w / v to about 2% w / v; the F-127 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Tween® 20 (polysorbate 20) is present in the printable base formulation at about 0% w / v to about 2% w / v; the Triton-X-100 is present in the printable base formulation at about 0% w / v to about 2% w / v; the Sucrose is present in the printable base formulation at about 0% w / v to about 60% w / v; the Trehalose is present in the printable base formulation at about 0% w / v to about 40% w / v; the Glycerol is present in the printable base formulation at about 0% w / v to about 8% w / v; the Carboxymethylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; the Methyl Cellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; and / or the Hydroxypropyl Methylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v. In some embodiments, the active pharmaceutical ingredient (API) comprises at least one selected from the group consisting of a small molecule, a biological molecule, a nucleotide, an oligonucleotide, a nucleic acid, a DNA, an RNA, an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), an amino acid, a peptide, a polypeptide, a protein, a hormone, an antigen, a vaccine, a virus-like particle (VLP), a mimetic, an agonist, an antagonist, an inhibitor, a biologic, an antibody or antigen-binding fragment thereof, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof. In some embodiments, the active pharmaceutical ingredient (API) comprises an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), or combinations thereof.In one aspect, the present disclosure provides, a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a three-dimensional (3D) printed structure selected from the group consisting of a consolidated microneedle tip, a microneedle base, and combinations thereof, wherein the consolidated microneedle tip is formed from a printable tip formulation comprising: (i) an active pharmaceutical ingredient (API); (ii) a water-soluble povidone polymer, or a water-soluble polyvinyl alcohol (PVA) polymer, present at a concentration of about 0.5% (w / v) to about 5% (w / v); and (iii) a water-soluble excipient present at a concentration of about 0.01% (w / v) to about 30% (w / v), wherein the water-soluble excipient is selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof. In some embodiments, the printable tip formulation further comprises at least one selected from the group consisting of a polymer comprising Povidone K 17 (PVP K17), an amino acid comprising proline, a surfactant comprising Kolliphor® EL, a salt comprising NaCl, a sugar comprising sucrose, a buffer comprising Tris-HCl, and combinations thereof. In some embodiments, the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is selected from the group consisting of selected from the group consisting of Semaglutide; Dulaglutide; Exenatide; Liraglutide; Lixisenatide; Tirzepatide; Albiglutide; Taspoglutide; pharmaceutically acceptable salts thereof; derivatives thereof; and combinations thereof.. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the printable tip formulation comprises about 100 mg / mL to about 300 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 0.1% w / v to about 2% w / v PVP K17, about 0.1% w / v to about 6% w / v Proline, about 0.01% w / v to about 0.5% w / v Kolliphor EL, about 50 mM to about 250 mM Tris-HCl buffer, and optionally about 0.1% w / v to about 2% w / v NaCl. In some embodiments, the printable tip formulation comprises about 180 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 1% w / v PVP K17, about 0.75% w / v Proline, about 0.1% w / v Kolliphor EL, about 0.9% w / v NaCl, and about 100 mM Tris-HCl buffer. In some embodiments, the printable tip formulation comprises about 180 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 1% w / v PVP K17, about 3% w / v Proline, about 0.1% w / v Kolliphor EL, and about 100 mM Tris-HCl buffer. In some embodiments, the microarray patch (MAP) comprises about 0.1 mg to about 30 mg of the glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the microarray patch (MAP) comprises about 0.25 mg to about 2.4 mg of Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is present in an amount of about 1 µg to about 20 µg per consolidated microneedle tip. In some embodiments, of any one of the microneedles, or the microarray patches (MAPs) described herein, wherein Semaglutide (Ozempic®, Rybelsus®, Wegovy®), a pharmaceutically acceptable salt thereof, or a derivative thereof, is present in an amount of at least about 2 µg per consolidated microneedle tip. In some embodiments, the active pharmaceutical ingredient (API) comprises a lipid nanoparticle–mRNA (LNP–mRNA) formulation. In some embodiments, the printable tip formulation comprises about 0.1% w / v to about 2% w / v PVA 4-88, about 3% w / v to about 7% w / v PVA PVP K17, about 8% w / v to about 12% w / v sucrose, and about 1X TE buffer. In some embodiments, the printable tip formulation comprises about 1% w / v PVA 4-88, about 5% w / v PVA PVP K17, about 10% w / v sucrose, and about 1X TE buffer. In some embodiments, the microarray patch (MAP) is configured for deployment onto the skin of a subject by using an applicator, wherein the MAP and the applicator are independently configured to function as a system to provide a consistent dose delivery of the active pharmaceutical ingredient (API), optionally wherein the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation, wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin. In some embodiments, of any one of the microarray patches (MAPs) described herein, wherein: (i) each of the plurality of microneedles is characterized by a needle strength of at least about 0.1 N, at least about 0.2 N, at least about 0.3 N, at least about 0.4 N, and / or at least about 0.5 N yield load to minimize deformation and to maximize delivery depth of the consolidated microneedle tip during deployment, optionally wherein each of the plurality of microneedles is characterized by a needle strength of about 0.1 N to about 0.5 yield load; (ii) each of the plurality of microneedles is characterized by a tip strength and / or a failure force of at least about 0.1 N, at least about 0.2 N, at least about 0.3 N, at least about 0.4 N, and / or at least about 0.5 N per microneedle; (iii) each of the plurality of microneedles comprises about 0.001 µg to about 20 µg of the glucagon-like peptide-1 (GLP-1) receptor agonist per consolidated microneedle tip; (iv) each of the plurality of microneedles is characterized by a primary needle height (also referred to as “a pre-deployment needle height”) of about 700 µm to about 1,250 µm; (v) the consolidated microneedle tip is characterized by a tip length of about 200 µm to about 500 µm; (vi) the consolidated microneedle tip is formed from about 10 nL to about 50 nL of the dispensable formulation; (vii) the consolidated microneedle tip is characterized by a substantially flat meniscus; (viii) no more than about 20% of the plurality of microneedles comprises a defect; and / or (ix) no more than about 10% of the plurality of microneedles comprises a consolidated microneedle tip characterized by a tip length greater than about 400 µm. In some embodiments, the microarray patch (MAP) comprises a microneedle array attached to a backing by an adhesive, wherein the microneedle array comprises a plurality of microneedles arranged in an array configuration, wherein each of the plurality of microneedles independently comprises the consolidated microneedle tip and the base, optionally wherein the adhesive is selected from the group consisting of an acrylic adhesive; an acrylate adhesive; a tackified adhesive, optionally a tackified acrylic adhesive and / or a tackified acrylate adhesive; a pressure sensitive adhesive; a synthetic rubber adhesive, optionally a pressure sensitive synthetic rubber adhesive; and combinations thereof. In some embodiments, the microarray patch (MAP) comprises a microneedle array characterized by an array size of about 50 to about 1,000 microneedles, optionally wherein the microneedle array is characterized by an array configuration that enables microneedle insertion and deployment of the consolidated microneedle tip to a consistent delivery depth of at least about 400 µm below the skin surface. In some embodiments, the MAP and the applicator are independently configured to provide an in vitro recovery of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist; and an ex vivo dose delivery efficiency of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, wherein less than about 30% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, is not delivered upon deployment.In one aspect, the present disclosure provides, a method of treating a disease or a condition, comprising deploying onto the skin of a subject the microneedle, or the microarray patch (MAP) as described herein.In one aspect, the present disclosure provides, a method of treating at least one condition selected from the group consisting of type 2 diabetes, overweight, obesity, cardiovascular disease, and combinations, comprising deploying onto the skin of a subject a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof. In some embodiments, the microneedle or the microarray patch (MAP) sustains the release of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the microneedle or the microarray patch (MAP) is configured for daily, weekly, or monthly administration, optionally wherein the microneedle or the microarray patch (MAP) is configured for once daily, once weekly, or once monthly administration, optionally wherein the microneedle or the microarray patch (MAP) is configured for multiple daily, multiple weekly, or multiple monthly administrations.In one aspect, the present disclosure provides, a high-throughput screening method for selecting a dispensable formulation suitable for microarray patch (MAP) manufacturing, comprising: providing a model air-dried film system comprising: (i) a printable tip formulation comprising an active pharmaceutical ingredient (API) formulation and a water-soluble excipient, and / or (ii) a printable base formulation comprising a water-soluble excipient, wherein the model air-dried film system was generated using a predefined printability parameter, optionally wherein the predefined printability parameter is selected from the group consisting of temperature, humidity, viscosity, solid content, dispense volume, dispense velocity, and combinations thereof. In one aspect, the present disclosure provides, a method wherein the dispensable formulation suitable for microarray patch (MAP) manufacturing is selected when the fluid properties of the dispensable formulation enable microarray patch (MAP) a manufacturing process, such that a microarray patch (MAP) generated using the predefined printability parameter is characterized by a morphology substantially free of defects, optionally wherein no more than about 0% to about 30% of the microneedles in the microarray patch (MAP) comprise a defect, and / or no more than about 0% to about 30% of the microneedles in the microarray patch (MAP) comprise a consolidated tip length of greater than 400 μm. In one aspect, the present disclosure provides, a method wherein the dispensable formulation suitable for microarray patch (MAP) manufacturing is selected when the fluid properties of the dispensable formulation enables (i) formation of a consolidated microneedle tip and / or a microneedle base configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment of without deformation, wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin; (ii) an in vitro recovery of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist; and / or (iii) an ex vivo dose delivery efficiency of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, wherein less than about 30% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, is not delivered upon deployment.In one aspect, the present disclosure provides, a method of manufacturing a microarray patch (MAP), comprising: (i) providing: (a) a microarray mold comprising a plurality of cavities which are characterized by a predefined criteria selected from the group consisting of: a microneedle height, a microneedle spacing, a microneedle base size, a microneedle tip size, an array size, and combinations thereof; (b) at least one print solution selected from the group consisting of a printable tip formulation, a printable base formulation, and a combination thereof, and (c) an active pharmaceutical ingredient (API), wherein the API is independently present or absent in the at least one print solution; (ii) printing a plurality of microneedles by independently filling at least one cavity of the plurality of cavities with a predefined dispense volume of the print solution, thereby forming a plurality of printed microneedles; (iii) applying a backing to a surface of the plurality of microneedles; and (iv) demolding the plurality of microneedles, thereby generating a microarray patch (MAP).In one aspect, the present disclosure provides, a microarray patch (MAP), comprising a plurality of microneedles described herein.In one aspect, the present disclosure provides, a microarray patch (MAP) system, comprising: (i) a microarray patch (MAP) described herein, wherein the MAP comprises a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip and a microneedle base, wherein the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation; and (ii) an applicator configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin.The present invention is further illustrated by the following detailed description and drawings. BRIEF DESCRIPTION OF THE DRAWINGSFIG. 1 shows a schematic of MIMIX MAP delivery and microneedle tip deployment. MIMIX MAPs are applied to the skin using a spring-loaded applicator. The moisture of the skin then dissolves the water-soluble base of each microneedle thereby deploying the tips. Deployed tips slowly dissolve and release the vaccine payload over time.FIG. 2 shows a schematic of MIMIX MAP printing, demolding and delivery. The additive manufacturing process is shown. The process begins with a silicone mold with cavities that determine the length, shape and number of microneedles. Print solution containing the payload and specific excipients is dispensed first to form the Tip of each microneedle. After drying, the Base solution is printed and allowed to dry. An adhesive backing is added prior to demolding of the MAP. A spring-loaded applicator is used to apply each MAP to the skin.FIG. 3 shows a schematic of MIMIX MAP Tip drying. 20-30 nL of print solution are typically dispensed into each mold cavity and allowed to dry. Extreme shell formation is depicted in the middle figure, while full consolidation into the Tip is shown on the right.FIG. 4 shows important parameters impacting MIMIX MAP Tip drying and consolidation. Tip formulation development aims to ensure high concentrations of payload avoid pinning while drying and consolidate to the tip of each mold cavity.FIG. 5 shows that PVP K17 improves consolidation of GLP-1 containing Tips. Visible light micrograph of cross sectioned molds showing dried tips. Each needle cavity is about 1 mm long. For each condition 0.1 mg / mL of AF-647 was added to the print solution to aid visualization of the Tips.FIG. 6 shows that PVP K17 improves overall Tip Lengths. Dried Tips were measured in cross sectioned molds by image processing calibrated with a stage micrometer.FIG. 7 shows the percent recovery of inactive semaglutide by RP-HPLC. Films containing various surfactants with the background formulation of 180 mg / mL GLP-1 + 1% PVP K17 + 1.37% Arg-HCl + 0.1 mg / mL AF-647 in 100 mM MOPS from GLP-045.FIG. 8 shows visible light micrographs of dry tips in a macromold model system in GLP-045. Each needle cavity in the macromold is 5 mm long and is filled with about 2.4 μL of formulation by pipette and centrifugation. Kolliphor EL and P188 have relatively better dry tip morphology.FIG. 9 shows surface tension over time as measured by the pendant drop method for tip formulations including various surfactants in GLP-045.FIG. 10 shows a summary of shell length as a portion of overall tip length during the feasibility evaluation phase of the program using inactivated semaglutide API. There is a drastic reduction in shell length after the introduction of PVP into the formulation in study GLP-019, however the shell length is still variable and is ideally minimized.FIG. 11 shows the percent (%) delivered from MAPs after deployment on ex vivo porcine skin. This test was not run on all groups throughout the feasibility phase of the program, often due to low yields. This is an important readout because it relates to the delivery efficiency of the platform. Results are highly variable, and may be below the desired target of >80%.FIG. 12 shows a summary of Mechanical strength of MAPs during the feasibility evaluation phase. Mechanical strength was infrequently measured during this phase, but was often below 0.4 N per needle.FIG. 13A-13E shows shallow delivery of microneedles and microneedle dimensions using the Feasibility Formulation and comparison with VX103 MAPs. FIG. 13A shows the ex vivo deployment results of the 3 separate ex vivo deployment sample sets of GLP-1 277 array MAPs compared to historical measurements of VX103 ex vivo deployments (VX103-245 and VX103-332, “2 drop” respectively). In a separate analysis, GLP-1 tip lengths (GLP-019-042) were compared against historical values for VX103 tip lengths. While the tip lengths are measured in two different ways, FIG. 13B, shows that there is a significant difference between the two groups. FIG. 13C shows unpaired t test comparison of Air Gap and Needle Height Lost deployment outcomes for 241-array VX103 and GLP-1 MAP’s. FIG. 13D shows the resultant load displacement curves of VX-103 MAPs compared to GLP-1 MAPs (left panel), and that the stiffness (middle panel) and ultimate strength (right panel) of the VX103 MAPs is higher than the GLP-1 MAPs. FIG. 13E shows the comparison of the compressive strengths of the MAPs constructed of the VX103 and GLP-1 base formulations only.FIG. 14 shows the GLP-067 Study Summary. Film studies show that PVP K17 (at all the concentrations tested) and 3% Dextran are compatible with GLP-1.FIG. 15 shows the GLP-073 Study Summary. A MAP study shows that higher concentrations of PVP K17 and 3% Dextran do not impact the mechanical strength of the GLP-1 Tip.FIG. 16 shows tips formulated with 1% PVP K17 and 1% Dextran have comparable failure forces in the Instron crush test.FIG. 17 shows tips formulated with Tris HCl are comparable to Tips formulated with MOPs in Tip lengths, percent consolidation and failure forces in the Instron compression test.FIG. 18 shows incorporation of 0.75% Proline lowers the shell length and significantly improves Tip strength in the instron crush test.FIG. 19 shows incorporation of 3% Proline improves Tip consolidation but reduces Tip strength.FIG. 20 shows incorporation of 0.9% NaCl improves Tip consolidation.FIG. 21 shows addition of NaCl (0.9%) improves Tip consolidationFIG.22 shows tip length and tip strength data for GLP-136 and GLP-142 for MAPs containing two different formulations (PPS and PHP).FIG. 23A-B show that the PPS and PHP formulations lead to less variable, lower Tip (FIG. 23A) and Shell (FIG. 23B) lengths.FIG. 24 shows that the PPS and PHP formulations lead to less variable delivery of the payload.FIG. 25A shows exemplary 60-microneedle and 90-microneedle rectangular sub-arrays formulated with approximately 324 µg of GLP-1 each. FIG. 25B shows exemplary 61-microneedle and 41-microneedle circular sub-arrays.FIG. 25C pilot rat PK studies show similar PK profiles for differing array sizes and Form 1 and 2. Top panel: shows comparable PK profile for delivery of semaglutide formulated in the PPS formulation (Form 1) for two different array sizes delivering the same total dose. Bottom panel: shows PPS (Form 1) and PHP (Form 2) formulations have similar PK profiles with potentially higher BA for both MAP formulations relative to SQ delivery.FIG. 26A shows a formal rat PK study evaluating the PPS (Form 1) and PHP (Form 2) formulations shows a faster Tmax and higher Cmax for MAP delivered semaglutide.FIG. 26B showsimages of MAP application sites showing a self-resolving light discoloration following MAP application.FIG. 26C shows MAP and subcutaneous delivery of GLP-1 led to ten percent weight loss by day 4 post dose.FIG. 27 shows a comparison of PK parameters for MAP delivery of GLP-1 formulated in Form 1 (PPS) or Form 2 (PHP) versus subcutaneous delivery of GLP-1 formulated in 100 mM Tris (pH 7.5).FIG. 28A shows minipig plasma concentration curves show modestly higher Cmax and comparable T1 / 2 for MAP delivery relative to SQ delivery. FIG. 28B shows Minipig PK analyses show a similar Tmax, modestly higher Cmax, comparable T1 / 2 and comparable AUC.FIG. 29A shows exemplary defective tips.FIGs. 29B-29C shows exemplary tips measured by image processing.FIG. 30 shows LNP-026 MAP Deployments. The number of in-tact tips visible on the MAP after deployments was compared to the starting number of tips on the array as a measure of deployment (left). The concentration of mRNA recovered from deployed MAPs was normalized to the average mRNA concentration recovered from undeployed control MAPs and expressed as ‘% undeployed release’ (right).FIG.31A shows a MAP delivering mRNA-LNP payload elicits anti-HA IgG titers superior to an equivalent dose of the same payload delivered via intramuscular or intradermal injection.FIG. 31B shows an mRNA-LNP vaccine delivered via MAP elicits increased levels of neutralizing antibodies, e.g., hemagglutination inhibition antibodies when compared to an equivalent dose of mRNA-LNP delivered either intramuscularly or intradermally.FIG.32A shows (left panel) a simple four-step application of a MAP: 1) Open the pouch and take out the product 2) Deploy onto the skin using the applicator 3) wear the MAP for 5 minutes 4) peel off adhesive backing. The middle panel shows a MIMIX system preloaded with a MAP, and the right panel shows a description of MIMIX components as tips could be modified.FIG.32Bshows (top panels) a schematic of an exemplary MAP fabrication process, (middle panels) top-down view of a mold, and (bottom panels) side view and cross-sectioned mold throughout the process.FIG.33 shows a MAP in vivo potency IVIS workflow.FIG.34 shows fluorescence imaging was used to verify tip consolidation in a MAP and how the dried tip and base interact in a needle. The tips were filled at the distal end of needles, and the fluorescence was distributed evenly throughout the consolidated tips indicating the tips dried uniformly.FIG.35A shows encapsulation efficiency was used to measure the stability of LNPs throughout the MAP drying process. N=4 MAPs from each of the two leading tip formulations were dissolved in buffer and subsequently assayed using the RiboGreen assay. The MIMIX platform was compatible with both leading tip formulations and different mRNA cargos (luciferase and hemagglutinin (HA) -encoding mRNA)FIG.35B represents the data shown in FIG. 35A with additional labels indicating the formulation components evaluated. Formulation details are also summarized in Table 12.FIG.36A shows MAPs containing mRNA-LNPs encoding for luciferase were solubilized and eluate was transfected into BHK-21 cells to determine in vitro potency. Five different groups varying tip and base formulations and drying conditions were evaluated. Stepwise improvements to in vitro potency were observed with optimized formulations and drying conditions, from 3% to 21%, compared to the liquid control.FIG.36B represents the data shown in FIG. 36A with additional labels indicating the formulation components evaluated. Formulation details are also summarized in Table 13.FIG.37showsMAPs containing DiD-labelled LNP tip formulation and AlexaFluor 488 base formulation were fabricated, deployed into excised vivo porcine skin, and characterized to evaluate deployment efficiency. A) Fluorescent side-view imaging shows MAPs clearly deployed well, with little to no dye remaining in tip post-deployment. B) The deployed MAPs showed distinct and bright tips that were embedded within the skin, demonstrating compatibility of the labeled antigen with this method. C) Quantitative fluorescence revealed only an average of 9% DiD remaining on MAPs, indicating 91% of LNP was successfully delivered into the porcine skin.FIG.38shows the potency of MAPs by IVIS in comparison to the same dose (Intramuscular) IM A) MAPs exhibited similar in vivo luciferase expression compared to IM. Delayed release kinetics from MAPs may also contribute to differences in expression B) Representative IVIS images.FIG.39showsHA-encoding mRNA MAPs were fabricated and stored for 1 month at 4C or 25C to determine mRNA stability via RiboGreen or CE. A) Encapsulation efficiency was retained in both liquid controls and MAPs at all temperature and time points, suggesting encapsulation efficiency likely not a good measure of mRNA stability. B) Significant loss in mRNA integrity observed in liquid format after 1 month storage. Largest contributor of degradation was due to mRNA aggregation / secondary structure formation. While there was some mRNA integrity loss through the manufacturing process, mRNA stored in the MAP format exhibited enhanced stability over liquid control, with no additional mRNA degradation observed after 1 month storage. DETAILED DESCRIPTIONDefinitionsIn order that the present invention may be more readily understood, certain terms are first defined. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. In addition, it should be noted that whenever a value or range of values are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the content clearly dictates otherwise. The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. The term “or” is used herein to mean, and is used interchangeably with, the term “and / or,” unless context clearly indicates otherwise.As used herein, the term “about,” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.As used herein, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.As used herein, “comprise,” “comprising,” “comprises,” and “comprised of” are meant to be synonymous with “include,” “including,” “includes,” or “contain,” “containing,” “contains” and are inclusive or open-ended terms that specifies the presence of what follows, e.g., component and do not exclude or preclude the presence of additional, non-recited components, features, element, members, steps, known in the art or disclosed therein. By way of example, the term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to.”As used herein, the terms “such as,” “for example,” and the like are intended to refer to exemplary embodiments and not to limit the scope of the present disclosure.As used herein, the terms “preventing” or “prevention” refer to a reduction in risk of acquiring a disease, disorder, and / or condition (e.g., causing at least one of the clinical symptoms of the disease, disorder, and / or condition not to develop in a subject that may be exposed to and / or predisposed to the disease, disorder, and / or condition but does not yet experience or display symptoms of the disease, disorder, and / or condition).As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, slowing, stopping, and / or reversing of the progression of a disease, disorder, and / or condition. As such, in some embodiments, “treating” means an application or administration of the methods, compositions, e.g., microneedles and / or microarray patches (MAP), and / or systems described herein to a subject in need thereof, e.g., a subject suffering from a disease, disorder, condition, and / or symptom thereof, where the purpose is to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease, disorder, condition, and / or symptom thereof. In some embodiments, the beneficial or desired result of treatment can be the alleviation and / or amelioration of one or more symptoms of the disease, disorder, and / or condition. In some embodiments, the beneficial or desired result of treatment can be to diminish the extent of the disease, disorder, and / or condition. In some embodiments, the beneficial or desired result of treatment can be a stabilized (e.g., not worsening) state of the disease, disorder, and / or condition. In some embodiments, the beneficial or desired result of treatment can be amelioration or palliation of the disease, disorder, and / or condition, whether detectable or undetectable. In some embodiments, “treatment" can also mean prolonging survival as compared to expected survival in the absence of treatment.As used interchangeably herein, the terms “dose,” “total dose,” and “total dose delivered,” in the context of a microarray patch (MAP), may refer to the total amount, e.g., by weight, of an API that is present in a MAP. In some embodiments, the “total dose delivered” by a MAP can be determined by the amount of an API (“payload”) that can be loaded onto and / or into each microneedle multiplied by the total number of microneedles present in the MAP. In some embodiments, the “total dose delivered” by a MAP can be determined by the amount of an API (“payload”) that can be loaded onto and / or into each consolidated microneedle tip multiplied by the total number of microneedles comprising said consolidated microneedle tip present in the MAP. In some embodiments, the “total dose delivered” by a MAP can be determined by the amount of an API (“payload”) that can be loaded onto and / or into each microneedle base multiplied by the total number of microneedles comprising said microneedle base present in the MAP. In some embodiments, an API (“payload”) may be loaded onto and / or into both the consolidated microneedle tip and the microneedle base.As used interchangeably herein, the terms “dose,” “total dose,” and “total dose delivered,” in the context of a microneedle, may refer to the total amount, e.g., by weight, of an API that is present in a microneedle (e.g., a single microneedle). As used interchangeably herein, the terms “dose,” “total dose,” and “total dose delivered,” in the context of a dispensable formulation, may refer to the total amount, e.g., by weight, of an API that is present in a dispense volume of the dispensable formulation, such as a tip fill volume and / or a base fill volume. In some embodiments, when the concentration of an API in the dispensable formulation can be defined, the “dose” may be expressed as a volume, e.g., a dispense volume of the dispensable formulation, such as a tip fill volume and / or a base fill volume. As used herein, the term “prophylactically effective amount,” is intended to include the amount of an active agent that, when administered to a subject who does not yet experience or display symptoms of a condition, disease, and / or disorder, but who may be predisposed to the condition, disease, and / or disorder, is sufficient to prevent or ameliorate the condition, disease, and / or disorder or one or more symptoms of the condition, disease, and / or disorder. Ameliorating the condition, disease, and / or disorder includes slowing the course of the condition, disease, and / or disorder or reducing the severity of later-developing condition, disease, and / or disorder. The “prophylactically effective amount” may vary depending on the active agent, how the active agent is administered, the degree of risk of condition, disease, and / or disorder, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated. A “therapeutically effective amount” or “prophylactically effective amount” also includes an amount of an active agent that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. Active agents employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit / risk ratio applicable to such treatment.As used herein, the term “administering” to a subject includes dispensing, delivering or applying a composition as described herein to a subject by any suitable route for delivery of the composition to the subject, including delivery by deploying a microneedle and / or a microarray patch (MAP) described herein. Exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion. “Injection” includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered intradermally and / or transdermally by a microneedle and / or a microarray patch (MAP) described herein. Alternatively or in combination, delivery can be by any route such as by the topical, parenteral or oral route, intracerebral injection, intramuscular injection, subcutaneous, intradermal injection, intravenous injection, buccal administration, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal, and / or respiratory tract route.In some embodiments, the term “administering” to a subject includes dispensing, delivering, or applying a microneedle and / or a microarray patch (MAP) described herein to the skin of a subject at any suitable site on the body (e.g., arm, abdomen, back, buttock, and / or upper torso) for delivery of the composition to the subject. In some embodiments, the microneedle and / or the microarray patch (MAP) can be applied to a dry, flat skin area on the upper arm, abdomen, back, buttock, and / or upper torso. In some embodiments, the site of application on the skin is substantially free of oils, scars, cuts, burns, and / or irritation. In some embodiments, the microneedle and / or the microarray patch (MAP) should not be applied to areas of the skin that have received prior treatment with the API and / or another therapy.As used herein, the term “adjust” or “modulate” and grammatical equivalents thereof means to alter (e.g., increase and / or decrease). In some embodiments, the term describes a level, an amount, and / or a concentration of a parameter, such as any physical and / or chemical property. In some embodiments, the term describes an alteration relative to a “control” or a “reference,” such as, for example, a control sample, a control subject, a control formulation, a reference drug, a reference level, and / or a reference parameter. As used herein, the terms “control” or “reference” generally refer to a standard of comparison. In some embodiments, alterations may be made to a level, an amount, and / or a concentration of, for example, a formulation component, such as an active pharmaceutical ingredient (API) and / or a water-soluble excipient, described herein. In some embodiments, alterations may be made to enhance a physical property and / or a chemical property of the microneedles and / or microarray patches (MAPs) described herein. Such alterations may include, for example, alterations to a dispensable formulation, such as a dispensable tip and / or a dispensable base formulation described herein. In some embodiments, alterations may be made to a manufacturing feasibility criteria, a printability parameter, and / or a process output to enhance a physical property and / or a chemical property of the microneedles and / or microarray patches (MAPs) described herein. The term “increase” refers to any increase, for example, an increase by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or up to and including an increase of at least about 100% or more (e.g., substantially above levels of detection), or any increase between about 1% to about 100% or more, as compared to a reference, e.g., a reference level. In some embodiments, an increase may be determined by a method that achieves, e.g., statistical significance (p <0.05).The term “decrease” or “reduce” refers to any decrease, for example, a decrease by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or up to and including a decrease of at least about 100% or more (e.g., below levels of detection), or any decrease between about 1% to about 100% or more, as compared to a reference, e.g., a reference level. In some embodiments, a decrease may be determined by a method that achieves, e.g., statistical significance (p <0.05).As used herein, the term “active agent” refers to a compound, macromolecule, drug, element, substance, or mixture that when administered to a subject, alone or in combination with another compound, macromolecule, drug, element, substance, or mixture, confers, directly or indirectly, a physiological effect on the subject. In some embodiments, salts, solvates (including hydrates), esters, analogues, derivatives, and / or prodrugs of the active agent are contemplated herein. In some embodiments, crystalline forms, non-crystalline forms, polymorphs, and any pseudopolymorphs of the active agent are also contemplated herein. In some embodiments, “active agent” and “active pharmaceutical ingredient” and “API” are used interchangeably.As used herein, the term “pharmacokinetic profile” has its ordinary meaning as understood by those skilled in the art and thus includes, by way of non-limiting example, a characteristic of the curve that results from plotting blood serum concentration of a API over time, following administration of the API to a subject. A pharmacokinetic profile thus includes a pharmacokinetic parameter or set of parameters that can be used to characterize the pharmacokinetics of a particular API or dosage form (e.g., a microneedle and / or a MAP described herein) when administered to a suitable patient population. Various pharmacokinetic parameters are known to those skilled in the art. In some embodiments, “pharmacokinetic parameters” refers to the in vivo characteristics of an API (or a reference drug) over time, such as plasma concentration (C), Cmax, Cn, C24, Tmax, and AUC. In some embodiments, “Cmax” refers to the measured concentration of the API, e.g., in the plasma, at the point of maximum concentration. In some embodiments, “Cn” refers to the measured concentration of an API, e.g., in the plasma, at about n hours after administration. In some embodiments, “C24” refers to the measured concentration of an API, e.g., in the plasma, at about 24 hours after administration. In some embodiments, “Tmax” refers to the time at which the measured concentration of an API, e.g., in the plasma, is the highest (i.e., Cmax) after administration of the API. In some embodiments, “AUC” refers to the area under the curve of a graph of the measured concentration of an API (e.g., plasma concentration) versus time, measured from one time point to another time point. For example, “AUC0-t” refers to the area under the curve of API concentration (e.g., plasma concentration) versus time from time 0 to time t. In some embodiments, “AUC0-INF” refers to the calculated area under the curve of API concentration (e.g., plasma concentration) versus time from time 0 to time infinity. AUClast indicates the area under the blood plasma concentration versus time curve from the time of administration until the time of the last measurable concentration. Pharmacokinetic parameters may be measured in various ways known to those skilled in the art, e.g., single dosage or steady-state. Differences in one or more of the pharmacokinetic profiles (e.g., Cmax) may indicate pharmacokinetic distinctness between two formulations.Those skilled in the art will understand that pharmacokinetic parameters may be determined by comparison to a reference standard using clinical trial methods known and accepted by those skilled in the art, e.g., as described in the examples set forth herein. Since the pharmacokinetics of a API can vary from patient to patient, such clinical trials generally involve multiple patients and appropriate statistical analyses of the resulting data (typically ANOVA at 90% confidence). Comparisons of pharmacokinetic parameters are on a dose-adjusted basis, as understood by those skilled in the art.As used herein, the term “bioavailability” generally means that the extent or rate at which an active pharmaceutical ingredient (API) is absorbed into a living system or is made available at the site of physiological activity. Bioavailability can be characterized by one or more pharmacokinetic parameters, as described herein. Generally, the term bioavailability refers to the fraction of an administered dose of the API, such as a GLP-1 peptide comprised in a pharmaceutical composition (e.g., a microneedle and / or a MAP) described herein, that reaches the systemic circulation unchanged. For example, when an API is administered intravenously, its bioavailability can be 100%. However, when an API is administered via other routes, e.g., orally, its bioavailability may decrease due to incomplete absorption and / or first-pass metabolism occurring in the gastrointestinal (GI) tract and liver. Transdermal and / or intradermal delivery of an API by a microneedle and / or a MAP described herein can bypasses first-pass metabolism by allowing the API to enter the systemic circulation directly. As used herein, the term “bioequivalence” generally means the absence of a significant difference in the rate and extent to which an active pharmaceutical ingredient (API) (or a reference drug) in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of action when administered in an appropriately designed study, such as a pharmacokinetic (PK) study described herein.As used herein, the term "stabilized" or "stable," in the context of a pharmaceutical composition comprising an API, such as a microneedle and / or a MAP described herein, refers to a pharmaceutical composition with increased chemical stability, increased physical stability or increased chemical and physical stability relative to a pharmaceutical composition without all the ingredients (e.g., water-soluble excipients) of the pharmaceutical composition of the present disclosure. In some embodiments, the term “stability,” in the context of a pharmaceutical composition comprising an API, such as a microneedle and / or a MAP described herein, refers to the shelf life of the composition.As used herein, the term “shelf stability” can refer to the longest length of time in the labeling or approval documentation accompanying a commercially approved formulation of an active pharmaceutical ingredient (API). A product's “shelf stability” or “shelf life” generally means the length of time expected for a product to look and act as expected and to stay safe for use. In some embodiments, the labeling or approval documentation originates from the European Medicines Agency. In some embodiments, the labeling or approval documentation originates from the U.S. Food and Drug Agency (FDA). In some embodiments, “shelf stability” can refer to either room temperature shelf conditions and / or cold-chain shelf conditions.As used herein, the terms “reference drug,” “reference listed drug (RLD),” and “reference standard” can refer to an active pharmaceutical ingredient (API) product as described in the U.S. Federal Food and Drug Administration's (FDA) Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations and / or the European Medicines Agency (EMEA) document “Note for Guidance on the Investigation of Bioavailability and Bioequivalence. In some embodiments, the reference drug comprises a GLP-1 receptor agonist, such as semaglutide, dulaglutide, exenatide, liraglutide, lixisenatide, tirzepatide, albiglutide, and / or taspoglutide.As used herein, the term “anti-drug antibody” or “ADA” refers to an antibody produced by the immune system of a subject that can specifically bind to an epitope on an active pharmaceutical ingredient (API), such as an epitope on a therapeutic protein. ADAs can be classified as either neutralizing antibodies (NAbs) or non-neutralizing antibodies (nNAbs). ADAs may affect the safety and efficacy of an API, and as such may be monitored when administering an API, such as a therapeutic protein, to a subject. Although an API (e.g., a therapeutic protein) may be therapeutically effective in various diseases, disorders, and / or conditions, its administration (or repeated administration) can also be highly immunogenic (e.g., inducing high titers of ADAs) and may elicit an undesirable immune response to the API (e.g., the therapeutic protein). The formation of an ADA immune response can interfere with the activity of the API or neutralize it, thereby altering the API's pharmacokinetic (PK) and pharmacodynamic (PD) properties and reducing its efficacy, and / or causing an adverse event in a subject. Immune-based adverse effects may be acute and / or delayed. A possible life-threatening consequence of ADA formation against an API (e.g., a therapeutic protein) is cross-reactivity with an endogenous protein that inhibits or neutralizes its activity when the protein has a non-redundant role in mediating important physiological functions. An additional potential consequence of cross-reactivity to an endogenous protein can result from antibody responses to an API that is a counterpart of an endogenous cell surface receptor or a counterpart of an endogenous cytokine that is membrane-expressed. Such ADAs may cross-reactively bind to the respective cell surface receptors or proteins, causing cytokine release and / or other undesirable manifestations of cellular activation. In general, the development of neutralizing ADA activity and / or the presence of sustained ADA titers may lead to loss of efficacy and / or an increased risk of an adverse reaction. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can decrease the potential for and / or the risk associated with an unwanted immune response developing to an API, such as a therapeutic protein. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can improve the immunogenicity profile, clinical safety, and / or efficacy of an API, such as a therapeutic protein. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can reduce the occurrence and / or severity of immunologically based adverse events, including, but not limited to, anaphylaxis, cytokine release syndrome, and cross-reactive neutralization of endogenous proteins. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can enhance the delivery of high-risk therapeutic protein products (e.g., therapeutic counterparts of nonredundant endogenous proteins), e.g., by reducing unwanted immunogenicity. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can reduce the development of neutralizing ADA activity, decrease the presence of sustained ADA titers that may lead to loss of efficacy, and / or reduce the risk of an adverse reaction. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can increase immune tolerance, e.g., when severe consequences result from immunogenicity. In some rare instances, an ADA may act as a carrier and enhance the half-life of an API and / or prolong its therapeutic effects. In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can help promote the development of an ADA with beneficial effects, such as a ADA that can act as a carrier and enhance the half-life of an API, such as a therapeutic protein (e.g., a GLP-1 receptor agonist) and / or prolong its therapeutic effects.As used herein, the term “neutralizing antibody” or “NAb” refers to a subset of anti-drug antibodies (ADAs) that can bind to an active pharmaceutical ingredient (API), such as a therapeutic protein, in a manner that can inhibit or neutralize its activity. In some embodiments, a neutralizing antibody may inhibit the activity of an API, such as a therapeutic protein, by binding to an epitope (e.g., a neutralizing epitope) within or close to an active site of the molecule or by causing conformational changes, thereby physically interfering with the ability of the API to bind its target. In some embodiments, a neutralizing antibody may inhibit the binding of an API to its target, thereby rendering the API partially or completely inactive. In some embodiments, a neutralizing antibody may block and / or interfere with an API's ability to bind its target, thereby rendering the API partially or completely inactive. For example, in some instances, a neutralizing antibody may block and / or interfere with the ability of an API, such as a soluble ligand drug (e.g., a GLP-1 receptor agonist), to bind its receptor (e.g., a GLP-1 receptor). In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can reduce the development of and / or effects of a neutralizing antibody that can block and / or interfere with the ability of an API, such as a soluble ligand drug (e.g., a GLP-1 receptor agonist), to bind its receptor (e.g., a GLP-1 receptor). In some embodiments, the microneedles, microarray patches (MAPs), and systems described herein can reduce the development of and / or the effects of a cross-reactive antibody to an endogenous counterpart of an API (e.g., an endogenous GLP-1). Neutralizing antibodies may affect the safety and efficacy of an API, and as such may be monitored when administering an API, such as a therapeutic protein, to a subject.As used herein, the term “non-neutralizing antibody” or “nNAb” refers to a subset of anti-drug antibodies (ADAs) that can bind to an active pharmaceutical ingredient (API), such as a therapeutic protein, in a manner that may modulate its activity. In some embodiments, a non-neutralizing antibody may modulate the activity of a API, such as a therapeutic protein, by binding to an epitope (e.g., a non-neutralizing epitope) that does not affect the API-target interaction (e.g., does not physically interfere with the ability of the API to bind its target). While non-neutralizing antibodies may not necessarily affect the API-target interaction, non-neutralizing antibodies may affect the safety of an API, e.g., by causing adverse events, such as hypersensitivity reactions and inflammatory responses; and / or may affect the efficacy of an API, e.g., by altering its clearance, cellular uptake, and / or half-life. Non-neutralizing antibodies may affect the safety and efficacy of an API, and as such may be monitored when administering an API, such as a therapeutic protein, to a subject.Amounts: throughout this disclosure, various aspects of the invention can be presented in a percent concentration format. The percent concentration of a material (e.g., an API and / or excipient described herein) in solution (e.g., a dispensable formulation described herein) can be expressed in several ways depending on how the material and solution are measured. Accordingly, the description of a percent concentration should be considered to have specifically disclosed all the possible ways the material and solution may be measured, unless the content clearly dictates otherwise. For example, the amount of a component, such as an API and / or a water-soluble excipient, present in a dispensable formulation (e.g., a dispense volume of a dispensable formulation) may be a weight per weight (% w / w), a weight per volume (% w / v), and / or a volume per volume (% v / v) percent concentration, unless the content clearly dictates otherwise. In should also be understood that the amount of a component, such as an API and / or a water-soluble excipient, present in a microneedle and / or a MAP described herein may relate to the amount of the component present in the dispensable formulation (e.g., in the dispense volume of the dispensable formulation) from which the microneedle and / or the MAP was formed. For example, the amount of a component, such as an API and / or a water-soluble excipient, present in a dispensable tip and / or base formulation (e.g., a dispense volume of a dispensable tip and / or base formulation) from which a microneedle and / or a MAP may be formed. In some embodiments, the amount of a component, such as an API and / or a water-soluble excipient, present in a microneedle and / or a MAP described herein may be determined, e.g., after drying. Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity, includes something with 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This applies regardless of the breadth of the range. COMPOSITIONSDispensable Formulations, Microneedles, and Microarray Patches (MAPs)The present disclosure relates, in one aspect, to microneedles and / or microarray patches (MAPs) that can facilitate simple, substantially pain-free, and consistent delivery of a wide range of active pharmaceutical ingredients (APIs) and doses. The microneedles and / or microarray patches (MAPs) can be formed from a dispensable formulation described herein, comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof. As disclosed herein, Applicant has surprisingly discovered specific combinations of water-soluble excipients that can, for example, effectively (1) enhance the stability of a high concentration of active pharmaceutical ingredients (API) for delivery of an effective dose of the API using a microneedle and / or a microarray patch (MAP) described herein; (2) enhance the fluid properties of a composition, such as a dispensable formulation, for manufacturing a microneedle and / or a microarray patch (MAP) described herein using, e.g., a liquid dispensing system; (3) enhance the consolidation of the API into the apex of a microneedle tip (e.g., a consolidated microneedle tip) during manufacturing; (4) enhance the strength of the microneedle, e.g., to resist deformation during deployment; and / or (5) minimize, or eliminate, manufacturing defects, such as shell formation and microneedle tip dislodgement, that can negatively affect microneedle morphology, strength, deployment efficiency, API delivery consistency, and pharmacodynamics.Accordingly, in one aspect, the present disclosure provides a composition, such as a dispensable formulation, comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof. In some embodiments, the dispensable formulation can be used for producing a microneedle and / or a microarray patch (MAP). Accordingly, in one aspect, the disclosure further provides a composition, such as a pharmaceutical composition, comprising an active pharmaceutical ingredient (API) and a water soluble excipient. Such compositions, e.g., pharmaceutical compositions, can be in the form of a microneedle and / or a microarray patch (MAP). In one embodiment, the present disclosure provides microneedles and / or microarray patches (MAPs), comprising an active pharmaceutical ingredient (API) and a water soluble excipient, demonstrating consistent dosing, extended shelf stability, therapeutically relevant dosing, and / or therapeutically relevant bioavailability. In one embodiment, the present disclosure provides microneedles and / or microarray patches (MAPs), comprising an active pharmaceutical ingredient (API) and a water soluble excipient, demonstrating bioequivalence to commercially approved formulations of the API.Accordingly, in one aspect, the disclosure provides a microneedle and / or a microarray patch (MAP), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof. In particular embodiments, the microneedle and / or the microarray patch (MAP), comprises an active pharmaceutical ingredient (API) and a water-soluble excipient. In particular embodiments, the microneedle and / or the microarray patch (MAP), comprises an active pharmaceutical ingredient (API) and a plurality of water-soluble excipients. The microneedles and / or microarray patches (MAPs) can be configured to deliver one or more active pharmaceutical ingredients (APIs) (e.g., small molecules, biologics, peptides, proteins, nucleic acids, mRNA, lipid nanoparticles (LNPs), vaccines, virus-like particles (VLPs), live attenuated viruses, inactivated viruses, adjuvanted vaccines, and combinations thereof) through the skin of a subject, and to provide release of the API immediately and / or over a prolonged period of time. In some embodiments, the microneedles and / or microarray patches (MAPs) can further comprise a consolidated microneedle tip. In some embodiments, the microneedles and / or microarray patches (MAPs) can further comprise a microneedle base. In some embodiments, the microneedles and / or microarray patches (MAPs) can further comprise a consolidated microneedle tip and a microneedle base. The consolidated microneedle tip and / or the microneedle base can be formed, independently, from a dispensable formulation (e.g., a dispensable tip formulation and / or a dispensable base formulation, respectively), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof. In some embodiments, the consolidated microneedle tip and / or the microneedle base can be formed, independently, from the same or different dispensable formulation. As such, in some embodiments, the consolidated microneedle tip and the microneedle base can comprise, independently, the same or different combination and / or amount of components (e.g., API and / or water-soluble excipient). The amount of a component (e.g., API and / or water-soluble excipient) can be based, for example, on the amount of the component (e.g., API and / or water-soluble excipient) present in a dispensable formulation (e.g., a dispensable tip formulation and / or a dispensable base formulation, respectively).Additional features and non-limiting examples of the dispensable formulations, microneedles, and microarray patches (MAPs) of the present disclosure are disclosed below. Dispensable FormulationsAccording to one aspect, the disclosure provides a dispensable formulation, e.g., comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof. Such dispensable formulations can be used to produce a microneedle and / or a microarray patch (MAP) described herein. In some embodiments, the present disclosure provides a dispensable formulation, e.g., comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, that can be used to form a consolidated microneedle tip and / or a microneedle base.As used herein, the term “dispensable formulation” is intended to broadly encompass any composition, such as a liquid composition, that can be dispensed (e.g., printed, ejected, jetted, and / or sprayed) from a liquid handling device. In some embodiments, it is desirable to provide a dispensable formulation, comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof for manufacturing a microneedle and / or a microarray patch (MAP), described herein, e.g., using a liquid dispensing system. In some embodiments, a dispensable formulation comprising an active pharmaceutical ingredient (API) and a water-soluble excipient can be used to form a consolidated microneedle tip (also referred to herein as a “tip formulation”). In some embodiments, a dispensable formulation comprising a water-soluble excipient may be used to form a microneedle base (also referred to herein as a “base formulation”).As used herein, the term “liquid dispensing system” refers to any device that can transfer a predefined amount of a liquid, e.g., a dispensable formulation described herein, to a target site, such as into a cavity, e.g., a microprojection shaped cavity, of a mold that defines the shape of a microneedle and / or a microarray patch (MAP). In some embodiment, the amount of liquid, e.g., dispensable formulation described herein, dispensed and the rate at which the liquid dispensing system dispenses the liquid to a target site may be adjusted manually and / or automatically. In some embodiment, the amount of a liquid, e.g., a dispensable formulation, that is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) may be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL). In some embodiments, the predefined amount of the liquid, e.g., the dispensable formulation, that is dispensed into the microprojection shaped cavity of the mold forms a consolidated microneedle tip. In some embodiment, the predefined amount of the liquid, e.g., the dispensable formulation, that is dispensed into the microprojection shaped cavity of the mold forms a microneedle base.As used herein, the term “target site” refers to a specific position on a solid support that can contain a liquid, e.g., a dispensable formulation. In some embodiments, the target site may be a specific microprojection shaped cavity of a mold that defines the shape of a microneedle array. Such a mold may contain one or more target sites, e.g., one or more microprojection shaped cavities, which may be arranged randomly or in an ordered array or other pattern.In some embodiments, the liquid dispensing system may be a vision-guided dispensing system capable of accurately dispensing a liquid, e.g., a dispensable formulation, in complex patterns and / or to specific target sites, such as to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle array. In some embodiments, the liquid dispensing system may be a low-volume dispensing system. As used herein, the term “low-volume dispensing” refers to any dispensing process with volumes in the nanoliter (nL) and / or picoliter (pL) range. In some embodiments, low-volume dispensing encompasses dispensing single liquid drops in the volume range of about 0.1 pL to more than about 1 µL.In some embodiments, the liquid dispensing system may be configured to provide dropwise dispensing. The term “dropwise,” as used herein, means that a liquid, e.g., a dispensable formulation, is provided in a drop-by-drop fashion. The terms “dropwise” and “drop-by-drop” are generally intended to mean that one discrete drop of a liquid, e.g., a dispensable formulation, irrespective of its drop size (e.g., diameter and / or volume) is provided or dispensed at a time and / or that a plurality of drops is provided in a consecutive manner, one at a time. In some embodiments, dropwise dispensing of a liquid, e.g., a dispensable formulation, is provided to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle array. The term “progressive fill,” as used herein, refers to a dropwise manner of dispensing a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein. In some embodiments, the term “progressive fill” refers to a dropwise manner of dispensing one or more drops of a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein, into a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP). In particular embodiments, the term “progressive fill” refers to a dropwise manner of dispensing a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein, that may include an intervening drying step between the dispense of one or more drops. For example, in some embodiments, a progressive fill may comprise the steps of (1) dispensing one or more drops of a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein, into a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP); (2) drying the dispensed volume of the dispensable formulation for a predetermined period of time (e.g., one or more seconds, minutes, hours, and / or days) at predetermined environmental conditions (e.g., ambient temperature and / or relative humidity) to form a dried or partially dried portion of a consolidated microneedle tip and / or microneedle base; (3) dispensing one or more drops of the dispensable formulation onto the dried or partially dried portion of the consolidated microneedle tip and / or the microneedle base; and optionally (4) repeating step (2) and / or (3) to fully form a consolidated microneedle tip and / or a microneedle base, thereby generating a microneedle and / or the microarray patch (MAP) described herein. In some embodiments, using a progressive fill to form a consolidated microneedle tip and / or a microneedle base may reduce and / or eliminate the occurrence of a defect during manufacturing of a microneedle and / or a microarray patch (MAP) described herein. In some embodiments, the term “progressive base fill,” refers to a dropwise manner of dispensing a dispensable base formulation. In some embodiments, subsequent to the formation of a consolidated microneedle tip, a microneedle base applied to the consolidated microneedle tip may be formed using a progressive base fill. It may be understood that the term “subsequent to the formation of a consolidated microneedle tip” encompasses, for example, the formation of a dried or partially dried consolidated microneedle tip from a dispensable tip formulation prior to the dispensing of one or more drops of a dispensable base formulation. For example, in some embodiments, a progressive base fill may comprise the steps of (1) dispensing one or more drops of a dispensable base formulation onto a dried or partially dried consolidated microneedle tip in a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP); (2) optionally drying the dispensed volume of the dispensable base formulation for a predetermined period of time (e.g., one or more seconds, minutes, hours, and / or days) at predetermined environmental conditions (e.g., ambient temperature and / or relative humidity) to form a dried or partially dried portion of a microneedle base; (3) optionally dispensing one or more drops of the dispensable base formulation onto the dried or partially dried portion of the consolidated microneedle tip and / or the microneedle base; and optionally (4) repeating step (2) and / or (3) to fully form a consolidated microneedle tip and / or a microneedle base, thereby generating a microneedle and / or the microarray patch (MAP) described herein. In some embodiments, using a progressive base fill to form a consolidated microneedle tip and / or a microneedle base may reduce and / or eliminate the occurrence of a defect during manufacturing of a microneedle and / or a microarray patch (MAP) described herein. As used herein, the terms “defect” and “manufacturing defect” and the like are broadly intended to encompass any kind of anomaly, imperfection, or undesirable feature formed on or within a microneedle and / or a microarray patch (MAP) described herein, e.g., during manufacturing. In some embodiments, the terms refer to an abnormality on the surface or within the volume of a material, such as a dispensable formulation, intended to form the consolidated microneedle tip and / or the microneedle base of a microneedle and / or a microarray patch (MAP) described herein. Defects may include non-uniformities, non-conformities, misalignments, flaws, damages, aberrations, and irregularities in the material or product.  In some embodiments, the defect may alter the morphology, the strength, and / or the deployment efficiency of a microneedle and / or a microarray patch (MAP) described herein. In some embodiments, the defect comprises a shell or shell-like structure formed, e.g., from the dispensable tip formulation, an incomplete consolidated microneedle tip, a missing consolidated microneedle tip, a missing base, a dislodgement of the consolidated microneedle tip (e.g., all or a portion of the consolidated microneedle tip is dislodged into the microneedle base), and / or resolubilization of the microneedle tip, that can negatively affect microneedle morphology, strength, and / or deployment efficiency. As used herein, the term “drop size” refers to the size of the drop dispensed, and may be expressed in units of volume and / or diameter. In some embodiments, drop size may be measured in microliters (µL). In some embodiments, drop size may be measured in microns (µm). In some embodiments, drop size may be measured in nanoliters (nL). In some embodiments, drop size may be measured in nanometers (nm). In some embodiments, drop size may be measured in picoliters (pL). In some embodiments, drop size may be measured in picometers (pm). In some embodiments, drop size may be inferred based on a determination of the speed of the dispensed drop, as larger drops are generally characterized by greater speed.In some embodiments, the drop size may be about 1 pL to about 1000 nL (e.g., about 1 pL to about 50 pL; about 1 pL to about 100 pL; about 1 pL to about 150 pL; about 1 pL to about 200 pL; about 1 pL to about 250 pL; about 1 pL to about 300 pL; about 1 pL to about 350 pL; about 1 pL to about 400 pL; about 1 pL to about 450 pL; about 1 pL to about 500 pL; about 1 pL to about 550 pL; about 1 pL to about 600 pL; about 1 pL to about 650 pL; about 1 pL to about 700 pL; about 1 pL to about 750 pL; about 1 pL to about 800 pL; about 1 pL to about 850 pL; about 1 pL to about 900 pL; about 1 pL to about 950 pL; about 1 pL to about 1000 pL; about 1 nL to about 50 nL; about 1 nL to about 100 nL; about 1 nL to about 150 nL; about 1 nL to about 200 nL; about 1 nL to about 250 nL; about 1 nL to about 300 nL; about 1 nL to about 350 nL; about 1 nL to about 400 nL; about 1 nL to about 450 nL; about 1 nL to about 500 nL; about 1 nL to about 550 nL; about 1 nL to about 600 nL; about 1 nL to about 650 nL; about 1 nL to about 700 nL; about 1 nL to about 750 nL; about 1 nL to about 800 nL; about 1 nL to about 850 nL; about 1 nL to about 900 nL; about 1 nL to about 950 nL; or about 1 nL to about 1000 nL).In some embodiments, the drop size may be about 1 pL to about 1000 pL (e.g., about 1 pL, about 5 pL, about 10 pL, about 15 pL, about 20 pL, about 25 pL, about 30 pL, about 35 pL, about 40 pL, about 45 pL, about 50 pL, about 55 pL, about 60 pL, about 65 pL, about 70 pL, about 75 pL, about 80 pL, about 85 pL, about 90 pL, about 95 pL, about 100 pL, about 105 pL, about 110 pL, about 115 pL, about 120 pL, about 125 pL, about 130 pL, about 135 pL, about 140 pL, about 145 pL, about 150 pL, about 155 pL, about 160 pL, about 165 pL, about 170 pL, about 175 pL, about 180 pL, about 185 pL, about 190 pL, about 195 pL, about 200 pL, about 205 pL, about 210 pL, about 215 pL, about 220 pL, about 225 pL, about 230 pL, about 235 pL, about 240 pL, about 245 pL, about 250 pL, about 255 pL, about 260 pL, about 265 pL, about 270 pL, about 275 pL, about 280 pL, about 285 pL, about 290 pL, about 295 pL, about 300 pL, about 305 pL, about 310 pL, about 315 pL, about 320 pL, about 325 pL, about 330 pL, about 335 pL, about 340 pL, about 345 pL, about 350 pL, about 355 pL, about 360 pL, about 365 pL, about 370 pL, about 375 pL, about 380 pL, about 385 pL, about 390 pL, about 395 pL, about 400 pL, about 405 pL, about 410 pL, about 415 pL, about 420 pL, about 425 pL, about 430 pL, about 435 pL, about 440 pL, about 445 pL, about 450 pL, about 455 pL, about 460 pL, about 465 pL, about 470 pL, about 475 pL, about 480 pL, about 485 pL, about 490 pL, about 495 pL, about 500 pL, about 505 pL, about 510 pL, about 515 pL, about 520 pL, about 525 pL, about 530 pL, about 535 pL, about 540 pL, about 545 pL, about 550 pL, about 555 pL, about 560 pL, about 565 pL, about 570 pL, about 575 pL, about 580 pL, about 585 pL, about 590 pL, about 595 pL, about 600 pL, about 605 pL, about 610 pL, about 615 pL, about 620 pL, about 625 pL, about 630 pL, about 635 pL, about 640 pL, about 645 pL, about 650 pL, about 655 pL, about 660 pL, about 665 pL, about 670 pL, about 675 pL, about 680 pL, about 685 pL, about 690 pL, about 695 pL, about 700 pL, about 705 pL, about 710 pL, about 715 pL, about 720 pL, about 725 pL, about 730 pL, about 735 pL, about 740 pL, about 745 pL, about 750 pL, about 755 pL, about 760 pL, about 765 pL, about 770 pL, about 775 pL, about 780 pL, about 785 pL, about 790 pL, about 795 pL, about 800 pL, about 805 pL, about 810 pL, about 815 pL, about 820 pL, about 825 pL, about 830 pL, about 835 pL, about 840 pL, about 845 pL, about 850 pL, about 855 pL, about 860 pL, about 865 pL, about 870 pL, about 875 pL, about 880 pL, about 885 pL, about 890 pL, about 895 pL, about 900 pL, about 905 pL, about 910 pL, about 915 pL, about 920 pL, about 925 pL, about 930 pL, about 935 pL, about 940 pL, about 945 pL, about 950 pL, about 955 pL, about 960 pL, about 965 pL, about 970 pL, about 975 pL, about 980 pL, about 985 pL, about 990 pL, about 995 pL, or about 1000 pL).In some embodiments, the drop size may be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL).As used herein, the term “dispense volume” refers to the total amount of liquid dispensed in a single drop and / or in a plurality of drops. In some embodiments, dispense volume may be measured in microliters (µL). In some embodiments, dispense volume may be measured in nanoliters (nL). In some embodiments, dispense volume may be measured in picoliters (pL). In some embodiments, the terms drop size and dispense volume may be used interchangeably. In some embodiments, the dispense volume may be about 1 pL to about 1000 nL (e.g., about 1 pL to about 50 pL; about 1 pL to about 100 pL; about 1 pL to about 150 pL; about 1 pL to about 200 pL; about 1 pL to about 250 pL; about 1 pL to about 300 pL; about 1 pL to about 350 pL; about 1 pL to about 400 pL; about 1 pL to about 450 pL; about 1 pL to about 500 pL; about 1 pL to about 550 pL; about 1 pL to about 600 pL; about 1 pL to about 650 pL; about 1 pL to about 700 pL; about 1 pL to about 750 pL; about 1 pL to about 800 pL; about 1 pL to about 850 pL; about 1 pL to about 900 pL; about 1 pL to about 950 pL; about 1 pL to about 1000 pL; about 1 nL to about 50 nL; about 1 nL to about 100 nL; about 1 nL to about 150 nL; about 1 nL to about 200 nL; about 1 nL to about 250 nL; about 1 nL to about 300 nL; about 1 nL to about 350 nL; about 1 nL to about 400 nL; about 1 nL to about 450 nL; about 1 nL to about 500 nL; about 1 nL to about 550 nL; about 1 nL to about 600 nL; about 1 nL to about 650 nL; about 1 nL to about 700 nL; about 1 nL to about 750 nL; about 1 nL to about 800 nL; about 1 nL to about 850 nL; about 1 nL to about 900 nL; about 1 nL to about 950 nL; or about 1 nL to about 1000 nL).In some embodiments, the dispense volume may be about 1 pL to about 1000 pL (e.g., about 1 pL, about 5 pL, about 10 pL, about 15 pL, about 20 pL, about 25 pL, about 30 pL, about 35 pL, about 40 pL, about 45 pL, about 50 pL, about 55 pL, about 60 pL, about 65 pL, about 70 pL, about 75 pL, about 80 pL, about 85 pL, about 90 pL, about 95 pL, about 100 pL, about 105 pL, about 110 pL, about 115 pL, about 120 pL, about 125 pL, about 130 pL, about 135 pL, about 140 pL, about 145 pL, about 150 pL, about 155 pL, about 160 pL, about 165 pL, about 170 pL, about 175 pL, about 180 pL, about 185 pL, about 190 pL, about 195 pL, about 200 pL, about 205 pL, about 210 pL, about 215 pL, about 220 pL, about 225 pL, about 230 pL, about 235 pL, about 240 pL, about 245 pL, about 250 pL, about 255 pL, about 260 pL, about 265 pL, about 270 pL, about 275 pL, about 280 pL, about 285 pL, about 290 pL, about 295 pL, about 300 pL, about 305 pL, about 310 pL, about 315 pL, about 320 pL, about 325 pL, about 330 pL, about 335 pL, about 340 pL, about 345 pL, about 350 pL, about 355 pL, about 360 pL, about 365 pL, about 370 pL, about 375 pL, about 380 pL, about 385 pL, about 390 pL, about 395 pL, about 400 pL, about 405 pL, about 410 pL, about 415 pL, about 420 pL, about 425 pL, about 430 pL, about 435 pL, about 440 pL, about 445 pL, about 450 pL, about 455 pL, about 460 pL, about 465 pL, about 470 pL, about 475 pL, about 480 pL, about 485 pL, about 490 pL, about 495 pL, about 500 pL, about 505 pL, about 510 pL, about 515 pL, about 520 pL, about 525 pL, about 530 pL, about 535 pL, about 540 pL, about 545 pL, about 550 pL, about 555 pL, about 560 pL, about 565 pL, about 570 pL, about 575 pL, about 580 pL, about 585 pL, about 590 pL, about 595 pL, about 600 pL, about 605 pL, about 610 pL, about 615 pL, about 620 pL, about 625 pL, about 630 pL, about 635 pL, about 640 pL, about 645 pL, about 650 pL, about 655 pL, about 660 pL, about 665 pL, about 670 pL, about 675 pL, about 680 pL, about 685 pL, about 690 pL, about 695 pL, about 700 pL, about 705 pL, about 710 pL, about 715 pL, about 720 pL, about 725 pL, about 730 pL, about 735 pL, about 740 pL, about 745 pL, about 750 pL, about 755 pL, about 760 pL, about 765 pL, about 770 pL, about 775 pL, about 780 pL, about 785 pL, about 790 pL, about 795 pL, about 800 pL, about 805 pL, about 810 pL, about 815 pL, about 820 pL, about 825 pL, about 830 pL, about 835 pL, about 840 pL, about 845 pL, about 850 pL, about 855 pL, about 860 pL, about 865 pL, about 870 pL, about 875 pL, about 880 pL, about 885 pL, about 890 pL, about 895 pL, about 900 pL, about 905 pL, about 910 pL, about 915 pL, about 920 pL, about 925 pL, about 930 pL, about 935 pL, about 940 pL, about 945 pL, about 950 pL, about 955 pL, about 960 pL, about 965 pL, about 970 pL, about 975 pL, about 980 pL, about 985 pL, about 990 pL, about 995 pL, or about 1000 pL).In some embodiments, the dispense volume may be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL).In some embodiments, the dispensable formulation can be characterized by a fluid property that enhances the mechanical properties of a microneedle and / or microneedle tip consolidation. Such fluid properties can also be referred to as “printability parameters” and can be selected from the group consisting of viscosity, surface tension, density, solids content, and combinations thereof. In some embodiments, a dispensable formulation, and / or the microneedle and / or MAP formed from the dispensable formulation, can be characterized by a process parameter for the dispense system that can be adjusted to enhance the mechanical and / or morphological properties of a microneedle and / or microneedle, such as tip consolidation. Such process parameters may also be referred to as “process inputs” or “process outputs.” In some embodiments, “process inputs” can be selected from the group consisting of temperature, humidity, and combinations thereof, and may be related to the environmental conditions present and / or the equipment settings utilized during microneedle and / or MAP manufacturing. In some embodiments, “process outputs” can be selected from the group consisting of dispense volume, dispense velocity , and combinations thereof. In some embodiments, the dispensable formulation can be characterized by a fluid property that can be adjusted to improve manufacturing precision, quality, efficiency and / or yield. In some embodiments, the dispensable formulation can be characterized by a fluid property that can be adjusted to improve formability of the microneedle and / or the microarray patch (MAP). In some embodiments, the dispensable formulation can be characterized by a fluid property that can be adjusted to improve a structural property of the microneedle and / or the microarray patch (MAP). In some embodiments, the dispensable formulation can be characterized by a fluid property that can be adjusted to enhance the deployability of the microneedle and / or the microarray patch (MAP). ViscosityIn some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a viscosity of about 1 cP to about 1750 cP (e.g., about 1 cP, about 25 cP, about 50 cP, about 75 cP, about 100 cP, about 125 cP, about 150 cP, about 175 cP, about 200 cP, about 225 cP, about 250 cP, about 275 cP, about 300 cP, about 325 cP, about 350 cP, about 375 cP, about 400 cP, about 425 cP, about 450 cP, about 475 cP, about 500 cP, about 525 cP, about 550 cP, about 575 cP, about 600 cP, about 625 cP, about 650 cP, about 675 cP, about 700 cP, about 725 cP, about 750 cP, about 775 cP, about 800 cP, about 825 cP, about 850 cP, about 875 cP, about 900 cP, about 925 cP, about 950 cP, about 975 cP, about 1000 cP, about 1025 cP, about 1050 cP, about 1075 cP, about 1100 cP, about 1125 cP, about 1150 cP, about 1175 cP, about 1200 cP, about 1225 cP, about 1250 cP, about 1275 cP, about 1300 cP, about 1325 cP, about 1350 cP, about 1375 cP, about 1400 cP, about 1425 cP, about 1450 cP, about 1475 cP, about 1500 cP, about 1525 cP, about 1550 cP, about 1575 cP, about 1600 cP, about 1625 cP, about 1650 cP, about 1675 cP, about 1700 cP, about 1725 cP, or about 1750 cP). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 1750 cP (e.g., about 1 cP, about 25 cP, about 50 cP, about 75 cP, about 100 cP, about 125 cP, about 150 cP, about 175 cP, about 200 cP, about 225 cP, about 250 cP, about 275 cP, about 300 cP, about 325 cP, about 350 cP, about 375 cP, about 400 cP, about 425 cP, about 450 cP, about 475 cP, about 500 cP, about 525 cP, about 550 cP, about 575 cP, about 600 cP, about 625 cP, about 650 cP, about 675 cP, about 700 cP, about 725 cP, about 750 cP, about 775 cP, about 800 cP, about 825 cP, about 850 cP, about 875 cP, about 900 cP, about 925 cP, about 950 cP, about 975 cP, about 1000 cP, about 1025 cP, about 1050 cP, about 1075 cP, about 1100 cP, about 1125 cP, about 1150 cP, about 1175 cP, about 1200 cP, about 1225 cP, about 1250 cP, about 1275 cP, about 1300 cP, about 1325 cP, about 1350 cP, about 1375 cP, about 1400 cP, about 1425 cP, about 1450 cP, about 1475 cP, about 1500 cP, about 1525 cP, about 1550 cP, about 1575 cP, about 1600 cP, about 1625 cP, about 1650 cP, about 1675 cP, about 1700 cP, about 1725 cP, or about 1750 cP). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 1750 cP (e.g., about 1 cP, about 25 cP, about 50 cP, about 75 cP, about 100 cP, about 125 cP, about 150 cP, about 175 cP, about 200 cP, about 225 cP, about 250 cP, about 275 cP, about 300 cP, about 325 cP, about 350 cP, about 375 cP, about 400 cP, about 425 cP, about 450 cP, about 475 cP, about 500 cP, about 525 cP, about 550 cP, about 575 cP, about 600 cP, about 625 cP, about 650 cP, about 675 cP, about 700 cP, about 725 cP, about 750 cP, about 775 cP, about 800 cP, about 825 cP, about 850 cP, about 875 cP, about 900 cP, about 925 cP, about 950 cP, about 975 cP, about 1000 cP, about 1025 cP, about 1050 cP, about 1075 cP, about 1100 cP, about 1125 cP, about 1150 cP, about 1175 cP, about 1200 cP, about 1225 cP, about 1250 cP, about 1275 cP, about 1300 cP, about 1325 cP, about 1350 cP, about 1375 cP, about 1400 cP, about 1425 cP, about 1450 cP, about 1475 cP, about 1500 cP, about 1525 cP, about 1550 cP, about 1575 cP, about 1600 cP, about 1625 cP, about 1650 cP, about 1675 cP, about 1700 cP, about 1725 cP, or about 1750 cP). In some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a viscosity of about 1 cP to about 10 cP (e.g., about 1 cP, about 1.25 cP, about 1.5 cP, about 1.75 cP, about 2 cP, about 2.25 cP, about 2.5 cP, about 2.75 cP, about 3 cP, about 3.25 cP, about 3.5 cP, about 3.75 cP, about 4 cP, about 4.25 cP, about 4.5 cP, about 4.75 cP, about 5 cP, about 5.25 cP, about 5.5 cP, about 5.75 cP, about 6 cP, about 6.25 cP, about 6.5 cP, about 6.75 cP, about 7 cP, about 7.25 cP, about 7.5 cP, about 7.75 cP, about 8 cP, about 8.25 cP, about 8.5 cP, about 8.75 cP, about 9 cP, about 9.25 cP, about 9.5 cP, about 9.75 cP, or about 10 cP). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 10 cP (e.g., about 1 cP, about 1.25 cP, about 1.5 cP, about 1.75 cP, about 2 cP, about 2.25 cP, about 2.5 cP, about 2.75 cP, about 3 cP, about 3.25 cP, about 3.5 cP, about 3.75 cP, about 4 cP, about 4.25 cP, about 4.5 cP, about 4.75 cP, about 5 cP, about 5.25 cP, about 5.5 cP, about 5.75 cP, about 6 cP, about 6.25 cP, about 6.5 cP, about 6.75 cP, about 7 cP, about 7.25 cP, about 7.5 cP, about 7.75 cP, about 8 cP, about 8.25 cP, about 8.5 cP, about 8.75 cP, about 9 cP, about 9.25 cP, about 9.5 cP, about 9.75 cP, or about 10 cP). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 10 cP (e.g., about 1 cP, about 1.25 cP, about 1.5 cP, about 1.75 cP, about 2 cP, about 2.25 cP, about 2.5 cP, about 2.75 cP, about 3 cP, about 3.25 cP, about 3.5 cP, about 3.75 cP, about 4 cP, about 4.25 cP, about 4.5 cP, about 4.75 cP, about 5 cP, about 5.25 cP, about 5.5 cP, about 5.75 cP, about 6 cP, about 6.25 cP, about 6.5 cP, about 6.75 cP, about 7 cP, about 7.25 cP, about 7.5 cP, about 7.75 cP, about 8 cP, about 8.25 cP, about 8.5 cP, about 8.75 cP, about 9 cP, about 9.25 cP, about 9.5 cP, about 9.75 cP, or about 10 cP).In some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a viscosity of about 1 cP to about 100 cP (e.g., about 1 cP, about 2 cP, about 3 cP, about 4 cP, about 5 cP, about 6 cP, about 7 cP, about 8 cP, about 9 cP, about 10 cP, about 11 cP, about 12 cP, about 13 cP, about 14 cP, about 15 cP, about 16 cP, about 17 cP, about 18 cP, about 19 cP, about 20 cP, about 21 cP, about 22 cP, about 23 cP, about 24 cP, about 25 cP, about 26 cP, about 27 cP, about 28 cP, about 29 cP, about 30 cP, about 31 cP, about 32 cP, about 33 cP, about 34 cP, about 35 cP, about 36 cP, about 37 cP, about 38 cP, about 39 cP, about 40 cP, about 41 cP, about 42 cP, about 43 cP, about 44 cP, about 45 cP, about 46 cP, about 47 cP, about 48 cP, about 49 cP, about 50 cP, about 51 cP, about 52 cP, about 53 cP, about 54 cP, about 55 cP, about 56 cP, about 57 cP, about 58 cP, about 59 cP, about 60 cP, about 61 cP, about 62 cP, about 63 cP, about 64 cP, about 65 cP, about 66 cP, about 67 cP, about 68 cP, about 69 cP, about 70 cP, about 71 cP, about 72 cP, about 73 cP, about 74 cP, about 75 cP, about 76 cP, about 77 cP, about 78 cP, about 79 cP, about 80 cP, about 81 cP, about 82 cP, about 83 cP, about 84 cP, about 85 cP, about 86 cP, about 87 cP, about 88 cP, about 89 cP, about 90 cP, about 91 cP, about 92 cP, about 93 cP, about 94 cP, about 95 cP, about 96 cP, about 97 cP, about 98 cP, about 99 cP, or about 100 cP). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 100 cP (e.g., about 1 cP, about 2 cP, about 3 cP, about 4 cP, about 5 cP, about 6 cP, about 7 cP, about 8 cP, about 9 cP, about 10 cP, about 11 cP, about 12 cP, about 13 cP, about 14 cP, about 15 cP, about 16 cP, about 17 cP, about 18 cP, about 19 cP, about 20 cP, about 21 cP, about 22 cP, about 23 cP, about 24 cP, about 25 cP, about 26 cP, about 27 cP, about 28 cP, about 29 cP, about 30 cP, about 31 cP, about 32 cP, about 33 cP, about 34 cP, about 35 cP, about 36 cP, about 37 cP, about 38 cP, about 39 cP, about 40 cP, about 41 cP, about 42 cP, about 43 cP, about 44 cP, about 45 cP, about 46 cP, about 47 cP, about 48 cP, about 49 cP, about 50 cP, about 51 cP, about 52 cP, about 53 cP, about 54 cP, about 55 cP, about 56 cP, about 57 cP, about 58 cP, about 59 cP, about 60 cP, about 61 cP, about 62 cP, about 63 cP, about 64 cP, about 65 cP, about 66 cP, about 67 cP, about 68 cP, about 69 cP, about 70 cP, about 71 cP, about 72 cP, about 73 cP, about 74 cP, about 75 cP, about 76 cP, about 77 cP, about 78 cP, about 79 cP, about 80 cP, about 81 cP, about 82 cP, about 83 cP, about 84 cP, about 85 cP, about 86 cP, about 87 cP, about 88 cP, about 89 cP, about 90 cP, about 91 cP, about 92 cP, about 93 cP, about 94 cP, about 95 cP, about 96 cP, about 97 cP, about 98 cP, about 99 cP, or about 100 cP). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a viscosity of about 1 cP to about 100 cP (e.g., about 1 cP, about 2 cP, about 3 cP, about 4 cP, about 5 cP, about 6 cP, about 7 cP, about 8 cP, about 9 cP, about 10 cP, about 11 cP, about 12 cP, about 13 cP, about 14 cP, about 15 cP, about 16 cP, about 17 cP, about 18 cP, about 19 cP, about 20 cP, about 21 cP, about 22 cP, about 23 cP, about 24 cP, about 25 cP, about 26 cP, about 27 cP, about 28 cP, about 29 cP, about 30 cP, about 31 cP, about 32 cP, about 33 cP, about 34 cP, about 35 cP, about 36 cP, about 37 cP, about 38 cP, about 39 cP, about 40 cP, about 41 cP, about 42 cP, about 43 cP, about 44 cP, about 45 cP, about 46 cP, about 47 cP, about 48 cP, about 49 cP, about 50 cP, about 51 cP, about 52 cP, about 53 cP, about 54 cP, about 55 cP, about 56 cP, about 57 cP, about 58 cP, about 59 cP, about 60 cP, about 61 cP, about 62 cP, about 63 cP, about 64 cP, about 65 cP, about 66 cP, about 67 cP, about 68 cP, about 69 cP, about 70 cP, about 71 cP, about 72 cP, about 73 cP, about 74 cP, about 75 cP, about 76 cP, about 77 cP, about 78 cP, about 79 cP, about 80 cP, about 81 cP, about 82 cP, about 83 cP, about 84 cP, about 85 cP, about 86 cP, about 87 cP, about 88 cP, about 89 cP, about 90 cP, about 91 cP, about 92 cP, about 93 cP, about 94 cP, about 95 cP, about 96 cP, about 97 cP, about 98 cP, about 99 cP, or about 100 cP).In some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a viscosity of about 100 cP to about 1500 cP (e.g., about 100 cP, about 110 cP, about 120 cP, about 130 cP, about 140 cP, about 150 cP, about 160 cP, about 170 cP, about 180 cP, about 190 cP, about 200 cP, about 210 cP, about 220 cP, about 230 cP, about 240 cP, about 250 cP, about 260 cP, about 270 cP, about 280 cP, about 290 cP, about 300 cP, about 310 cP, about 320 cP, about 330 cP, about 340 cP, about 350 cP, about 360 cP, about 370 cP, about 380 cP, about 390 cP, about 400 cP, about 410 cP, about 420 cP, about 430 cP, about 440 cP, about 450 cP, about 460 cP, about 470 cP, about 480 cP, about 490 cP, about 500 cP, about 510 cP, about 520 cP, about 530 cP, about 540 cP, about 550 cP, about 560 cP, about 570 cP, about 580 cP, about 590 cP, about 600 cP, about 610 cP, about 620 cP, about 630 cP, about 640 cP, about 650 cP, about 660 cP, about 670 cP, about 680 cP, about 690 cP, about 700 cP, about 710 cP, about 720 cP, about 730 cP, about 740 cP, about 750 cP, about 760 cP, about 770 cP, about 780 cP, about 790 cP, about 800 cP, about 810 cP, about 820 cP, about 830 cP, about 840 cP, about 850 cP, about 860 cP, about 870 cP, about 880 cP, about 890 cP, about 900 cP, about 910 cP, about 920 cP, about 930 cP, about 940 cP, about 950 cP, about 960 cP, about 970 cP, about 980 cP, about 990 cP, about 1000 cP, about 1010 cP, about 1020 cP, about 1030 cP, about 1040 cP, about 1050 cP, about 1060 cP, about 1070 cP, about 1080 cP, about 1090 cP, about 1100 cP, about 1110 cP, about 1120 cP, about 1130 cP, about 1140 cP, about 1150 cP, about 1160 cP, about 1170 cP, about 1180 cP, about 1190 cP, about 1200 cP, about 1210 cP, about 1220 cP, about 1230 cP, about 1240 cP, about 1250 cP, about 1260 cP, about 1270 cP, about 1280 cP, about 1290 cP, about 1300 cP, about 1310 cP, about 1320 cP, about 1330 cP, about 1340 cP, about 1350 cP, about 1360 cP, about 1370 cP, about 1380 cP, about 1390 cP, about 1400 cP, about 1410 cP, about 1420 cP, about 1430 cP, about 1440 cP, about 1450 cP, about 1460 cP, about 1470 cP, about 1480 cP, about 1490 cP, or about 1500 cP). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a viscosity of about 100 cP to about 1500 cP (e.g., about 100 cP, about 110 cP, about 120 cP, about 130 cP, about 140 cP, about 150 cP, about 160 cP, about 170 cP, about 180 cP, about 190 cP, about 200 cP, about 210 cP, about 220 cP, about 230 cP, about 240 cP, about 250 cP, about 260 cP, about 270 cP, about 280 cP, about 290 cP, about 300 cP, about 310 cP, about 320 cP, about 330 cP, about 340 cP, about 350 cP, about 360 cP, about 370 cP, about 380 cP, about 390 cP, about 400 cP, about 410 cP, about 420 cP, about 430 cP, about 440 cP, about 450 cP, about 460 cP, about 470 cP, about 480 cP, about 490 cP, about 500 cP, about 510 cP, about 520 cP, about 530 cP, about 540 cP, about 550 cP, about 560 cP, about 570 cP, about 580 cP, about 590 cP, about 600 cP, about 610 cP, about 620 cP, about 630 cP, about 640 cP, about 650 cP, about 660 cP, about 670 cP, about 680 cP, about 690 cP, about 700 cP, about 710 cP, about 720 cP, about 730 cP, about 740 cP, about 750 cP, about 760 cP, about 770 cP, about 780 cP, about 790 cP, about 800 cP, about 810 cP, about 820 cP, about 830 cP, about 840 cP, about 850 cP, about 860 cP, about 870 cP, about 880 cP, about 890 cP, about 900 cP, about 910 cP, about 920 cP, about 930 cP, about 940 cP, about 950 cP, about 960 cP, about 970 cP, about 980 cP, about 990 cP, about 1000 cP, about 1010 cP, about 1020 cP, about 1030 cP, about 1040 cP, about 1050 cP, about 1060 cP, about 1070 cP, about 1080 cP, about 1090 cP, about 1100 cP, about 1110 cP, about 1120 cP, about 1130 cP, about 1140 cP, about 1150 cP, about 1160 cP, about 1170 cP, about 1180 cP, about 1190 cP, about 1200 cP, about 1210 cP, about 1220 cP, about 1230 cP, about 1240 cP, about 1250 cP, about 1260 cP, about 1270 cP, about 1280 cP, about 1290 cP, about 1300 cP, about 1310 cP, about 1320 cP, about 1330 cP, about 1340 cP, about 1350 cP, about 1360 cP, about 1370 cP, about 1380 cP, about 1390 cP, about 1400 cP, about 1410 cP, about 1420 cP, about 1430 cP, about 1440 cP, about 1450 cP, about 1460 cP, about 1470 cP, about 1480 cP, about 1490 cP, or about 1500 cP). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a viscosity of about 100 cP to about 1500 cP (e.g., about 100 cP, about 110 cP, about 120 cP, about 130 cP, about 140 cP, about 150 cP, about 160 cP, about 170 cP, about 180 cP, about 190 cP, about 200 cP, about 210 cP, about 220 cP, about 230 cP, about 240 cP, about 250 cP, about 260 cP, about 270 cP, about 280 cP, about 290 cP, about 300 cP, about 310 cP, about 320 cP, about 330 cP, about 340 cP, about 350 cP, about 360 cP, about 370 cP, about 380 cP, about 390 cP, about 400 cP, about 410 cP, about 420 cP, about 430 cP, about 440 cP, about 450 cP, about 460 cP, about 470 cP, about 480 cP, about 490 cP, about 500 cP, about 510 cP, about 520 cP, about 530 cP, about 540 cP, about 550 cP, about 560 cP, about 570 cP, about 580 cP, about 590 cP, about 600 cP, about 610 cP, about 620 cP, about 630 cP, about 640 cP, about 650 cP, about 660 cP, about 670 cP, about 680 cP, about 690 cP, about 700 cP, about 710 cP, about 720 cP, about 730 cP, about 740 cP, about 750 cP, about 760 cP, about 770 cP, about 780 cP, about 790 cP, about 800 cP, about 810 cP, about 820 cP, about 830 cP, about 840 cP, about 850 cP, about 860 cP, about 870 cP, about 880 cP, about 890 cP, about 900 cP, about 910 cP, about 920 cP, about 930 cP, about 940 cP, about 950 cP, about 960 cP, about 970 cP, about 980 cP, about 990 cP, about 1000 cP, about 1010 cP, about 1020 cP, about 1030 cP, about 1040 cP, about 1050 cP, about 1060 cP, about 1070 cP, about 1080 cP, about 1090 cP, about 1100 cP, about 1110 cP, about 1120 cP, about 1130 cP, about 1140 cP, about 1150 cP, about 1160 cP, about 1170 cP, about 1180 cP, about 1190 cP, about 1200 cP, about 1210 cP, about 1220 cP, about 1230 cP, about 1240 cP, about 1250 cP, about 1260 cP, about 1270 cP, about 1280 cP, about 1290 cP, about 1300 cP, about 1310 cP, about 1320 cP, about 1330 cP, about 1340 cP, about 1350 cP, about 1360 cP, about 1370 cP, about 1380 cP, about 1390 cP, about 1400 cP, about 1410 cP, about 1420 cP, about 1430 cP, about 1440 cP, about 1450 cP, about 1460 cP, about 1470 cP, about 1480 cP, about 1490 cP, or about 1500 cP).Surface tensionIn some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a surface tension of less than about 75 mN / m (e.g., less than about 5 mN / m, less than about 10 mN / m, less than about 15 mN / m, less than about 20 mN / m, less than about 25 mN / m, less than about 30 mN / m, less than about 35 mN / m, less than about 40 mN / m, less than about 45 mN / m, less than about 50 mN / m, less than about 55 mN / m, less than about 60 mN / m, less than about 65 mN / m, less than about 70 mN / m, or less than about 75 mN / m). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a surface tension of less than about 75 mN / m (e.g., less than about 5 mN / m, less than about 10 mN / m, less than about 15 mN / m, less than about 20 mN / m, less than about 25 mN / m, less than about 30 mN / m, less than about 35 mN / m, less than about 40 mN / m, less than about 45 mN / m, less than about 50 mN / m, less than about 55 mN / m, less than about 60 mN / m, less than about 65 mN / m, less than about 70 mN / m, or less than about 75 mN / m). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a surface tension of less than about 75 mN / m (e.g., less than about 5 mN / m, less than about 10 mN / m, less than about 15 mN / m, less than about 20 mN / m, less than about 25 mN / m, less than about 30 mN / m, less than about 35 mN / m, less than about 40 mN / m, less than about 45 mN / m, less than about 50 mN / m, less than about 55 mN / m, less than about 60 mN / m, less than about 65 mN / m, less than about 70 mN / m, or less than about 75 mN / m).In some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a surface tension of about 1 mN / m to about 75 mN / m (e.g., about 1 mN / m, about 2 mN / m, about 3 mN / m, about 4 mN / m, about 5 mN / m, about 6 mN / m, about 7 mN / m, about 8 mN / m, about 9 mN / m, about 10 mN / m, about 11 mN / m, about 12 mN / m, about 13 mN / m, about 14 mN / m, about 15 mN / m, about 16 mN / m, about 17 mN / m, about 18 mN / m, about 19 mN / m, about 20 mN / m, about 21 mN / m, about 22 mN / m, about 23 mN / m, about 24 mN / m, about 25 mN / m, about 26 mN / m, about 27 mN / m, about 28 mN / m, about 29 mN / m, about 30 mN / m, about 31 mN / m, about 32 mN / m, about 33 mN / m, about 34 mN / m, about 35 mN / m, about 36 mN / m, about 37 mN / m, about 38 mN / m, about 39 mN / m, about 40 mN / m, about 41 mN / m, about 42 mN / m, about 43 mN / m, about 44 mN / m, about 45 mN / m, about 46 mN / m, about 47 mN / m, about 48 mN / m, about 49 mN / m, about 50 mN / m, about 51 mN / m, about 52 mN / m, about 53 mN / m, about 54 mN / m, about 55 mN / m, about 56 mN / m, about 57 mN / m, about 58 mN / m, about 59 mN / m, about 60 mN / m, about 61 mN / m, about 62 mN / m, about 63 mN / m, about 64 mN / m, about 65 mN / m, about 66 mN / m, about 67 mN / m, about 68 mN / m, about 69 mN / m, about 70 mN / m, about 71 mN / m, about 72 mN / m, about 73 mN / m, about 74 mN / m, or about 75 mN / m). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a surface tension of about 1 mN / m to about 75 mN / m (e.g., about 1 mN / m, about 2 mN / m, about 3 mN / m, about 4 mN / m, about 5 mN / m, about 6 mN / m, about 7 mN / m, about 8 mN / m, about 9 mN / m, about 10 mN / m, about 11 mN / m, about 12 mN / m, about 13 mN / m, about 14 mN / m, about 15 mN / m, about 16 mN / m, about 17 mN / m, about 18 mN / m, about 19 mN / m, about 20 mN / m, about 21 mN / m, about 22 mN / m, about 23 mN / m, about 24 mN / m, about 25 mN / m, about 26 mN / m, about 27 mN / m, about 28 mN / m, about 29 mN / m, about 30 mN / m, about 31 mN / m, about 32 mN / m, about 33 mN / m, about 34 mN / m, about 35 mN / m, about 36 mN / m, about 37 mN / m, about 38 mN / m, about 39 mN / m, about 40 mN / m, about 41 mN / m, about 42 mN / m, about 43 mN / m, about 44 mN / m, about 45 mN / m, about 46 mN / m, about 47 mN / m, about 48 mN / m, about 49 mN / m, about 50 mN / m, about 51 mN / m, about 52 mN / m, about 53 mN / m, about 54 mN / m, about 55 mN / m, about 56 mN / m, about 57 mN / m, about 58 mN / m, about 59 mN / m, about 60 mN / m, about 61 mN / m, about 62 mN / m, about 63 mN / m, about 64 mN / m, about 65 mN / m, about 66 mN / m, about 67 mN / m, about 68 mN / m, about 69 mN / m, about 70 mN / m, about 71 mN / m, about 72 mN / m, about 73 mN / m, about 74 mN / m, or about 75 mN / m). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a surface tension of about 1 mN / m to about 75 mN / m (e.g., about 1 mN / m, about 2 mN / m, about 3 mN / m, about 4 mN / m, about 5 mN / m, about 6 mN / m, about 7 mN / m, about 8 mN / m, about 9 mN / m, about 10 mN / m, about 11 mN / m, about 12 mN / m, about 13 mN / m, about 14 mN / m, about 15 mN / m, about 16 mN / m, about 17 mN / m, about 18 mN / m, about 19 mN / m, about 20 mN / m, about 21 mN / m, about 22 mN / m, about 23 mN / m, about 24 mN / m, about 25 mN / m, about 26 mN / m, about 27 mN / m, about 28 mN / m, about 29 mN / m, about 30 mN / m, about 31 mN / m, about 32 mN / m, about 33 mN / m, about 34 mN / m, about 35 mN / m, about 36 mN / m, about 37 mN / m, about 38 mN / m, about 39 mN / m, about 40 mN / m, about 41 mN / m, about 42 mN / m, about 43 mN / m, about 44 mN / m, about 45 mN / m, about 46 mN / m, about 47 mN / m, about 48 mN / m, about 49 mN / m, about 50 mN / m, about 51 mN / m, about 52 mN / m, about 53 mN / m, about 54 mN / m, about 55 mN / m, about 56 mN / m, about 57 mN / m, about 58 mN / m, about 59 mN / m, about 60 mN / m, about 61 mN / m, about 62 mN / m, about 63 mN / m, about 64 mN / m, about 65 mN / m, about 66 mN / m, about 67 mN / m, about 68 mN / m, about 69 mN / m, about 70 mN / m, about 71 mN / m, about 72 mN / m, about 73 mN / m, about 74 mN / m, or about 75 mN / m).DensityIn some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a density of about 0.5 g / mL to about 1.5 g / mL (e.g., about 0.5 g / mL, about 0.55 g / mL, about 0.6 g / mL, about 0.65 g / mL, about 0.7 g / mL, about 0.75 g / mL, about 0.8 g / mL, about 0.85 g / mL, about 0.9 g / mL, about 0.95 g / mL, about 1 g / mL, about 1.05 g / mL, about 1.1 g / mL, about 1.15 g / mL, about 1.2 g / mL, about 1.25 g / mL, about 1.3 g / mL, about 1.35 g / mL, about 1.4 g / mL, about 1.45 g / mL, or about 1.5 g / mL). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a density of about 0.5 g / mL to about 1.5 g / mL (e.g., about 0.5 g / mL, about 0.55 g / mL, about 0.6 g / mL, about 0.65 g / mL, about 0.7 g / mL, about 0.75 g / mL, about 0.8 g / mL, about 0.85 g / mL, about 0.9 g / mL, about 0.95 g / mL, about 1 g / mL, about 1.05 g / mL, about 1.1 g / mL, about 1.15 g / mL, about 1.2 g / mL, about 1.25 g / mL, about 1.3 g / mL, about 1.35 g / mL, about 1.4 g / mL, about 1.45 g / mL, or about 1.5 g / mL). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a density of about 0.5 g / mL to about 1.5 g / mL (e.g., about 0.5 g / mL, about 0.55 g / mL, about 0.6 g / mL, about 0.65 g / mL, about 0.7 g / mL, about 0.75 g / mL, about 0.8 g / mL, about 0.85 g / mL, about 0.9 g / mL, about 0.95 g / mL, about 1 g / mL, about 1.05 g / mL, about 1.1 g / mL, about 1.15 g / mL, about 1.2 g / mL, about 1.25 g / mL, about 1.3 g / mL, about 1.35 g / mL, about 1.4 g / mL, about 1.45 g / mL, or about 1.5 g / mL).In some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a density of about 1 g / mL to about 1.1 g / mL (e.g., about 1 g / mL, about 1.01 g / mL, about 1.02 g / mL, about 1.03 g / mL, about 1.04 g / mL, about 1.05 g / mL, about 1.06 g / mL, about 1.07 g / mL, about 1.08 g / mL, about 1.09 g / mL, or about 1.1 g / mL). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a density of about 1 g / mL to about 1.1 g / mL (e.g., about 1 g / mL, about 1.01 g / mL, about 1.02 g / mL, about 1.03 g / mL, about 1.04 g / mL, about 1.05 g / mL, about 1.06 g / mL, about 1.07 g / mL, about 1.08 g / mL, about 1.09 g / mL, or about 1.1 g / mL). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a density of about 1 g / mL to about 1.1 g / mL (e.g., about 1 g / mL, about 1.01 g / mL, about 1.02 g / mL, about 1.03 g / mL, about 1.04 g / mL, about 1.05 g / mL, about 1.06 g / mL, about 1.07 g / mL, about 1.08 g / mL, about 1.09 g / mL, or about 1.1 g / mL).Solids contentIn some embodiments, in the context of manufacturing a microneedle and / or a microarray patch (MAP), a dispensable formulation (e.g., a tip formulation and / or a base formulation), comprising at least one selected from the group consisting of an active pharmaceutical ingredient (API), a water-soluble excipient, and combinations thereof, can be characterized by a solid content of about 1% to about 75% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, or about 75%). In some embodiments, a dispensable tip formulation, e.g., comprising an API and a water-soluble excipient, can be characterized by a solid content of about 1% to about 75% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, or about 75%). In some embodiments, a dispensable base formulation, e.g., comprising a water-soluble excipient, can be characterized by a solid content of about 1% to about 75% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, or about 75%). Microneedles and Microarray Patches (MAPs)According to one aspect, the disclosure provides a microneedle and / or a microarray patch (MAP), e.g., comprising an active pharmaceutical ingredient (API) and a water soluble excipient. In one aspect, the disclosure provides a microneedle, comprising an active pharmaceutical ingredient (API) and a water soluble excipient. In one aspect, the disclosure provides a microarray patch (MAP), comprising an active pharmaceutical ingredient (API) and a water soluble excipient. In some embodiments, the microneedles and / or microarray patches (MAPs), e.g., comprising an active pharmaceutical ingredient (API) and a water soluble excipient, can be configured and utilized to provide consistent dosing, extended shelf stability, therapeutically relevant dosing, and / or therapeutically relevant bioavailability. Such microneedles and / or microarray patches (MAPs) may demonstrate bioequivalence to a commercially approved formulation of the API and / or a reference drug. In some embodiments, the microneedles and / or microarray patches (MAPs), e.g., comprising an active pharmaceutical ingredient (API) and a water soluble excipient, can be configured and utilized to provide bioequivalent pharmacokinetics to delivery of a similar dose of the API and / or a reference drug using a different dosage form and / or a different route of administration. In some embodiments, the microneedles and / or microarray patches (MAPs) can provide bioequivalent pharmacokinetics to a commercially approved formulation of the API and / or a reference drug. In some embodiments, the microneedles and / or microarray patches (MAPs) can provide bioequivalent pharmacokinetics to delivery via other routes of administration (e.g., via parenteral, subcutaneous, intravenous, intramuscular, and / or oral administration) of a similar dose of the API and / or a reference drug.As used interchangeably herein, the terms “microneedle” and “microprojection” refer to a three-dimensional (3D) microstructure, such as a micron-sized needle or needle-like structure, that can be configured to penetrate or cut through a biological barrier, a tissue, and / or a cell. Microneedles can be configured and utilized for various applications, including, e.g., biomedical applications, such as drug delivery, biosensing, biomolecular and cellular sampling, disease diagnosis, disease mitigation, disease treatment, disease prevention, and / or health monitoring; and cosmetic applications, such as nutrient and / or cosmeceutical delivery. In particular embodiments, the microneedles described herein can comprise a consolidated microneedle tip and a microneedle base.As used interchangeably herein, the terms “microarray patch (MAP)” and “microneedle array patch (MAP)” refer to a device comprising a plurality of microneedles arranged in a random or predefined two-dimensional or three-dimensional configuration, such as an array. In some embodiments, the configuration of the microneedles can be regular or irregular according to a repeating geometric pattern. Suitable geometric patterns include, e.g., hexagonal grids, square grids, triangular grids, and staggered arrays. In some embodiments, the microarray patch (MAP) comprises a plurality of microneedles arranged in a hexagonal grid. In some embodiments, the microarray patch (MAP) comprises a plurality of microneedles arranged in a square grid. In some embodiments, the microarray patch (MAP) comprises a plurality of microneedles arranged in a triangular grid. In some embodiments, the microarray patch (MAP) comprises a plurality of microneedles arranged in a staggered array. In some embodiments, a staggered array can be used, for example, to achieve different penetration depths by varying the needle lengths within the array. In some embodiments, the microarray patch (MAP) comprises a plurality of microneedles comprising one or more active pharmaceutical ingredients (APIs).Conventional microneedles can be characterized by a limited dosing capacity, given that the microneedles’ size can restrict the total amount of an active pharmaceutical ingredient (API) that they can carry. Conventional microneedles can also be characterized by inconsistent pharmacokinetics, due in part to factors related to the architecture of human skin which can impede microneedle insertion, leading to inconsistent delivery of an active pharmaceutical ingredient (API). The architecture of human skin can have clinical relevance, because specific features of human skin can affect how the skin responds to external stimuli, such as the insertion of microneedles. Specific features of the skin, e.g., thickness of the stratum corneum, spread or expansion of the subcutaneous adipose layer, and density of skin appendages, such as hair follicles, sweat, and sebaceous glands, can also vary at different body sites. Ensuring reproducible insertion of microneedles into the skin of a subject can also be challenging because individual microneedles in a microarray patch (MAP) can exhibit, e.g., different insertion behaviors, such as deformation, based on their specific position within the microarray, leading to inconsistent delivery of an active pharmaceutical ingredient (API). Without wishing to be bound by theory, the insertion behavior of microneedles, e.g., in a microarray patch (MAP), is based, at least in part, upon the mechanical properties of the skin, microneedle material, the microarray geometry, and the distribution of the microneedles in the microarray. As disclosed herein, Applicant has surprisingly discovered specific combinations of water-soluble excipients that can, for example, effectively (1) enhance the stability of a high concentration of active pharmaceutical ingredients (API) for delivery of an effective dose of the API using a microneedle and / or a microarray patch (MAP) described herein; (2) enhance the fluid properties of a composition, such as a dispensable formulation, for manufacturing a microneedle and / or a microarray patch (MAP) described herein using, e.g., a liquid dispensing system; (3) enhance the consolidation of the API into the apex of a microneedle tip (e.g., a consolidated microneedle tip) during manufacturing; (4) enhance the strength of the microneedle, e.g., to resist deformation during deployment; and / or (5) minimize, or eliminate, manufacturing defects, such as shell formation and microneedle tip dislodgement, that can negatively affect microneedle morphology, strength, deployment efficiency, API delivery consistency, and pharmacodynamics.In some embodiments, the microarray patch (MAP) comprises a backing. In some embodiments, the microarray patch (MAP) comprises about 10 to about 10000 microneedles (e.g., about 10, about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5450, 5500, 5550, 5600, 5650, 5700, 5750, 5800, 5850, 5900, 5950, 6000, 6050, 6100, 6150, 6200, 6250, 6300, 6350, 6400, 6450, 6500, 6550, 6600, 6650, 6700, 6750, 6800, 6850, 6900, 6950, 7000, 7050, 7100, 7150, 7200, 7250, 7300, 7350, 7400, 7450, 7500, 7550, 7600, 7650, 7700, 7750, 7800, 7850, 7900, 7950, 8000, 8050, 8100, 8150, 8200, 8250, 8300, 8350, 8400, 8450, 8500, 8550, 8600, 8650, 8700, 8750, 8800, 8850, 8900, 8950, 9000, 9050, 9100, 9150, 9200, 9250, 9300, 9350, 9400, 9450, 9500, 9550, 9600, 9650, 9700, 9750, 9800, 9850, 9900, 9950, or 10000 microneedles). In some embodiments, the microarray patch (MAP) comprises about 10 to about 9000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 8000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 7000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 6000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 5000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 4000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 3000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 2000 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 1000 microneedles (e.g., about 10, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 microneedles). In some embodiments, the microarray patch (MAP) comprises about 10 to about 500 microneedles (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, or 500 microneedles). In some embodiments, the microarray patch (MAP) comprises about 10 to about 400 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 300 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 200 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 100 microneedles. In some embodiments, the microarray patch (MAP) comprises about 10 to about 50 microneedles. The number of microneedles in the microarray patch (MAP) can also be referred to as the “array size.” As used herein, the term “backing” refers to a material that is suitable for attaching to a component of a microneedle. In some embodiments, a backing material is suitable for attaching to the base of a microneedle described herein. Exemplary backing materials that can be used in the fabrication of a microneedle and / or a MAP described herein include, but are not limited to, a solid support, e.g., a paper-based material, a plastic material, a polymeric material, or a polyester-based material (e.g., a Whatman 903 paper, a polymeric tape, a plastic tape, an adhesive-backed polyester tape, or other medical tape). In some embodiments, the backing comprises a Whatman 903 paper. In some embodiments, the backing comprises a polyester tape. In some embodiments, the polyester tape comprises an adhesive-backed polyester tape. In some embodiments, the backing material may be coated (e.g., at least on one side) with an adhesive suitable for bonding to and / or adhering to the microneedle base described herein. In some embodiments, a backing can be attached to the microneedle by an adhesive, such as an adhesive compatible with the active pharmaceutical ingredients (API). The term “compatible with the active pharmaceutical ingredients (API)” means an adhesive that may be in contact with the microneedle and / or the microarray patch (MAP) for an extended period of time without significantly damaging and / or degrading the active pharmaceutical ingredient (API). The backing may include an adhesive to improve contact with the skin.The backing materials used in the microneedles of the invention may have various properties, including, but not limited to, the ability to bond and / or adhere to the dissolving base layer to permit demolding. A backing material must be strong enough for the backing to maintain patch integrity, e.g., if the dissolving base layer has cracks or discontinuities. The backing material may be sufficiently flexible so as to conform, for example, to a non-flat surface, such as a skin surface. In particular, the backing must be flexible enough during wear time, such as after the patch is applied (e.g., pressed into) the skin. The backing may comprise and / or consist of a non-dissolving material, such that the backing maintains its integrity after patch application to a skin surface and during patch removal from a skin surface. The backing may have any suitable dimension, e.g., to accommodate the microneedle array, and / or to better suit the intended site of application. Microneedles can be made from a variety of materials, which can affect the microneedle's biocompatibility, mechanical properties, and other characteristics. Microneedles can be classified based on fabrication process, shapes, types, active pharmaceutical ingredients (API) delivery approaches, and materials. Microneedles can be formed to have a variety of different geometric shapes, for example, cylinder, cone, pyramid, tapered, spear, spherical pedestal, candle-like, bullet shaped, spike, lancet, domed, beveled, and the like. Based on the types and API delivery approach, microneedles can be classified, for example, as solid microneedles, hollow microneedles, coated microneedles, dissolvable / dissolving microneedles, and hydrogel-forming microneedles. In some embodiments, solid microneedles can be configured to be inserted into the skin to generate pores that enable active pharmaceutical ingredients (API) to be released into the body, e.g., by diffusion. In some embodiments, coated microneedles can include solid microneedles coated with active pharmaceutical ingredients (API). In some embodiments, the coating of active pharmaceutical ingredients (API) can be applied by a film coating process, e.g., spraying. In some embodiments, hollow microneedles can be configured to have a hollow path for carrying and delivering active pharmaceutical ingredients (API). In some embodiments, dissolving microneedles can be configured to dissolved over a predetermined period of time once inserted into the skin.In some embodiments, the active pharmaceutical ingredients (API) release profile of the microneedles can be configured based on the type of microneedles and / or the microneedle materials. In some embodiments, the microneedles can be configured to release a predefined amount of an active pharmaceutical ingredients (API) (e.g., about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the API) in a predefined period of time (e.g., about 5 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, or about 60 seconds; or about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes; or about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours; or about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days; or about 1 week, about 2 weeks, about 3 weeks, about 4 weeks; or about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months; or about 1 year, about 2 years, about 3 years, about 4 years, or about 5 years or more). In some embodiments, the microneedles can be configured to release a predefined amount of active pharmaceutical ingredients (API) in a predefined period of time though a dissolution-diffusion mechanism. In some embodiments, the microneedles can be configured to release a predefined amount of active pharmaceutical ingredients (API) though an immediate-release mechanism. In some embodiments, the microneedles can be configured to release a predefined amount of active pharmaceutical ingredients (API) in a predefined period of time though a modified-release mechanism. Exemplary modified release mechanisms can include, e.g., controlled-release, sustained-release, and / or long-acting API products and / or microneedle formulations. The distinct characteristic of each type of microneedle can allow a variety of clinical applications, including diagnosis and treatment.The microneedles described herein can be used for intradermal and / or transdermal delivery of an active pharmaceutical ingredient (API). In particular, the microneedles can be configured to penetrate the surface of the skin (i.e., the stratum corneum) of a subject, so as to allow an API to reach a deeper layer of the skin, such as the underlying epidermis layer, or epidermis and dermis layers, rich in blood vessels and lymphatics for localized and / or systemic absorption. As such, the microneedles, microarray patches (MAPs), and systems described herein can provide precise and consistent delivery of an API, including both small and large molecules, and can facilitate both localized and / or systemic therapeutic effects. The microneedles and microarray patches (MAPs) described herein can be configured to have different structural and functional characteristics depending on their application. In some embodiments, the microneedle and / or the microarray patch (MAP) can be configured to have any dimension and / or geometry to enable the deployment of a microneedle tip (e.g., a consolidated microneedle tip) at a depth of at least about 100 µm to about 1000 µm (e.g., about 100 µm, about 125 µm, about 150 µm, about 175 µm, about 200 µm, about 225 µm, about 250 µm, about 275 µm, about 300 µm, about 325 µm, about 350 µm, about 375 µm, about 400 µm, about 425 µm, about 450 µm, about 475 µm, about 500 µm, about 525 µm, about 550 µm, about 575 µm, about 600 µm, about 625 µm, about 650 µm, about 675 µm, about 700 µm, about 725 µm, about 750 µm, about 775 µm, about 800 µm, about 825 µm, about 850 µm, about 875 µm, about 900 µm, about 925 µm, about 950 µm, about 975 µm, or about 1000 µm) below the surface of the skin of a subject for release of an active pharmaceutical ingredient (API). In some embodiments, the specific dimensions and geometries of the microneedle and / or the microarray patch (MAP) can be expressed as an average value. In some embodiments, the specific dimensions and geometries of the microneedle and / or the microarray patch (MAP) can be expressed as a mean value.In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a pre-deployment needle height (or “needle height”), an air gap, a post-deployment needle height, a deployed tip depth, and / or a height delivered.As used herein, the terms “pre-deployment needle height,” “primary needle height,” “microneedle height,” and “needle height” interchangeably refer to the full height of undeployed microneedles. In some embodiments, the “primary needle height” may be calculated using the formula: Primary Needle Height = Consolidated Microneedle Tip Length + Base Length. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a pre-deployment needle height (or “needle height”) of about 25 µm to about 3000 µm (e.g., about 25 µm, about 50 µm, about 75 µm, about 100 µm, about 125 µm, about 150 µm, about 175 µm, about 200 µm, about 225 µm, about 250 µm, about 275 µm, about 300 µm, about 325 µm, about 350 µm, about 375 µm, about 400 µm, about 425 µm, about 450 µm, about 475 µm, about 500 µm, about 525 µm, about 550 µm, about 575 µm, about 600 µm, about 625 µm, about 650 µm, about 675 µm, about 700 µm, about 725 µm, about 750 µm, about 775 µm, about 800 µm, about 825 µm, about 850 µm, about 875 µm, about 900 µm, about 925 µm, about 950 µm, about 975 µm, about 1000 µm, about 1025 µm, about 1050 µm, about 1075 µm, about 1100 µm, about 1125 µm, about 1150 µm, about 1175 µm, about 1200 µm, about 1225 µm, about 1250 µm, about 1275 µm, about 1300 µm, about 1325 µm, about 1350 µm, about 1375 µm, about 1400 µm, about 1425 µm, about 1450 µm, about 1475 µm, about 1500 µm, about 1525 µm, about 1550 µm, about 1575 µm, about 1600 µm, about 1625 µm, about 1650 µm, about 1675 µm, about 1700 µm, about 1725 µm, about 1750 µm, about 1775 µm, about 1800 µm, about 1825 µm, about 1850 µm, about 1875 µm, about 1900 µm, about 1925 µm, about 1950 µm, about 1975 µm, about 2000 µm, about 2025 µm, about 2050 µm, about 2075 µm, about 2100 µm, about 2125 µm, about 2150 µm, about 2175 µm, about 2200 µm, about 2225 µm, about 2250 µm, about 2275 µm, about 2300 µm, about 2325 µm, about 2350 µm, about 2375 µm, about 2400 µm, about 2425 µm, about 2450 µm, about 2475 µm, about 2500 µm, about 2525 µm, about 2550 µm, about 2575 µm, about 2600 µm, about 2625 µm, about 2650 µm, about 2675 µm, about 2700 µm, about 2725 µm, about 2750 µm, about 2775 µm, about 2800 µm, about 2825 µm, about 2850 µm, about 2875 µm, about 2900 µm, about 2925 µm, about 2950 µm, about 2975 µm, or about 3000 µm). In some embodiments, the needle height can be measured from the apex of the consolidated microneedle tip to the bottom of the microneedle base. In some embodiments, at least about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the microneedle height can be inserted into the skin of a subject upon deployment.As used herein, the term “air gap” refers to the space between the bottom of the adhesive of the MAP backing and the skin surface, measured while the MAP is deployed. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by an air gap of about 100 µm to about 600 µm (e.g., about 100 µm, about 105 µm, about 110 µm, about 115 µm, about 120 µm, about 125 µm, about 130 µm, about 135 µm, about 140 µm, about 145 µm, about 150 µm, about 155 µm, about 160 µm, about 165 µm, about 170 µm, about 175 µm, about 180 µm, about 185 µm, about 190 µm, about 195 µm, about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, or about 600 µm).As used herein, the term “post-deployment needle height” or “residual needle height” refers to the height of needles after the MAP has been removed from tissue following deployment. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a post-deployment needle height of about 0 µm to about 600 µm (e.g., about 0 µm, about 1 µm, about 5 µm, about 10 µm, about 15 µm, about 20 µm, about 25 µm, about 30 µm, about 35 µm, about 40 µm, about 45 µm, about 50 µm, about 55 µm, about 60 µm, about 65 µm, about 70 µm, about 75 µm, about 80 µm, about 85 µm, about 90 µm, about 95 µm, about 100 µm, about 105 µm, about 110 µm, about 115 µm, about 120 µm, about 125 µm, about 130 µm, about 135 µm, about 140 µm, about 145 µm, about 150 µm, about 155 µm, about 160 µm, about 165 µm, about 170 µm, about 175 µm, about 180 µm, about 185 µm, about 190 µm, about 195 µm, about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, or about 600 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a post-deployment needle height of less than about 600 µm (e.g., less than about 25 µm, less than about 50 µm, less than about 75 µm, less than about 100 µm, less than about 125 µm, less than about 150 µm, less than about 175 µm, less than about 200 µm, less than about 225 µm, less than about 250 µm, less than about 275 µm, less than about 300 µm, less than about 325 µm, less than about 350 µm, less than about 375 µm, less than about 400 µm, less than about 425 µm, less than about 450 µm, less than about 475 µm, less than about 500 µm, less than about 525 µm, less than about 550 µm, less than about 575 µm, or less than about 600 µm).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a percentage of needle height lost of about 30% to about 60% (e.g., about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60%).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a percentage of undeployed API not delivered which is measured following MAP deployment by dissolving the MAP in vitro and measuring residual API by RP-HPLC (or other) API specific assay (e.g., average % Post Deployment-In Vitro Release (PD-IVR), e.g., by RP-HPLC) of about 1% to about 50% (e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a dose delivered per needle (or dispense volume loaded into each needle) of about 0.1 nL to about 10 nL (e.g., about 0.1 nL, about 0.2 nL, about 0.3 nL, about 0.4 nL, about 0.5 nL, about 0.6 nL, about 0.7 nL, about 0.8 nL, about 0.9 nL, about 1 nL, about 1.1 nL, about 1.2 nL, about 1.3 nL, about 1.4 nL, about 1.5 nL, about 1.6 nL, about 1.7 nL, about 1.8 nL, about 1.9 nL, about 2 nL, about 2.1 nL, about 2.2 nL, about 2.3 nL, about 2.4 nL, about 2.5 nL, about 2.6 nL, about 2.7 nL, about 2.8 nL, about 2.9 nL, about 3 nL, about 3.1 nL, about 3.2 nL, about 3.3 nL, about 3.4 nL, about 3.5 nL, about 3.6 nL, about 3.7 nL, about 3.8 nL, about 3.9 nL, about 4 nL, about 4.1 nL, about 4.2 nL, about 4.3 nL, about 4.4 nL, about 4.5 nL, about 4.6 nL, about 4.7 nL, about 4.8 nL, about 4.9 nL, about 5 nL, about 5.1 nL, about 5.2 nL, about 5.3 nL, about 5.4 nL, about 5.5 nL, about 5.6 nL, about 5.7 nL, about 5.8 nL, about 5.9 nL, about 6 nL, about 6.1 nL, about 6.2 nL, about 6.3 nL, about 6.4 nL, about 6.5 nL, about 6.6 nL, about 6.7 nL, about 6.8 nL, about 6.9 nL, about 7 nL, about 7.1 nL, about 7.2 nL, about 7.3 nL, about 7.4 nL, about 7.5 nL, about 7.6 nL, about 7.7 nL, about 7.8 nL, about 7.9 nL, about 8 nL, about 8.1 nL, about 8.2 nL, about 8.3 nL, about 8.4 nL, about 8.5 nL, about 8.6 nL, about 8.7 nL, about 8.8 nL, about 8.9 nL, about 9 nL, about 9.1 nL, about 9.2 nL, about 9.3 nL, about 9.4 nL, about 9.5 nL, about 9.6 nL, about 9.7 nL, about 9.8 nL, about 9.9 nL, or about 10 nL) of an active pharmaceutical ingredient (API), e.g., described herein.As used herein, the terms “deployed tip depth,” “deployment depth,” and “penetration depth” interchangeably refer to the length between the skin surface and the apex of a deployed tip, such as a tip deployed into the skin of a subject, measured post-deployment after the MAP is removed. In some embodiments, the “penetration depth” may be calculated using the formula: Penetration Depth = Primary Needle Height - Air Gap. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a deployed tip depth of about at least about 250 µm, e.g., about 250 µm to about 1000 µm (e.g., about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, about 600 µm, about 605 µm, about 610 µm, about 615 µm, about 620 µm, about 625 µm, about 630 µm, about 635 µm, about 640 µm, about 645 µm, about 650 µm, about 655 µm, about 660 µm, about 665 µm, about 670 µm, about 675 µm, about 680 µm, about 685 µm, about 690 µm, about 695 µm, about 700 µm, about 705 µm, about 710 µm, about 715 µm, about 720 µm, about 725 µm, about 730 µm, about 735 µm, about 740 µm, about 745 µm, about 750 µm, about 755 µm, about 760 µm, about 765 µm, about 770 µm, about 775 µm, about 780 µm, about 785 µm, about 790 µm, about 795 µm, about 800 µm, about 805 µm, about 810 µm, about 815 µm, about 820 µm, about 825 µm, about 830 µm, about 835 µm, about 840 µm, about 845 µm, about 850 µm, about 855 µm, about 860 µm, about 865 µm, about 870 µm, about 875 µm, about 880 µm, about 885 µm, about 890 µm, about 895 µm, about 900 µm, about 905 µm, about 910 µm, about 915 µm, about 920 µm, about 925 µm, about 930 µm, about 935 µm, about 940 µm, about 945 µm, about 950 µm, about 955 µm, about 960 µm, about 965 µm, about 970 µm, about 975 µm, about 980 µm, about 985 µm, about 990 µm, about 995 µm, or about 1000 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a deployed tip depth of about 250 µm to about 600 µm. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a deployed tip depth of about 250 µm to about 500 µm. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a deployed tip depth of about 300 µm to about 400 µm.As used herein, the term “height delivered” refers to the difference between the pre-deployment needle height and post-deployment needle height measurements, representing the length of the needle that has been deployed and left behind. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a height delivered of about 50 µm to about 1000 µm (e.g., about 50 µm, about 75 µm, about 100 µm, about 125 µm, about 150 µm, about 175 µm, about 200 µm, about 225 µm, about 250 µm, about 275 µm, about 300 µm, about 325 µm, about 350 µm, about 375 µm, about 400 µm, about 425 µm, about 450 µm, about 475 µm, about 500 µm, about 525 µm, about 550 µm, about 575 µm, about 600 µm, about 625 µm, about 650 µm, about 675 µm, about 700 µm, about 725 µm, about 750 µm, about 775 µm, about 800 µm, about 825 µm, about 850 µm, about 875 µm, about 900 µm, about 925 µm, about 950 µm, about 975 µm, or about 1000 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a height delivered of about 50 µm to about 600 µm (e.g., about 50 µm, about 55 µm, about 60 µm, about 65 µm, about 70 µm, about 75 µm, about 80 µm, about 85 µm, about 90 µm, about 95 µm, about 100 µm, about 105 µm, about 110 µm, about 115 µm, about 120 µm, about 125 µm, about 130 µm, about 135 µm, about 140 µm, about 145 µm, about 150 µm, about 155 µm, about 160 µm, about 165 µm, about 170 µm, about 175 µm, about 180 µm, about 185 µm, about 190 µm, about 195 µm, about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, or about 600 µm).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a microneedle dimension comprising a width of about 1 µm to about 650 µm (e.g., about 1 µm, about 2 µm, about 3 µm, about 4 µm, about 5 µm, about 6 µm, about 7 µm, about 8 µm, about 9 µm, about 10 µm, about 15 µm, about 25 µm, about 30 µm, about 35 µm, about 40 µm, about 45 µm, about 50 µm, about 55 µm, about 60 µm, about 65 µm, about 70 µm, about 75 µm, about 80 µm, about 85 µm, about 90 µm, about 95 µm, about 100 µm, about 105 µm, about 110 µm, about 115 µm, about 120 µm, about 125 µm, about 130 µm, about 135 µm, about 140 µm, about 145 µm, about 150 µm, about 155 µm, about 160 µm, about 165 µm, about 170 µm, about 175 µm, about 180 µm, about 185 µm, about 190 µm, about 195 µm, about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, about 600 µm, about 605 µm, about 610 µm, about 615 µm, about 620 µm, about 625 µm, about 630 µm, about 635 µm, about 640 µm, about 645 µm, or about 650 µm). The width may be measured at any point along the length of the microneedle. In some embodiments, the width can be measured across the base of the microneedle. In some embodiments, the width can be measured across the consolidated tip of the microneedle.Width of the array is related to needle spacing and number of needles. Tested array widths range from about 3 mm to about 29 mm wide. In some embodiments, the width of an array can be about 2 mm to about 200 mm (e.g., about 5 mm, about 10 mm, about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, about 50 mm, about 55 mm, about 60 mm, about 65 mm, about 70 mm, about 75 mm, about 80 mm, about 85 mm, about 90 mm, about 95 mm, about 100 mm, about 105 mm, about 110 mm, about 115 mm, about 120 mm, about 125 mm, about 130 mm, about 135 mm, about 140 mm, about 145 mm, about 150 mm, about 155 mm, about 160 mm, about 165 mm, about 170 mm, about 175 mm, about 180 mm, about 185 mm, about 190 mm, about 195 mm, or about 200 mm).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by spacing between the microneedles of about 25 µm to about 3000 µm (e.g., about 25 µm, about 50 µm, about 75 µm, about 100 µm, about 125 µm, about 150 µm, about 175 µm, about 200 µm, about 225 µm, about 250 µm, about 275 µm, about 300 µm, about 325 µm, about 350 µm, about 375 µm, about 400 µm, about 425 µm, about 450 µm, about 475 µm, about 500 µm, about 525 µm, about 550 µm, about 575 µm, about 600 µm, about 625 µm, about 650 µm, about 675 µm, about 700 µm, about 725 µm, about 750 µm, about 775 µm, about 800 µm, about 825 µm, about 850 µm, about 875 µm, about 900 µm, about 925 µm, about 950 µm, about 975 µm, about 1000 µm, about 1025 µm, about 1050 µm, about 1075 µm, about 1100 µm, about 1125 µm, about 1150 µm, about 1175 µm, about 1200 µm, about 1225 µm, about 1250 µm, about 1275 µm, about 1300 µm, about 1325 µm, about 1350 µm, about 1375 µm, about 1400 µm, about 1425 µm, about 1450 µm, about 1475 µm, about 1500 µm, about 1525 µm, about 1550 µm, about 1575 µm, about 1600 µm, about 1625 µm, about 1650 µm, about 1675 µm, about 1700 µm, about 1725 µm, about 1750 µm, about 1775 µm, about 1800 µm, about 1825 µm, about 1850 µm, about 1875 µm, about 1900 µm, about 1925 µm, about 1950 µm, about 1975 µm, about 2000 µm, about 2025 µm, about 2050 µm, about 2075 µm, about 2100 µm, about 2125 µm, about 2150 µm, about 2175 µm, about 2200 µm, about 2225 µm, about 2250 µm, about 2275 µm, about 2300 µm, about 2325 µm, about 2350 µm, about 2375 µm, about 2400 µm, about 2425 µm, about 2450 µm, about 2475 µm, about 2500 µm, about 2525 µm, about 2550 µm, about 2575 µm, about 2600 µm, about 2625 µm, about 2650 µm, about 2675 µm, about 2700 µm, about 2725 µm, about 2750 µm, about 2775 µm, about 2800 µm, about 2825 µm, about 2850 µm, about 2875 µm, about 2900 µm, about 2925 µm, about 2950 µm, about 2975 µm, or about 3000 µm). In some embodiments, the microneedles can be evenly spaced. In some embodiments, the spacing between the microneedles can be measured from the center of the microneedle (also referred to as “center-to-center spacing). In some embodiments, the spacing between the microneedles can be measured from the tip of the microneedle (also referred to as “tip-to-tip spacing”). In some embodiments, the spacing between the microneedles can be measured from the edge of the microneedle base (also referred to as “edge-to-edge” spacing). In some embodiments, the microneedle and / or the microarray patch (MAP) can be configured to deliver the consolidated microneedle tip to a depth of at least about 250 µm below the surface of the subject’s skin, e.g., about 200 µm to about 1000 µm (e.g., about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, about 500 µm, about 505 µm, about 510 µm, about 515 µm, about 520 µm, about 525 µm, about 530 µm, about 535 µm, about 540 µm, about 545 µm, about 550 µm, about 555 µm, about 560 µm, about 565 µm, about 570 µm, about 575 µm, about 580 µm, about 585 µm, about 590 µm, about 595 µm, about 600 µm, about 605 µm, about 610 µm, about 615 µm, about 620 µm, about 625 µm, about 630 µm, about 635 µm, about 640 µm, about 645 µm, about 650 µm, about 655 µm, about 660 µm, about 665 µm, about 670 µm, about 675 µm, about 680 µm, about 685 µm, about 690 µm, about 695 µm, about 700 µm, about 705 µm, about 710 µm, about 715 µm, about 720 µm, about 725 µm, about 730 µm, about 735 µm, about 740 µm, about 745 µm, about 750 µm, about 755 µm, about 760 µm, about 765 µm, about 770 µm, about 775 µm, about 780 µm, about 785 µm, about 790 µm, about 795 µm, about 800 µm, about 805 µm, about 810 µm, about 815 µm, about 820 µm, about 825 µm, about 830 µm, about 835 µm, about 840 µm, about 845 µm, about 850 µm, about 855 µm, about 860 µm, about 865 µm, about 870 µm, about 875 µm, about 880 µm, about 885 µm, about 890 µm, about 895 µm, about 900 µm, about 905 µm, about 910 µm, about 915 µm, about 920 µm, about 925 µm, about 930 µm, about 935 µm, about 940 µm, about 945 µm, about 950 µm, about 955 µm, about 960 µm, about 965 µm, about 970 µm, about 975 µm, about 980 µm, about 985 µm, about 990 µm, about 995 µm, or about 1000 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can comprise a plurality of layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the microneedle comprises at least 2 layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the microneedle comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, each layer can independently be formed from a predefined volume of the dispensable formulation. In some embodiments, the predefined volume of the dispensable formulation can be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL). In some embodiments, each layer can independently be formed from a single drop of the dispensable formulation. Consolidated Microneedle TipIn some embodiments, the microneedle comprises a consolidated microneedle tip, comprising an active pharmaceutical ingredient (API) and a water-soluble excipient. As used herein, the term “consolidated microneedle tip” refers to the apical portion, or apex, of the microneedle within which a predefined amount of an active pharmaceutical ingredient (API) can be concentrated, e.g., to reduce the risk of delivery of an insufficient amount of API if needle insertion fails and / or if partial needle penetration occurred. In some embodiments, the term “apex” refers to the end of the body of the microneedle that is furthest from the microneedle base. In some embodiments, the term “apex” refers to the sharpest portion of a microneedle, which can be characterized by, e.g., a tip radius, a tip diameter, and / or a tip angle. In some embodiments, the term “tip radius” or “consolidated tip radius” may refer to the radius of a circle equivalent in cross-sectional area to the smallest aspect of a microneedle, e.g., at the apex. In some embodiments, the term “tip diameter” or “consolidated tip diameter” may refer to the radius of a circle equivalent in cross-sectional area to the smallest aspect of a microneedle, e.g., at the apex. In some embodiments, the term “apex” refers to the portion of the microneedle that can be delivered to the deepest depth below the surface of the subject’s skin, such that an indicated deployment depth “below the surface of the subject’s skin” may refer to a portion of the microneedle having a three-dimensional structure defined by a “length” or a “percentage of the pre-deployment needle height” corresponding to the distance between the apex of the inserted microneedle (e.g., delivered to the deepest depth below the surface of the subject’s skin) and the surface of the subject’s skin. In some embodiments, an indicated deployment depth “below the surface of the subject’s skin” may be expressed as a single value and / or as a range of values related to the “length” or the “percentage of the pre-deployment needle height” of the microneedle inserted into, that is “below the surface” of the subject’s skin. Thus, it may be understood that API present within such a portion of the deployed microneedle may be effectively delivered to the subject by an appropriate release mechanism, while API present in portions of the microneedle (e.g., portions of the consolidated microneedle tip and / or microneedle base) that are not inserted may not be delivered to the subject. Accordingly, the consistency of deployment may be related to the number of and / or percentage of microneedles in a MAP that can be reliably inserted “below the surface” of the subject’s skin to achieve delivery of an API. In some embodiments, the consistency of deployment may also be related to the percentage of the pre-deployment needle height that can be reliably inserted “below the surface” of the subject’s skin to achieve delivery of an API. In some embodiments, a defect such as a shell or shell-like structure formed, e.g., from the dispensable tip formulation comprising an API, can lead to delivery of an insufficient amount of API if needle insertion fails and / or if partial needle penetration occurs. In some embodiments, the consolidated microneedle tip may be characterized by a meniscus. In general, the term “meniscus” refers to the convex surface of liquid which is formed by surface tension. In the context of a meniscus, "concavity" refers to the curved, downward facing shape of the liquid surface, where the liquid appears to "curve up" the sides of the container, creating a concave appearance; this typically happens when the liquid molecules are more attracted to the container walls than to each other. In some embodiments, the consolidated microneedle tip may be characterized by a meniscus having a substantially concave shape. In the context of a meniscus, “convexity” refers to a curved upward surface of a liquid where the liquid molecules are more attracted to each other than to the container walls, causing the liquid to curve upwards, creating a dome-like shape. In some embodiments, the consolidated microneedle tip, e.g., after drying, may be characterized by a meniscus having a substantially convex shape. In some embodiments, the consolidated microneedle tip is characterized by a substantially flat meniscus. A "meniscus curvature angle" may refer to the angle formed by the curve of a meniscus, which may be the curved surface of a liquid within a container, generally describing how much the liquid curves at the edge of the container, and may be primarily influenced by the surface tension of the liquid and its adhesion to the container walls; a larger angle may indicate a more pronounced curve, while a smaller angle may indicate a flatter meniscus. A “flatter meniscus” or a “substantially flat meniscus” may have a meniscus curvature angle closer to 90 degrees, meaning that the contact angle between the liquid and the container wall is nearly perpendicular, resulting in a relatively flat surface at the liquid-air interface; generally, a flatter meniscus may indicate a contact angle approaching 90 degrees. In some embodiments, the consolidated microneedle tip is characterized by contact angles approaching 90 degrees. In some embodiments, the consolidated microneedle tip is characterized by contact angles of about 60 degrees to about 120 degrees (e.g., about 60 degrees, about 61 degrees, about 62 degrees, about 63 degrees, about 64 degrees, about 65 degrees, about 66 degrees, about 67 degrees, about 68 degrees, about 69 degrees, about 70 degrees, about 71 degrees, about 72 degrees, about 73 degrees, about 74 degrees, about 75 degrees, about 76 degrees, about 77 degrees, about 78 degrees, about 79 degrees, about 80 degrees, about 81 degrees, about 82 degrees, about 83 degrees, about 84 degrees, about 85 degrees, about 86 degrees, about 87 degrees, about 88 degrees, about 89 degrees, about 90 degrees, about 91 degrees, about 92 degrees, about 93 degrees, about 94 degrees, about 95 degrees, about 96 degrees, about 97 degrees, about 98 degrees, about 99 degrees, about 100 degrees, about 101 degrees, about 102 degrees, about 103 degrees, about 104 degrees, about 105 degrees, about 106 degrees, about 107 degrees, about 108 degrees, about 109 degrees, about 110 degrees, about 111 degrees, about 112 degrees, about 113 degrees, about 114 degrees, about 115 degrees, about 116 degrees, about 117 degrees, about 118 degrees, about 119 degrees, or about 120 degrees). In some embodiments, the consolidated microneedle tip is characterized by contact angles of about 70 degrees to about 110 degrees.The meniscus curvature angle and / or the meniscus shape may be related to the liquid-air interface of a meniscus at the point where it touches the wall of a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) described herein during manufacturing. In some embodiments, the consolidated microneedle tip is characterized by a meniscus curvature angle and / or a meniscus shape that enhances the formation of the consolidated microneedle tip. In some embodiments, the meniscus curvature angle and / or the meniscus shape may be related to the formation of a defect, such as a shell or shell-like structure formed, e.g., from the dispensable tip formulation comprising an API, and which can lead to delivery of an insufficient amount of API if needle insertion fails and / or if partial needle penetration occurs. In particular embodiments, the consolidated microneedle tip does not comprise a shell and / or a shell-like structure. In some embodiments, the meniscus curvature angle and / or the meniscus shape may be determined before and / or after drying.Without wishing to be bound by theory, Applicant has surprisingly discovered that specific combinations of water-soluble excipients can enhance, e.g., the consolidation of the API into the apex of the microneedle tip during manufacturing. In some embodiments, the consolidated microneedle tip can be configured to release a predefined amount of an active pharmaceutical ingredients (API) (e.g., about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the API) in a predefined period of time (e.g., about 5 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, or about 60 seconds; or about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes; or about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours; or about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days; or about 1 week, about 2 weeks, about 3 weeks, about 4 weeks; or about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months; or about 1 year, about 2 years, about 3 years, about 4 years, or about 5 years or more). In some embodiments, the consolidated microneedle tip can be configured to release a predefined amount of an active pharmaceutical ingredients (API) in a predefined period of time though a dissolution-diffusion mechanism. In some embodiments, the consolidated microneedle tip can be configured to release a predefined amount of an active pharmaceutical ingredients (API) though an immediate-release mechanism. In some embodiments, the consolidated microneedle tip can be configured to release a predefined amount of an active pharmaceutical ingredients (API) in a predefined period of time though a modified-release mechanism. Exemplary modified release mechanisms can include, e.g., controlled-release, sustained-release, and / or long-acting API products and / or consolidated microneedle tip formulations. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated microneedle tip length of about 200 µm to about 500 µm (e.g., about 200 µm, about 205 µm, about 210 µm, about 215 µm, about 220 µm, about 225 µm, about 230 µm, about 235 µm, about 240 µm, about 245 µm, about 250 µm, about 255 µm, about 260 µm, about 265 µm, about 270 µm, about 275 µm, about 280 µm, about 285 µm, about 290 µm, about 295 µm, about 300 µm, about 305 µm, about 310 µm, about 315 µm, about 320 µm, about 325 µm, about 330 µm, about 335 µm, about 340 µm, about 345 µm, about 350 µm, about 355 µm, about 360 µm, about 365 µm, about 370 µm, about 375 µm, about 380 µm, about 385 µm, about 390 µm, about 395 µm, about 400 µm, about 405 µm, about 410 µm, about 415 µm, about 420 µm, about 425 µm, about 430 µm, about 435 µm, about 440 µm, about 445 µm, about 450 µm, about 455 µm, about 460 µm, about 465 µm, about 470 µm, about 475 µm, about 480 µm, about 485 µm, about 490 µm, about 495 µm, or about 500 µm).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated microneedle tip length of greater than about 300 µm, e.g., about 300 µm to about 500 µm (e.g., about 300 µm, about 301 µm, about 302 µm, about 303 µm, about 304 µm, about 305 µm, about 306 µm, about 307 µm, about 308 µm, about 309 µm, about 310 µm, about 311 µm, about 312 µm, about 313 µm, about 314 µm, about 315 µm, about 316 µm, about 317 µm, about 318 µm, about 319 µm, about 320 µm, about 321 µm, about 322 µm, about 323 µm, about 324 µm, about 325 µm, about 326 µm, about 327 µm, about 328 µm, about 329 µm, about 330 µm, about 331 µm, about 332 µm, about 333 µm, about 334 µm, about 335 µm, about 336 µm, about 337 µm, about 338 µm, about 339 µm, about 340 µm, about 341 µm, about 342 µm, about 343 µm, about 344 µm, about 345 µm, about 346 µm, about 347 µm, about 348 µm, about 349 µm, about 350 µm, about 351 µm, about 352 µm, about 353 µm, about 354 µm, about 355 µm, about 356 µm, about 357 µm, about 358 µm, about 359 µm, about 360 µm, about 361 µm, about 362 µm, about 363 µm, about 364 µm, about 365 µm, about 366 µm, about 367 µm, about 368 µm, about 369 µm, about 370 µm, about 371 µm, about 372 µm, about 373 µm, about 374 µm, about 375 µm, about 376 µm, about 377 µm, about 378 µm, about 379 µm, about 380 µm, about 381 µm, about 382 µm, about 383 µm, about 384 µm, about 385 µm, about 386 µm, about 387 µm, about 388 µm, about 389 µm, about 390 µm, about 391 µm, about 392 µm, about 393 µm, about 394 µm, about 395 µm, about 396 µm, about 397 µm, about 398 µm, about 399 µm, about 400 µm, about 401 µm, about 402 µm, about 403 µm, about 404 µm, about 405 µm, about 406 µm, about 407 µm, about 408 µm, about 409 µm, about 410 µm, about 411 µm, about 412 µm, about 413 µm, about 414 µm, about 415 µm, about 416 µm, about 417 µm, about 418 µm, about 419 µm, about 420 µm, about 421 µm, about 422 µm, about 423 µm, about 424 µm, about 425 µm, about 426 µm, about 427 µm, about 428 µm, about 429 µm, about 430 µm, about 431 µm, about 432 µm, about 433 µm, about 434 µm, about 435 µm, about 436 µm, about 437 µm, about 438 µm, about 439 µm, about 440 µm, about 441 µm, about 442 µm, about 443 µm, about 444 µm, about 445 µm, about 446 µm, about 447 µm, about 448 µm, about 449 µm, about 450 µm, about 451 µm, about 452 µm, about 453 µm, about 454 µm, about 455 µm, about 456 µm, about 457 µm, about 458 µm, about 459 µm, about 460 µm, about 461 µm, about 462 µm, about 463 µm, about 464 µm, about 465 µm, about 466 µm, about 467 µm, about 468 µm, about 469 µm, about 470 µm, about 471 µm, about 472 µm, about 473 µm, about 474 µm, about 475 µm, about 476 µm, about 477 µm, about 478 µm, about 479 µm, about 480 µm, about 481 µm, about 482 µm, about 483 µm, about 484 µm, about 485 µm, about 486 µm, about 487 µm, about 488 µm, about 489 µm, about 490 µm, about 491 µm, about 492 µm, about 493 µm, about 494 µm, about 495 µm, about 496 µm, about 497 µm, about 498 µm, about 499 µm, or about 500 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated microneedle tip length of greater than about 400 µm, e.g., about 400 µm to about 500 µm (e.g., about 400 µm, about 401 µm, about 402 µm, about 403 µm, about 404 µm, about 405 µm, about 406 µm, about 407 µm, about 408 µm, about 409 µm, about 410 µm, about 411 µm, about 412 µm, about 413 µm, about 414 µm, about 415 µm, about 416 µm, about 417 µm, about 418 µm, about 419 µm, about 420 µm, about 421 µm, about 422 µm, about 423 µm, about 424 µm, about 425 µm, about 426 µm, about 427 µm, about 428 µm, about 429 µm, about 430 µm, about 431 µm, about 432 µm, about 433 µm, about 434 µm, about 435 µm, about 436 µm, about 437 µm, about 438 µm, about 439 µm, about 440 µm, about 441 µm, about 442 µm, about 443 µm, about 444 µm, about 445 µm, about 446 µm, about 447 µm, about 448 µm, about 449 µm, about 450 µm, about 451 µm, about 452 µm, about 453 µm, about 454 µm, about 455 µm, about 456 µm, about 457 µm, about 458 µm, about 459 µm, about 460 µm, about 461 µm, about 462 µm, about 463 µm, about 464 µm, about 465 µm, about 466 µm, about 467 µm, about 468 µm, about 469 µm, about 470 µm, about 471 µm, about 472 µm, about 473 µm, about 474 µm, about 475 µm, about 476 µm, about 477 µm, about 478 µm, about 479 µm, about 480 µm, about 481 µm, about 482 µm, about 483 µm, about 484 µm, about 485 µm, about 486 µm, about 487 µm, about 488 µm, about 489 µm, about 490 µm, about 491 µm, about 492 µm, about 493 µm, about 494 µm, about 495 µm, about 496 µm, about 497 µm, about 498 µm, about 499 µm, or about 500 µm). In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated tip diameter of about 0.25 µm to about 50 µm (e.g., about 0.25 µm, about 0.5 µm, about 1 µm, about 2 µm, about 3 µm, about 4 µm, about 5 µm, about 6 µm, about 7 µm, about 8 µm, about 9 µm, about 10 µm, about 11 µm, about 12 µm, about 13 µm, about 14 µm, about 15 µm, about 16 µm, about 17 µm, about 18 µm, about 19 µm, about 20 µm, about 21 µm, about 22 µm, about 23 µm, about 24 µm, about 25 µm, about 26 µm, about 27 µm, about 28 µm, about 29 µm, about 30 µm, about 31 µm, about 32 µm, about 33 µm, about 34 µm, about 35 µm, about 36 µm, about 37 µm, about 38 µm, about 39 µm, about 40 µm, about 41 µm, about 42 µm, about 43 µm, about 44 µm, about 45 µm, about 46 µm, about 47 µm, about 48 µm, about 49 µm, or about 50 µm). In some embodiments, the microneedles described herein can be characterized by a consolidated tip diameter of about 1 µm to about 25 µm. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated tip diameter of about 1 µm to about 15 µm. In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a consolidated tip diameter of about 1 µm to about 5 µm.In some embodiments, the microneedles and / or microarray patches (MAPs) described can be characterized by a consolidated tip angle of about 5° to about 50° (e.g., about 5°, about 6°, about 7°, about 8°, about 9°, about 10°, about 11°, about 12°, about 13°, about 14°, about 15°, about 16°, about 17°, about 18°, about 19°, about 20°, about 21°, about 22°, about 23°, about 24°, about 25°, about 26°, about 27°, about 28°, about 29°, about 30°, about 31°, about 32°, about 33°, about 34°, about 35°, about 36°, about 37°, about 38°, about 39°, about 40°, about 41°, about 42°, about 43°, about 44°, about 45°, about 46°, about 47°, about 48°, about 49°, or about 50°).In some embodiments, the consolidated microneedle tip comprises a plurality of layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the consolidated microneedle tip comprises at least 2 layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the consolidated microneedle tip comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, each layer can independently be formed from a predefined volume of the dispensable formulation. In some embodiments, the predefined volume of the dispensable formulation can be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL). In some embodiments, each layer can independently be formed from a single drop of the dispensable formulation. Microneedle BaseIn some embodiments, the microneedle comprises a microneedle base, comprising a water-soluble excipient. As used herein, the term “microneedle base” refers to the portion of the microneedle that functions as a support or pedestal for the consolidated microneedle tip, and / or that functions to connect adjacent microneedles to form a continuous microarray patch (MAP). In some embodiments, the microneedle base is dissolvable. In some embodiments, at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the microneedle base is dissolved upon application to the skin of a subject in a predefined period of time (e.g., about 5 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, or about 60 seconds; or about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, or about 30 minutes). In some embodiments, at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the microneedle base is inserted into the skin of a subject upon deployment. In some embodiments, the microneedle base comprises a material that can dissolve into the skin, e.g., within the intended wear time (e.g., about five minutes). In some embodiments, the at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the dissolvable base layer is dissolved after application, e.g., to the skin, within the intended wear time (e.g., about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes or more).In some embodiments, the microneedle base comprises less than 100% (e.g., less than about 1%, less than about 5%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, less than about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%) of the total amount (e.g., dose) of a API loaded into the microneedle and / or the MAP. In some embodiments, the microneedle base does not comprise, e.g., a detectable amount of an API. In some embodiments, the microneedle base is formulated to limit and / or reduce the amount of API leakage (e.g., diffusion) from the consolidated microneedle tip into the microneedle base. In some embodiments, the microneedle base comprises a material that can dissolve into the skin, e.g., within the intended wear time (e.g., about five minutes). In some embodiments, at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of the microneedle base is dissolved after application, e.g., to the skin, within the intended wear time (e.g., about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes or more).In some embodiments, the consolidated microneedle tip comprises a material that can dissolve into the skin, e.g., within the intended wear time (e.g., about five minutes). In some embodiments, at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of the consolidated microneedle tip is dissolved after application, e.g., to the skin, within the intended wear time (e.g., about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes or more).In some embodiments, the microneedle and / or the microarray patch (MAP) can be characterized by a base length of about 25 µm to about 2500 µm (e.g., about 25 µm, about 50 µm, about 75 µm, about 100 µm, about 125 µm, about 150 µm, about 175 µm, about 200 µm, about 225 µm, about 250 µm, about 275 µm, about 300 µm, about 325 µm, about 350 µm, about 375 µm, about 400 µm, about 425 µm, about 450 µm, about 475 µm, about 500 µm, about 525 µm, about 550 µm, about 575 µm, about 600 µm, about 625 µm, about 650 µm, about 675 µm, about 700 µm, about 725 µm, about 750 µm, about 775 µm, about 800 µm, about 825 µm, about 850 µm, about 875 µm, about 900 µm, about 925 µm, about 950 µm, about 975 µm, about 1000 µm, about 1025 µm, about 1050 µm, about 1075 µm, about 1100 µm, about 1125 µm, about 1150 µm, about 1175 µm, about 1200 µm, about 1225 µm, about 1250 µm, about 1275 µm, about 1300 µm, about 1325 µm, about 1350 µm, about 1375 µm, about 1400 µm, about 1425 µm, about 1450 µm, about 1475 µm, about 1500 µm, about 1525 µm, about 1550 µm, about 1575 µm, about 1600 µm, about 1625 µm, about 1650 µm, about 1675 µm, about 1700 µm, about 1725 µm, about 1750 µm, about 1775 µm, about 1800 µm, about 1825 µm, about 1850 µm, about 1875 µm, about 1900 µm, about 1925 µm, about 1950 µm, about 1975 µm, about 2000 µm, about 2025 µm, about 2050 µm, about 2075 µm, about 2100 µm, about 2125 µm, about 2150 µm, about 2175 µm, about 2200 µm, about 2225 µm, about 2250 µm, about 2275 µm, about 2300 µm, about 2325 µm, about 2350 µm, about 2375 µm, about 2400 µm, about 2425 µm, about 2450 µm, about 2475 µm, or about 2500 µm). In some embodiments, the microneedle base comprises a plurality of layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the microneedle base comprises at least 2 layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, the microneedle base comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more layers, wherein each layer is independently formed from a dispensable formulation described herein. In some embodiments, each layer can independently be formed from a predefined volume of the dispensable formulation. In some embodiments, the predefined volume of the dispensable formulation can be about 1 nL to about 1000 nL (e.g., about 1 nL, about 5 nL, about 10 nL, about 15 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, about 50 nL, about 55 nL, about 60 nL, about 65 nL, about 70 nL, about 75 nL, about 80 nL, about 85 nL, about 90 nL, about 95 nL, about 100 nL, about 105 nL, about 110 nL, about 115 nL, about 120 nL, about 125 nL, about 130 nL, about 135 nL, about 140 nL, about 145 nL, about 150 nL, about 155 nL, about 160 nL, about 165 nL, about 170 nL, about 175 nL, about 180 nL, about 185 nL, about 190 nL, about 195 nL, about 200 nL, about 205 nL, about 210 nL, about 215 nL, about 220 nL, about 225 nL, about 230 nL, about 235 nL, about 240 nL, about 245 nL, about 250 nL, about 255 nL, about 260 nL, about 265 nL, about 270 nL, about 275 nL, about 280 nL, about 285 nL, about 290 nL, about 295 nL, about 300 nL, about 305 nL, about 310 nL, about 315 nL, about 320 nL, about 325 nL, about 330 nL, about 335 nL, about 340 nL, about 345 nL, about 350 nL, about 355 nL, about 360 nL, about 365 nL, about 370 nL, about 375 nL, about 380 nL, about 385 nL, about 390 nL, about 395 nL, about 400 nL, about 405 nL, about 410 nL, about 415 nL, about 420 nL, about 425 nL, about 430 nL, about 435 nL, about 440 nL, about 445 nL, about 450 nL, about 455 nL, about 460 nL, about 465 nL, about 470 nL, about 475 nL, about 480 nL, about 485 nL, about 490 nL, about 495 nL, about 500 nL, about 505 nL, about 510 nL, about 515 nL, about 520 nL, about 525 nL, about 530 nL, about 535 nL, about 540 nL, about 545 nL, about 550 nL, about 555 nL, about 560 nL, about 565 nL, about 570 nL, about 575 nL, about 580 nL, about 585 nL, about 590 nL, about 595 nL, about 600 nL, about 605 nL, about 610 nL, about 615 nL, about 620 nL, about 625 nL, about 630 nL, about 635 nL, about 640 nL, about 645 nL, about 650 nL, about 655 nL, about 660 nL, about 665 nL, about 670 nL, about 675 nL, about 680 nL, about 685 nL, about 690 nL, about 695 nL, about 700 nL, about 705 nL, about 710 nL, about 715 nL, about 720 nL, about 725 nL, about 730 nL, about 735 nL, about 740 nL, about 745 nL, about 750 nL, about 755 nL, about 760 nL, about 765 nL, about 770 nL, about 775 nL, about 780 nL, about 785 nL, about 790 nL, about 795 nL, about 800 nL, about 805 nL, about 810 nL, about 815 nL, about 820 nL, about 825 nL, about 830 nL, about 835 nL, about 840 nL, about 845 nL, about 850 nL, about 855 nL, about 860 nL, about 865 nL, about 870 nL, about 875 nL, about 880 nL, about 885 nL, about 890 nL, about 895 nL, about 900 nL, about 905 nL, about 910 nL, about 915 nL, about 920 nL, about 925 nL, about 930 nL, about 935 nL, about 940 nL, about 945 nL, about 950 nL, about 955 nL, about 960 nL, about 965 nL, about 970 nL, about 975 nL, about 980 nL, about 985 nL, about 990 nL, about 995 nL, or about 1000 nL). In some embodiments, each layer can independently be formed from a single drop of the dispensable formulation.In some embodiments, the microneedles and / or microarray patches (MAPs) described herein can be formed from a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein. In some embodiments, the consolidated microneedle tip can be formed from about 10 nL to about 100 nL (e.g., about 10 nL, about 11 nL, about 12 nL, about 13 nL, about 14 nL, about 15 nL, about 16 nL, about 17 nL, about 18 nL, about 19 nL, about 20 nL, about 21 nL, about 22 nL, about 23 nL, about 24 nL, about 25 nL, about 26 nL, about 27 nL, about 28 nL, about 29 nL, about 30 nL, about 31 nL, about 32 nL, about 33 nL, about 34 nL, about 35 nL, about 36 nL, about 37 nL, about 38 nL, about 39 nL, about 40 nL, about 41 nL, about 42 nL, about 43 nL, about 44 nL, about 45 nL, about 46 nL, about 47 nL, about 48 nL, about 49 nL, about 50 nL, about 51 nL, about 52 nL, about 53 nL, about 54 nL, about 55 nL, about 56 nL, about 57 nL, about 58 nL, about 59 nL, about 60 nL, about 61 nL, about 62 nL, about 63 nL, about 64 nL, about 65 nL, about 66 nL, about 67 nL, about 68 nL, about 69 nL, about 70 nL, about 71 nL, about 72 nL, about 73 nL, about 74 nL, about 75 nL, about 76 nL, about 77 nL, about 78 nL, about 79 nL, about 80 nL, about 81 nL, about 82 nL, about 83 nL, about 84 nL, about 85 nL, about 86 nL, about 87 nL, about 88 nL, about 89 nL, about 90 nL, about 91 nL, about 92 nL, about 93 nL, about 94 nL, about 95 nL, about 96 nL, about 97 nL, about 98 nL, about 99 nL, or about 100 nL) of a dispensable tip formulation described herein (also referred to herein as the “tip fill volume”). In some embodiments, the tip fill volume may be dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) described herein. In some embodiments, the tip fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) prior to, or concurrently with, the base fill volume. In some embodiments, the tip fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) in a single drop. In some embodiments, the tip fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) in a dropwise manner. In some embodiments, the microneedle base can be formed from about 50 nL to about 5000 nL (e.g., 50 nL, about 75 nL, about 100 nL, about 125 nL, about 150 nL, about 175 nL, about 200 nL, about 225 nL, about 250 nL, about 275 nL, about 300 nL, about 325 nL, about 350 nL, about 375 nL, about 400 nL, about 425 nL, about 450 nL, about 475 nL, about 500 nL, about 525 nL, about 550 nL, about 575 nL, about 600 nL, about 625 nL, about 650 nL, about 675 nL, about 700 nL, about 725 nL, about 750 nL, about 775 nL, about 800 nL, about 825 nL, about 850 nL, about 875 nL, about 900 nL, about 925 nL, about 950 nL, about 975 nL, about 1000 nL, about 1025 nL, about 1050 nL, about 1075 nL, about 1100 nL, about 1125 nL, about 1150 nL, about 1175 nL, about 1200 nL, about 1225 nL, about 1250 nL, about 1275 nL, about 1300 nL, about 1325 nL, about 1350 nL, about 1375 nL, about 1400 nL, about 1425 nL, about 1450 nL, about 1475 nL, about 1500 nL, about 1525 nL, about 1550 nL, about 1575 nL, about 1600 nL, about 1625 nL, about 1650 nL, about 1675 nL, about 1700 nL, about 1725 nL, about 1750 nL, about 1775 nL, about 1800 nL, about 1825 nL, about 1850 nL, about 1875 nL, about 1900 nL, about 1925 nL, about 1950 nL, about 1975 nL, about 2000 nL, about 2025 nL, about 2050 nL, about 2075 nL, about 2100 nL, about 2125 nL, about 2150 nL, about 2175 nL, about 2200 nL, about 2225 nL, about 2250 nL, about 2275 nL, about 2300 nL, about 2325 nL, about 2350 nL, about 2375 nL, about 2400 nL, about 2425 nL, about 2450 nL, about 2475 nL, about 2500 nL, about 2525 nL, about 2550 nL, about 2575 nL, about 2600 nL, about 2625 nL, about 2650 nL, about 2675 nL, about 2700 nL, about 2725 nL, about 2750 nL, about 2775 nL, about 2800 nL, about 2825 nL, about 2850 nL, about 2875 nL, about 2900 nL, about 2925 nL, about 2950 nL, about 2975 nL, about 3000 nL, about 3025 nL, about 3050 nL, about 3075 nL, about 3100 nL, about 3125 nL, about 3150 nL, about 3175 nL, about 3200 nL, about 3225 nL, about 3250 nL, about 3275 nL, about 3300 nL, about 3325 nL, about 3350 nL, about 3375 nL, about 3400 nL, about 3425 nL, about 3450 nL, about 3475 nL, about 3500 nL, about 3525 nL, about 3550 nL, about 3575 nL, about 3600 nL, about 3625 nL, about 3650 nL, about 3675 nL, about 3700 nL, about 3725 nL, about 3750 nL, about 3775 nL, about 3800 nL, about 3825 nL, about 3850 nL, about 3875 nL, about 3900 nL, about 3925 nL, about 3950 nL, about 3975 nL, about 4000 nL, about 4025 nL, about 4050 nL, about 4075 nL, about 4100 nL, about 4125 nL, about 4150 nL, about 4175 nL, about 4200 nL, about 4225 nL, about 4250 nL, about 4275 nL, about 4300 nL, about 4325 nL, about 4350 nL, about 4375 nL, about 4400 nL, about 4425 nL, about 4450 nL, about 4475 nL, about 4500 nL, about 4525 nL, about 4550 nL, about 4575 nL, about 4600 nL, about 4625 nL, about 4650 nL, about 4675 nL, about 4700 nL, about 4725 nL, about 4750 nL, about 4775 nL, about 4800 nL, about 4825 nL, about 4850 nL, about 4875 nL, about 4900 nL, about 4925 nL, about 4950 nL, about 4975 nL, or about 5000 nL) of a dispensable base formulation described herein (also referred to herein as the “base fill volume”). In some embodiments, the base fill volume may be dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) described herein. In some embodiments, the base fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) concurrently with, or subsequent to, the tip fill volume. In some embodiments, the base fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) in a dropwise manner, e.g., using a progressive base fill. In some embodiments, the base fill volume is dispensed to fill, or to partially fill, a microprojection shaped cavity of a mold that defines the shape of a microneedle and / or a microarray patch (MAP) in a single drop.Microneedle and Microarray Patch (MAP) Systems The microneedles and / or microarray patches (MAPs) described herein can be applied, e.g., to the skin of a subject, using a device, such as an applicator. Accordingly, in one aspect, the disclosure provides a system, comprising: (i) a microneedle and / or a MAP; and (ii) a device, such as an applicator. The device, e.g., the applicator, can be configured to facilitate consistent deployment of the microneedles and / or MAPs described herein to achieve effective API delivery. Exemplary devices, applicators, and systems are described, for example, in International Publication No. WO2023 / 250117, International Application No. PCT / US2024 / 034901, and International Application No. PCT / US2024 / XXXXXX filed December 26, 2024, the contents of which are incorporated herein by reference in their entirety. It is generally known in the art that microneedles can often suffer from insufficient skin insertion. This can occur when microneedles are not able to sufficiently puncture and penetrate into the skin, leading to inconsistent delivery of an active pharmaceutical ingredient (API). In some instances, deformation, fracture, or breakage of microneedles during or after patch administration can alter the release profile of the API, which may lead to changes in the pharmacokinetics of the API. Numerous factors can affect the efficiency of microneedle insertion, including, but not limited to the materials and processes that are used to form the microneedle, microneedle geometry, needle type, density, size, shape, tip and base diameters, height, needle density, indentation forces, minimum curvature radius to pierce the stratum corneum, skin thickness, and / or skin elasticity. The mechanical strength of the microneedles may also be altered by the presence of an API and / or water-soluble excipient. Moreover, the while the ability to insert efficiently is an important factor when manufacturing microneedles, other factors should also be considered, such as cost, biocompatibility, and batch production capabilities. As such, microneedles that readily insert into the skin may not necessarily be considered viable for clinical applications due to the combination of these other factors. One of skill in the art will appreciate that the dispensable formulations, systems, and methods provided herein can be used to achieve the desired mechanical properties and consistent deployment of the microneedles and / or MAPs described herein to achieve effective API delivery for specific clinical applications. In certain embodiments, the applicator can be specifically configured to provide a predetermined force (e.g., impact energy) sufficient to achieve skin penetration and deployment of a consolidated microneedle tip (e.g., formed from a dispensable tip formulation described herein), e.g., at a sufficient depth within or beneath the surface of a subject’s skin for successful API delivery.In order to improve consistency and effectiveness of MAP application, an automated applicator device may be desirable. Accordingly, in some embodiments, the present disclosure provides an applicator device having one or more features or advantages over existing devices or simple manual application. The disclosed devices may be configured for repeated or single use, and the devices may be pre-loaded with a MAP (i.e., as a kit or system product including applicator and MAP). Alternatively, the applicator may be separate from a MAP, and a MAP may be selected and loaded to the device (e.g., based on desired APIs, patient characteristics, or need for additional applications for more than one patient or for a patient that needs more than one MAP). In some embodiments, the applicator can improve MAP application by one or more of (1) properly holding, stretching, and / or pre-tensioning skin to receive the MAP, (2) applying a reliable degree of force and / or depth of force against the skin to ensure proper microneedle placement, and / or (3) controlling distribution of application force across the MAP and / or microneedles.As used herein, the term “consistent” in the context of the deployment of the microneedles and / or MAPs described herein generally refers to the repeatability of achieving the appropriate level of microneedle penetration required for successful API delivery. In some embodiments, such consistency is more easily achieved by utilizing the system, comprising: (i) a microneedle and / or a MAP; and (ii) a device, such as an applicator, described herein. In certain embodiments, the applicator can be specifically configured to provide a predetermined force (e.g., impact energy) sufficient to achieve skin penetration and deployment of at least about 50% of the consolidated microneedle tips present in a microarray patch (MAP), e.g., at a sufficient depth within or beneath the surface of a subject’s skin for successful API delivery. In some embodiments, the sufficiency of deployment of the microneedles and / or the MAPs may be characterized by a pre-deployment needle height (or “needle height”), an air gap, a post-deployment needle height, a deployed tip depth, and / or a height delivered that can be achieved in using the system with applicator described herein.In some embodiments, the microneedles and / or microarray patches (MAPs) can be applied, e.g., to the skin of a subject, using an applicator characterized by a piston velocity of about 0.5 m / s to about 20 m / s (e.g., about 0.5 m / s, about 1 m / s, about 1.5 m / s, about 2 m / s, about 2.5 m / s, about 3 m / s, about 3.5 m / s, about 4 m / s, about 4.5 m / s, about 5 m / s, about 5.5 m / s, about 6 m / s, about 6.5 m / s, about 7 m / s, about 7.5 m / s, about 8 m / s, about 8.5 m / s, about 9 m / s, about 9.5 m / s, about 10 m / s, about 10.5 m / s, about 11 m / s, about 11.5 m / s, about 12 m / s, about 12.5 m / s, about 13 m / s, about 13.5 m / s, about 14 m / s, about 14.5 m / s, about 15 m / s, about 15.5 m / s, about 16 m / s, about 16.5 m / s, about 17 m / s, about 17.5 m / s, about 18 m / s, about 18.5 m / s, about 19 m / s, about 19.5 m / s, or about 20 m / s).In some embodiments, the microneedles and / or microarray patches (MAPs) can be applied, e.g., to the skin of a subject, using an applicator characterized by an energy per needle of about 0.1 mJ to about 5 mJ (e.g., about 0.1 mJ, about 0.2 mJ, about 0.3 mJ, about 0.4 mJ, about 0.5 mJ, about 0.6 mJ, about 0.7 mJ, about 0.8 mJ, about 0.9 mJ, about 1 mJ, about 1.1 mJ, about 1.2 mJ, about 1.3 mJ, about 1.4 mJ, about 1.5 mJ, about 1.6 mJ, about 1.7 mJ, about 1.8 mJ, about 1.9 mJ, about 2 mJ, about 2.1 mJ, about 2.2 mJ, about 2.3 mJ, about 2.4 mJ, about 2.5 mJ, about 2.6 mJ, about 2.7 mJ, about 2.8 mJ, about 2.9 mJ, about 3 mJ, about 3.1 mJ, about 3.2 mJ, about 3.3 mJ, about 3.4 mJ, about 3.5 mJ, about 3.6 mJ, about 3.7 mJ, about 3.8 mJ, about 3.9 mJ, about 4 mJ, about 4.1 mJ, about 4.2 mJ, about 4.3 mJ, about 4.4 mJ, about 4.5 mJ, about 4.6 mJ, about 4.7 mJ, about 4.8 mJ, about 4.9 mJ, or about 5 mJ).In some embodiments, the applicator can be specifically configured to apply substantially the same amount of force (e.g., impact energy) to each of the plurality of microneedles in a microarray patch (MAP) to achieve a sufficient deployment depth below the surface of the subject’s skin to then achieve transdermal and / or intradermal delivery of at least about 75% or more (e.g., about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) of the API from the MAP to a subject. In some embodiments, the applicator can be specifically configured to apply substantially the same amount of force (e.g., impact energy) to each of the plurality of microneedles in a microarray patch (MAP) to achieve a deployment depth of at least about 400 um below the surface of the subject’s skin to then achieve delivery of at least about 80% of the API from the MAP to a delivery depth of at least about 300 µm below the surface of the subject’s skin.According to one aspect, the disclosure provides a microneedle and / or a microarray patch (MAP), e.g., comprising an active pharmaceutical ingredient (API) and a water soluble excipient. In one aspect, the disclosure provides a microneedle, comprising an active pharmaceutical ingredient (API) and a water soluble excipient. In one aspect, the disclosure provides a microarray patch (MAP), comprising an active pharmaceutical ingredient (API) and a water soluble excipient.   Accordingly, the present disclosure provides improved systems comprising devices for application of medical patches, including biodegradable MAPs described herein. The systems can allow reliable application of a MAP, including even and reliable application such that a sufficient force and / or depth of skin penetration is achieved to ensure that needle-like portions of the patch are positioned at a desired depth within or beneath a portion of the skin. The applicator can be configured to provide a predetermined force to quickly and reliably apply the patch to a desired location, thereby helping to improve delivery of APIs (e.g., drugs, vaccines, biologics, or other materials) using the selected MAP. In some embodiments, the applicator may include a top portion having a top surface and a sidewall, wherein the top portion includes an activation mechanism; a bottom portion having a bottom surface and a sidewall; a middle portion connected to the top portion and the bottom portion; a piston portion connected to the top portion and the middle portion; and a compressible member positioned between the middle portion and the piston portion and configured to apply downward pressure to the piston portion, wherein when the activation mechanism is activated, the piston portion is released from the top portion and the middle portion and moves towards the bottom surface; wherein a MAP can be held in a patch holder near the bottom surface of the bottom portion, and when the piston portion moves downwards, the MAP is released from the patch holder and pushed downward by the piston portion through the patch holder onto subject’s skin. Active Pharmaceutical Ingredients (APIs)The present disclosure provides, in some embodiments, dispensable formulations, microneedles and / or microarray patches (MAPs) comprising an active pharmaceutical ingredient (API). The present disclosure also provides combination treatment methods for administering a microneedle and / or a microarray patch (MAP) disclosed herein with an additional therapy. As used herein, the term “active pharmaceutical ingredient (API)” (also referred to as a “drug,” an “active agent,” or a “therapeutic agent”) refers to any type of pharmaceutically active compound or derivative that is useful in the prevention, diagnosis, stabilization, treatment, or management of a condition, disorder or disease. The term “an active pharmaceutical ingredient (API)” generally refers to an agent that is administered to a subject to treat a disease, disorder, or other clinically recognized condition, or for prophylactic purposes, and has a therapeutic and / or clinically significant effect on the body of the subject to treat, prevent, and / or diagnose the disease, disorder, or condition. The active pharmaceutical ingredient may be delivered to a subject in a quantity greater than a trace amount to affect a therapeutic response in the subject. In some embodiments, an active pharmaceutical ingredient (API) may include, but is not limited to, any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to a subject (e.g., a human or nonhuman animal), induces a desired pharmacologic, immunogenic, and / or physiologic effect by local and / or systemic action. Examples of APIs are described in well-known literature references such as the Merck Index, the Physician’s Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. Various forms of an API may be used which are capable of being released from the microneedles and / or the microarray patches (MAPs) described herein into adjacent tissues and / or fluids upon administration, e.g., to the skin of a subject. Accordingly, it should be understood that the APIs described herein are not limited to any particular type of API.In some embodiments, “active pharmaceutical ingredient (API)” refers to an agent that possesses therapeutic, prophylactic, or diagnostic properties in vivo, for example when administered to a human subject or an animal, including mammals and domestic animals. Examples of active agents include, but are not limited to, amino acids, proteins, peptides, hormones, biologics, antibodies, growth factors, nucleic acids, such as DNA, RNA, and mRNA, gene constructs, and vectors, lipid nanoparticles (LNPs), sugars, antigens, vaccines, viruses, live attenuated viruses, inactivated viruses, adjuvanted vaccines, viral-like particles, enzymes, cells, small molecules, antibiotics, drugs, and any combination thereof. The term “active agent” or “active pharmaceutical ingredient” or “API” includes the compound(s), pharmaceutically acceptable salts thereof, isomers, solvates, prodrugs, derivatives, complexes and hydrates, anhydrous forms thereof, and any polymorphic or amorphous forms or combinations thereof.In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise and / or can be administered in combination with a therapeutically effective amount and / or or a prophylactically effective amount of an active pharmaceutical ingredient (API). In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise and / or can be administered in combination with an active pharmaceutical ingredient (API) in an amount that produces some desired local and / or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. APIs employed in the methods of the present disclosure may be administered in a sufficient amount to produce a reasonable benefit / risk ratio applicable to such treatment using a microneedle and / or a microarray patch (MAP) described herein.In some embodiments, a dispensable formulation (e.g., a dispense volume of a dispensable formulation), a microneedle (e.g., a single microneedle), and / or a MAP (e.g., a plurality of microneedles) can comprise about 0.001 µg to about 1000 mg of an API. In some embodiments, the amount of API present in a dispensable formulation (e.g., a dispense volume of a dispensable formulation), a microneedle (e.g., a single microneedle), and / or a MAP (e.g., a plurality of microneedles) can be (% w / w) weight by weight, (% w / v) weight by volume, and / or (% v / v) volume by volume. In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise about 0.1 µg to about 1000 µg (e.g., about 0.1 µg, about 1 µg, about 5 µg, about 10 µg, about 15 µg, about 20 µg, about 25 µg, about 30 µg, about 35 µg, about 40 µg, about 45 µg, about 50 µg, about 55 µg, about 60 µg, about 65 µg, about 70 µg, about 75 µg, about 80 µg, about 85 µg, about 90 µg, about 95 µg, about 100 µg, about 105 µg, about 110 µg, about 115 µg, about 120 µg, about 125 µg, about 130 µg, about 135 µg, about 140 µg, about 145 µg, about 150 µg, about 155 µg, about 160 µg, about 165 µg, about 170 µg, about 175 µg, about 180 µg, about 185 µg, about 190 µg, about 195 µg, about 200 µg, about 205 µg, about 210 µg, about 215 µg, about 220 µg, about 225 µg, about 230 µg, about 235 µg, about 240 µg, about 245 µg, about 250 µg, about 255 µg, about 260 µg, about 265 µg, about 270 µg, about 275 µg, about 280 µg, about 285 µg, about 290 µg, about 295 µg, about 300 µg, about 305 µg, about 310 µg, about 315 µg, about 320 µg, about 325 µg, about 330 µg, about 335 µg, about 340 µg, about 345 µg, about 350 µg, about 355 µg, about 360 µg, about 365 µg, about 370 µg, about 375 µg, about 380 µg, about 385 µg, about 390 µg, about 395 µg, about 400 µg, about 405 µg, about 410 µg, about 415 µg, about 420 µg, about 425 µg, about 430 µg, about 435 µg, about 440 µg, about 445 µg, about 450 µg, about 455 µg, about 460 µg, about 465 µg, about 470 µg, about 475 µg, about 480 µg, about 485 µg, about 490 µg, about 495 µg, about 500 µg, about 505 µg, about 510 µg, about 515 µg, about 520 µg, about 525 µg, about 530 µg, about 535 µg, about 540 µg, about 545 µg, about 550 µg, about 555 µg, about 560 µg, about 565 µg, about 570 µg, about 575 µg, about 580 µg, about 585 µg, about 590 µg, about 595 µg, about 600 µg, about 605 µg, about 610 µg, about 615 µg, about 620 µg, about 625 µg, about 630 µg, about 635 µg, about 640 µg, about 645 µg, about 650 µg, about 655 µg, about 660 µg, about 665 µg, about 670 µg, about 675 µg, about 680 µg, about 685 µg, about 690 µg, about 695 µg, about 700 µg, about 705 µg, about 710 µg, about 715 µg, about 720 µg, about 725 µg, about 730 µg, about 735 µg, about 740 µg, about 745 µg, about 750 µg, about 755 µg, about 760 µg, about 765 µg, about 770 µg, about 775 µg, about 780 µg, about 785 µg, about 790 µg, about 795 µg, about 800 µg, about 805 µg, about 810 µg, about 815 µg, about 820 µg, about 825 µg, about 830 µg, about 835 µg, about 840 µg, about 845 µg, about 850 µg, about 855 µg, about 860 µg, about 865 µg, about 870 µg, about 875 µg, about 880 µg, about 885 µg, about 890 µg, about 895 µg, about 900 µg, about 905 µg, about 910 µg, about 915 µg, about 920 µg, about 925 µg, about 930 µg, about 935 µg, about 940 µg, about 945 µg, about 950 µg, about 955 µg, about 960 µg, about 965 µg, about 970 µg, about 975 µg, about 980 µg, about 985 µg, about 990 µg, about 995 µg, or about 1000 µg) of an active pharmaceutical ingredient (API), e.g., described herein. In some embodiments, a dispense volume of a dispensable formulation, such as a dispensable tip formulation and / or a dispensable base formulation described herein, can comprise about 0.1 µg to about 1000 mg of the active pharmaceutical ingredient (API). In some embodiments, a microneedle, e.g., a microneedle present in a microarray patch (MAP), can comprise about 0.1 µg to about 1000 mg of the API. In some embodiments, each microneedle in a microarray patch (MAP) can independently comprise about 0.1 µg to about 1000 mg of an active pharmaceutical ingredient (API), e.g., per microneedle. In some embodiments, the microarray patch (MAP) can comprise a total amount of about 0.1 µg to about 1000 mg of an active pharmaceutical ingredient (API), e.g., per MAP.In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise about 0.1 mg to about 1000 mg (e.g., about 0.1 mg, about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 805 mg, about 810 mg, about 815 mg, about 820 mg, about 825 mg, about 830 mg, about 835 mg, about 840 mg, about 845 mg, about 850 mg, about 855 mg, about 860 mg, about 865 mg, about 870 mg, about 875 mg, about 880 mg, about 885 mg, about 890 mg, about 895 mg, about 900 mg, about 905 mg, about 910 mg, about 915 mg, about 920 mg, about 925 mg, about 930 mg, about 935 mg, about 940 mg, about 945 mg, about 950 mg, about 955 mg, about 960 mg, about 965 mg, about 970 mg, about 975 mg, about 980 mg, about 985 mg, about 990 mg, about 995 mg, about 1000 mg) of an active pharmaceutical ingredient (API), e.g., described herein. In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise about 0.1% (w / v) to about 100% (w / v) (e.g., about 0.1% (w / v), about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v), about 10% (w / v), about 11% (w / v), about 12% (w / v), about 13% (w / v), about 14% (w / v), about 15% (w / v), about 16% (w / v), about 17% (w / v), about 18% (w / v), about 19% (w / v), about 20% (w / v), about 21% (w / v), about 22% (w / v), about 23% (w / v), about 24% (w / v), about 25% (w / v), about 26% (w / v), about 27% (w / v), about 28% (w / v), about 29% (w / v), about 30% (w / v), about 31% (w / v), about 32% (w / v), about 33% (w / v), about 34% (w / v), about 35% (w / v), about 36% (w / v), about 37% (w / v), about 38% (w / v), about 39% (w / v), about 40% (w / v), about 41% (w / v), about 42% (w / v), about 43% (w / v), about 44% (w / v), about 45% (w / v), about 46% (w / v), about 47% (w / v), about 48% (w / v), about 49% (w / v), about 50% (w / v), about 51% (w / v), about 52% (w / v), about 53% (w / v), about 54% (w / v), about 55% (w / v), about 56% (w / v), about 57% (w / v), about 58% (w / v), about 59% (w / v), about 60% (w / v), about 61% (w / v), about 62% (w / v), about 63% (w / v), about 64% (w / v), about 65% (w / v), about 66% (w / v), about 67% (w / v), about 68% (w / v), about 69% (w / v), about 70% (w / v), about 71% (w / v), about 72% (w / v), about 73% (w / v), about 74% (w / v), about 75% (w / v), about 76% (w / v), about 77% (w / v), about 78% (w / v), about 79% (w / v), about 80% (w / v), about 81% (w / v), about 82% (w / v), about 83% (w / v), about 84% (w / v), about 85% (w / v), about 86% (w / v), about 87% (w / v), about 88% (w / v), about 89% (w / v), about 90% (w / v), about 91% (w / v), about 92% (w / v), about 93% (w / v), about 94% (w / v), about 95% (w / v), about 96% (w / v), about 97% (w / v), about 98% (w / v), about 99% (w / v), about 100% (w / v)) of an active pharmaceutical ingredient (API), e.g., described herein. In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise about 0.1 nL to about 10 nL (e.g., about 0.1 nL, about 0.2 nL, about 0.3 nL, about 0.4 nL, about 0.5 nL, about 0.6 nL, about 0.7 nL, about 0.8 nL, about 0.9 nL, about 1 nL, about 1.1 nL, about 1.2 nL, about 1.3 nL, about 1.4 nL, about 1.5 nL, about 1.6 nL, about 1.7 nL, about 1.8 nL, about 1.9 nL, about 2 nL, about 2.1 nL, about 2.2 nL, about 2.3 nL, about 2.4 nL, about 2.5 nL, about 2.6 nL, about 2.7 nL, about 2.8 nL, about 2.9 nL, about 3 nL, about 3.1 nL, about 3.2 nL, about 3.3 nL, about 3.4 nL, about 3.5 nL, about 3.6 nL, about 3.7 nL, about 3.8 nL, about 3.9 nL, about 4 nL, about 4.1 nL, about 4.2 nL, about 4.3 nL, about 4.4 nL, about 4.5 nL, about 4.6 nL, about 4.7 nL, about 4.8 nL, about 4.9 nL, about 5 nL, about 5.1 nL, about 5.2 nL, about 5.3 nL, about 5.4 nL, about 5.5 nL, about 5.6 nL, about 5.7 nL, about 5.8 nL, about 5.9 nL, about 6 nL, about 6.1 nL, about 6.2 nL, about 6.3 nL, about 6.4 nL, about 6.5 nL, about 6.6 nL, about 6.7 nL, about 6.8 nL, about 6.9 nL, about 7 nL, about 7.1 nL, about 7.2 nL, about 7.3 nL, about 7.4 nL, about 7.5 nL, about 7.6 nL, about 7.7 nL, about 7.8 nL, about 7.9 nL, about 8 nL, about 8.1 nL, about 8.2 nL, about 8.3 nL, about 8.4 nL, about 8.5 nL, about 8.6 nL, about 8.7 nL, about 8.8 nL, about 8.9 nL, about 9 nL, about 9.1 nL, about 9.2 nL, about 9.3 nL, about 9.4 nL, about 9.5 nL, about 9.6 nL, about 9.7 nL, about 9.8 nL, about 9.9 nL, or about 10 nL) of an active pharmaceutical ingredient (API), e.g., described herein. In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise about 0.1 mg / mL to about 500 mg / mL (e.g., about 0.1 mg / mL, about 1 mg / mL, about 5 mg / mL, about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 135 mg / mL, about 140 mg / mL, about 145 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, about 260 mg / mL, about 265 mg / mL, about 270 mg / mL, about 275 mg / mL, about 280 mg / mL, about 285 mg / mL, about 290 mg / mL, about 295 mg / mL, about 300 mg / mL, about 305 mg / mL, about 310 mg / mL, about 315 mg / mL, about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 405 mg / mL, about 410 mg / mL, about 415 mg / mL, about 420 mg / mL, about 425 mg / mL, about 430 mg / mL, about 435 mg / mL, about 440 mg / mL, about 445 mg / mL, about 450 mg / mL, about 455 mg / mL, about 460 mg / mL, about 465 mg / mL, about 470 mg / mL, about 475 mg / mL, about 480 mg / mL, about 485 mg / mL, about 490 mg / mL, about 495 mg / mL, about 500 mg / mL) of an active pharmaceutical ingredient (API), e.g., described herein.  Additional non-limiting examples of active pharmaceutical ingredient (API) which can be incorporated into the dispensable formulations, microneedles and / or a microarray patches (MAPs) of the present disclosure, and / or that can be administered as a combination therapy are disclosed below. PeptidesIn some embodiments, the active pharmaceutical ingredient (API) comprises an amino acid, a peptide, a polypeptide, and / or a protein. As used herein, the term “peptide” refers to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds or by other bonds (e.g., as esters, ethers, and the like). The term "peptide" is used herein generically to refer to peptides (e.g., polyamino acids of from 2 to about 20 residues), polypeptides (e.g., peptides of from about 20 residues to about 100 residues), and / or proteins (e.g., peptides having about 100 or more residues). In some embodiments, the peptide is a protein therapeutic. In some embodiments, the terms “protein therapeutic,” “therapeutic protein,” and the like refer to a peptide and / or a protein that has a biological effect in the body, or on a region in the body on which it directly acts, or on a region of the body on which it remotely acts via intermediates, etc. Examples of therapeutic proteins include, but are not limited to, peptides; proteins; enzymes; receptors; receptor fusions; soluble receptors; soluble receptor fusions; antibodies (e.g., monoclonal antibodies (mAbs) and / or polyclonal antibodies); antigen-binding fragments of an antibody; Fc fusion proteins; cytokines; hormones; incretins, regulatory factors; growth factors; coagulation and / or clotting factors; blood proteins; plasma proteins; serum proteins; albumins; globulins; fibrinogens; regulatory proteins; antigen-binding agents; glucagon-like peptide-1 (GLP-1) polypeptides, such as a GLP-1 receptor agonist, a GLP-1 analogue, a GLP-1 derivative, and / or a salt thereof; a gastric inhibitory polypeptide (GIP), also known as a glucose-dependent insulinotropic polypeptide, such as a GIP receptor agonist, a GIP analogue, a GIP derivative, and / or a salt thereof; glucagon receptor agonists (GCGs); amylin receptor agonists (Amylins); Y1 and Y2 receptor agonists (PYYs); insulin; insulin analogues, insulin-like growth factor 1 (IGF-1). The above list of proteins is merely exemplary in nature, and is not intended to be a limiting recitation.In some embodiments, the active pharmaceutical ingredient (API) comprises an antibody. The term “antibody” as used herein refers to a polypeptide or a protein complex that specifically binds an epitope of an antigen. An antibody includes an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding and includes chimeric, humanized, fully human, and bispecific antibodies. Binding fragments include, but are not limited to, Fab, Fab′, F(ab′)2, Fv, and single-chain antibodies. In some embodiments, an antibody is referred to as an immunoglobulin and includes the various classes and isotypes, such as IgA (IgA1 and IgA2), IgD, IgE, IgM, and IgG (IgG1, IgG3 and IgG4) etc. In some embodiments, the antibody is polyclonal or monoclonal. In some embodiments, the antibody is from any origin, such as mouse or human, including a chimeric antibody thereof. In some embodiments, the antibody is humanized.In some embodiments, the active pharmaceutical ingredient (API) comprises an amino acid. As used herein, the term "amino acid" refers to either natural and / or unnatural or synthetic amino acids, including glycine and both D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. While the term "protein" encompasses the term "polypeptide", a "polypeptide" may be less than a full-length protein, e.g., a biologically active fragment of a polypeptide. The term "biologically active fragment", "biologically active form", "biologically active equivalent", and "functional derivative" of a wild-type protein, means a substance that possesses a biological activity that is at least substantially equal (e.g., not significantly different from) the biological activity of the wild type protein as measured using an assay suitable for detecting the activity.  Glucagon-like peptide-1 (GLP-1) polypeptides and GLP-1 receptor agonistsIn some embodiments, the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) polypeptide, such as a GLP-1 receptor agonist, a GLP-1 analogue, a GLP-1 derivative, and / or a salt thereof. In some embodiments, the dispensable formulation, the microneedle and / or the microarray patch (MAP) can comprise and / or can be administered in combination with a GLP-1 polypeptide, such as a GLP-1 receptor agonist, a GLP-1 analogue, a GLP-1 derivative, and / or a salt thereof.As used herein, the term “GLP-1 polypeptide” refers to a polypeptide which is capable of binding to a GLP-1 receptor and / or to activating a GLP-1 receptor. In some embodiments, a GLP-1 polypeptide is a polypeptide which has GLP-1 activity. In some embodiments, a GLP-1 polypeptide is a GLP-1 receptor agonist. As used herein, the term “GLP-1 receptor agonist” refers to a compound which is capable of binding to a GLP-1 receptor and / or to activating a GLP-1 receptor. Such a GLP-1 receptor agonist may be characterized as having “GLP-1 activity.” A GLP-1 receptor agonist may be based on any type of molecular scaffold, including, for example, a polypeptide, a protein, a small molecule, an antibody, a fusion protein, or any combination hereof. In some embodiments, the GLP-1 receptor agonist can comprise one or more moieties which are capable of binding to a GLP-1 receptor and / or to activating a GLP-1 receptor. Exemplary GLP-1 receptor agonists include, without limitation, semaglutide; dulaglutide; exenatide; liraglutide; lixisenatide; tirzepatide; albiglutide; taspoglutide; pharmaceutically acceptable salts thereof; derivatives thereof; analogues thereof; and combinations thereof.As used herein, the term “GLP-1 activity” refers to the capability of a compound to activate a GLP-1 receptor. Accordingly, a GLP-1 polypeptide, such as a GLP-1 receptor agonist, a GLP-1 analogue, a GLP-1 derivative, and / or a salt thereof, can be characterized by “GLP-1 activity” which refers to the ability of the compound to bind to the GLP-1 receptor and initiate a signal transduction pathway resulting in, e.g., insulinotropic action or other physiological effects as is known in the art. In some embodiments the “GLP-1 agonist” binds to a GLP-1 receptor, e.g., with an affinity constant (KD) or activate the receptor with a potency (EC50) of below about 1 pM, e.g., below about 100 nM as measured by methods known in the art and exhibits insulinotropic activity, where insulinotropic activity may be measured in vivo or in vitro assays known to those of ordinary skill in the art. For example, the GLP-1 agonist may be administered to an animal with increased blood glucose (e.g., obtained using an Intravenous Glucose Tolerance Test (IVGTT). A person skilled in the art will be able to determine a suitable glucose dosage and a suitable blood sampling regime, e.g., depending on the species of the animal, for the IVGTT and measure the plasma insulin concentration over time. As used herein, the term “GLP-1 analogue” refers to an analogue (or variant) of a GLP-1 polypeptide. In some embodiments, a GLP-1 analogue comprises an analogue (or variant) of the human glucagon-like peptide-1 (GLP-1 (7-37)). The amino acid sequence of human GLP-1 (7-37) is HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 1). In some embodiments, the amino acid sequence of a GLP-1 analogue can comprise one or more amino acid changes as compared to GLP-1 (7-37). In some embodiments, the amino acid changes may include amino acid additions, substitutions, and or deletions. In some embodiments, the term GLP-1 analogue is characterized by about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to GLP-1 (7-37). In some embodiments, the GLP-1 analogue comprises the amino acid sequence of semaglutide.As used herein, the term “GLP-1 derivative” refers to a chemically modified GLP-1 polypeptide, in which one or more substituents have been covalently attached to the GLP-1 polypeptide. In some embodiments, the GLP-1 derivative comprises a GLP-1 analogue to which one or more substituents are covalently linked. In some embodiments, the GLP-1 derivative comprises semaglutide.In some embodiments, the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) agonist and / or similar agonists. For example, it may be understood that the API may encompass APIs relevant to the treatment of T2D, obesity, NASH (Nonalcoholic steatohepatitis), MASH (Metabolic dysfunction-associated steatohepatitis), NAFLD (nonalcoholic fatty liver disease), short bowel syndrome, Alzheimer’s, chronic heart failure, chronic kidney disease, osteoarthritis, obstructive sleep apnea, psoriasis and other inflammatory cutaneous diseases, and drug addiction.Accordingly, in one aspect, the present disclosure provides a composition (e.g., a dispensable formulation, a microneedle and / or a microarray patch (MAP)), comprising: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.In one aspect, the present disclosure provides a composition (e.g., a dispensable formulation, a microneedle and / or a microarray patch (MAP)), comprising: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 10% (w / v).In one aspect, the present disclosure provides a microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.In one aspect, the present disclosure provides a microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 10% (w / v).In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 180 mg / mL. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist comprises semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the composition (e.g., a dispensable formulation, a microneedle and / or a microarray patch (MAP)), further comprises an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof. In some embodiments, the microneedle comprises (i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%; (iii) the surfactant is present in the printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v); (iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (v) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); and / or (vi) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM. In some embodiments, the consolidated tip comprises a proline amino acid, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a NaCl salt. In some embodiments, the consolidated tip comprises a Tris-HCl buffer. In some embodiments, the microneedle further comprises a microneedle base formed from a dispensable formulation, wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 30% (w / v) to about 90% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 3% (w / v); (iii) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and(iv) combinations thereof. In some embodiments, the microneedle base comprises at least one selected from the group consisting of (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a 1x TE buffer; and (iv) combinations thereof.In one aspect, the present disclosure provides a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises: (i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and (ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.In some embodiments, the microarray patch (MAP) of claim 14, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present at a concentration of about 180 mg / mL. In some embodiments, the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof. In some embodiments, the microarray patch (MAP) further comprises an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof. In some embodiments, the microarray patch (MAP) comprises (i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%; (iii) the surfactant is present in printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v); (iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (iii) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); and / or (iv) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM. In some embodiments, the consolidated tip comprises a proline amino acid, or a derivative thereof. In some embodiments, the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof. In some embodiments, the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof. In some embodiments, the consolidated tip comprises a NaCl salt. In some embodiments, the MAP comprises a Tris-HCl buffer. In some embodiments, (a) each of the plurality of microneedles of the MAP further comprises a microneedle base formed from a dispensable formulation, wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 30% (w / v) to about 90% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 3% (w / v); (iii) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and (iv) combinations thereof; and / or (b) the microarray patch (MAP) further comprises a backing attached to the plurality of microneedles, wherein the backing is attached with an adhesive that is compatible with the glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the microneedle base comprises at least one selected from the group consisting of (i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a 1x TE buffer; and (iv) combinations thereof. In some embodiments, the microarray patch (MAP) is configured for deployment onto the skin of a subject by using an applicator, wherein the MAP and the applicator are independently configured to function as a system to provide a consistent dose delivery of the glucagon-like peptide-1 (GLP-1) receptor agonist. In some embodiments, the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation, wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 80% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm at least about 400 µm below the surface of the subject’s skin. In some embodiments, (i) each of the plurality of microneedles is characterized by a total array strength of at least about 50 N yield load to minimize deformation and to maximize delivery depth of the consolidated microneedle tip during deployment; (ii) each of the plurality of microneedles is characterized by a tip strength of at least about 0.4 N per microneedle and a failure force of at least about 0.3 N per microneedle; (iii) each of the plurality of microneedles comprises about 1 µg to about 20 µg of the glucagon-like peptide-1 (GLP-1) receptor agonist per consolidated microneedle tip; (iv) each of the plurality of microneedles is characterized by a primary needle height (also referred to as “a pre-deployment needle height”) of about 700 µm to about 1,250 µm; (v) the consolidated microneedle tip is characterized by a tip length of about 200 µm to about 500 µm; (vi) the consolidated microneedle tip is formed from about 10 nL to about 50 nL of the dispensable formulation; (vii) the consolidated microneedle tip is characterized by a flat meniscus; (viii) no more than about 20% of the plurality of microneedles comprises a defect; and / or (ix) no more than about 10% of the plurality of microneedles comprises a consolidated microneedle tip characterized by a tip length greater than about 400 µm. In some embodiments, the MAP and the applicator are independently configured to provide an in vitro recovery of at least about 70% of the glucagon-like peptide-1 (GLP-1) receptor agonist; and an ex vivo dose delivery efficiency of at least about 70% of the glucagon-like peptide-1 (GLP-1) receptor agonist, wherein less than about 20% of the glucagon-like peptide-1 (GLP-1) receptor agonist is not delivered upon deployment.In one aspect, the present disclosure provides a method of treating at subject in need thereof, comprising deploying onto the skin of the subject a microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plur...

Claims

1. A microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) an active pharmaceutical ingredient (API); and(ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 90% (w / v).

2. The microneedle of claim 1, wherein the dispensable formulation comprises an active pharmaceutical ingredient (API) at a concentration of greater than about 100 mg / mL.

3. The microneedle of claim 1 or 2, wherein the dispensable formulation comprises a water-soluble excipient at a concentration of about 0.01% (w / v) to about 30% (w / v).

4. The microneedle of any one of the preceding claims, wherein the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof.

5. The microneedle of any one of the preceding claims, wherein the dispensable formulation comprises a glucagon-like peptide-1 (GLP-1) receptor agonist.

6. A microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and(ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.

7. A microneedle, comprising a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and(ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 10% (w / v).

8. The microneedle of any one of the preceding claims, wherein the water-soluble excipient is selected from the group consisting of an amino acid, a surfactant, and combinations thereof.

9. The microneedle of any one of the preceding claims, wherein the water-soluble excipient comprises an amino acid.

10. The microneedle of any one of the preceding claims, wherein the water-soluble comprises a surfactant.

11. The microneedle of any one of the preceding claims, wherein the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a povidone polymer, a polyvinyl alcohol (PVA) polymer, and combinations thereof.

12. The microneedle of any one of the preceding claims, wherein the water-soluble excipient comprises a polymer selected from the group consisting of(i) a polyvinylpyrrolidone (PVP) polymer (povidone), optionally wherein the PVP polymer (povidone) is selected from the group consisting of Povidone K 12 (PVP K12), Povidone K 17 (PVP K17), Povidone K 30 (PVP K30), and combinations thereof;(ii) a polyvinyl alcohol (PVA) polymer, optionally wherein the PVA polymer comprises PVA 4-88; (iii) a vinylpyrrolidone-vinyl acetate (VP-VA) copolymer (copovidone), optionally wherein the VP-VA copolymer (copovidone) is selected from the group consisting of Kollidon® VA 64, Plasdone® S-630, and combinations thereof;(iv) a polyvinyl alcohol-poly-ethylene glycol (PEG-PVA) graft copolymer, optionally wherein the PEG-PVA graft polymer comprises Kollicoat® Protect;(v) a polysaccharide, optionally wherein the polysaccharide is selected from the group consisting of Pullulan, Dextran 40, Methyl Cellulose (MC), Hydroxypropyl Methylcellulose (HPMC), Carboxymethyl cellulose (CMC), and combinations thereof; (vi) a fibroin protein, optionally wherein the fibroin protein comprise a silk fibroin protein; and(vii) combinations thereof.

13. The microneedle of any one of the preceding claims, wherein the water-soluble excipient is selected from the group consisting of(i) the polymer is selected from the group consisting of silk fibroin, Povidone K 12 (PVP K12), Povidone K 17 (PVP K17), Povidone K 30 (PVP K30), PVA 4-88, Kollidon® VA 64, Dextran 40, Methyl Cellulose (MC), Hydroxypropyl Methylcellulose (HPMC), Carboxymethyl cellulose (CMC), Plasdone® S-630, Pullulan, Kollicoat® Protect, and combinations thereof;(ii) the sugar is selected from the group consisting of sucrose, trehalose, lactose, and combinations thereof;(iii) the sugar alcohol is selected from the group consisting of mannitol, xylitol, sorbitol, glyercol, and combinations thereof;(iv) the amino acid is selected from the group consisting of arginine-HCl, proline, histidine, methionine, aspartic acid, glutamic acid, and combinations thereof;(v) the antioxidant is selected from the group consisting of sodium metabisulfite, sodium pyruvate, sodium ascorbate, and combinations thereof;(v) the buffer is selected from the group consisting of Tris-HCl, PBS, TE, MOPS, Phosphate, Bis-tris, HEPES, and combinations thereof;(vi) the surfactant is selected from the group consisting of Kolliphor® EL, Kolliphor® HS 15, Pluronic® F-127 (Poloxamer 407), Pluronic® F-68 (Poloxamer 188), Tween® 20 (polysorbate 20), Tween® 80 (polysorbate 80), Soluplus®, P124, CHAPS, and combinations thereof; and / or(vii) the salt is selected from the group consisting of NaCl, CaCl2, ZnCl2, MgCl2, urea, and combinations thereof.

14. The microneedle of any one of the preceding claims, wherein:the silk fibroin is present in the printable tip formulation at about 0% w / v to about 2% w / v;the PVP K12 is present in the printable tip formulation at about 0% w / v to about 70% w / v;the PVP K17 is present in the printable tip formulation at about 0% w / v to about 70% w / v;the PVP K30 is present in the printable tip formulation at about 0% w / v to about 50% w / v;the PVA 4-88 is present in the printable tip formulation at about 0% w / v to about 20% w / v;the Kollidon® VA 64 is present in the printable tip formulation at about 0% w / v to about 70% w / v;the Dextran 40 is present in the printable tip formulation at about 0% w / v to about 30% w / v;the Methyl Cellulose is present in the printable tip formulation at about 0% w / v to about 8% w / v;the Hydroxypropyl Methylcellulose is present in the printable tip formulation at about 0% w / v to about 14% w / v;the Carboxymethyl cellulose is present in the printable tip formulation at about 0% w / v to about 4% w / v;the Plasdone® S-630 is present in the printable tip formulation at about 0% w / v to about 70% w / v;the Pullulan is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Kollicoat® Protect is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Sucrose is present in the printable tip formulation at about 0% w / v to about 60% w / v;the Trehalose is present in the printable tip formulation at about 0% w / v to about 20% w / v;the Lactose is present in the printable tip formulation at about 0% w / v to about 20% w / v;the Mannitol is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Xylitol is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Sorbitol is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Glyercol is present in the printable tip formulation at about 0% w / v to about 10% w / v;the Arginine-HCl is present in the printable tip formulation at about 0% w / v to about 20% w / v;the Proline is present in the printable tip formulation at about 0% w / v to about 6% w / v;the Histidine is present in the printable tip formulation at about 0% w / v to about 6% w / v;the Methionine is present in the printable tip formulation at about 0% w / v to about 6% w / v;the Aspartic Acid is present in the printable tip formulation at about 0% w / v to about 6% w / v;the Glutamic Acid is present in the printable tip formulation at about 0% w / v to about 6% w / v;the Sodium metabisulfite is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Sodium pyruvate is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Sodium ascorbate is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Tris-HCl is present in the printable tip formulation at about 0 mM to about 350 mM;the PBS is present in the printable tip formulation at about 0X to about 2X;the TE is present in the printable tip formulation at about 0X to about 2X;the MOPS is present in the printable tip formulation at about 0 mM to about 350 mM;the Phosphate is present in the printable tip formulation at about 0 mM to about 350 mM;the Bis-tris is present in the printable tip formulation at about 0 mM to about 350 mM;the HEPES is present in the printable tip formulation at about 0 mM to about 350 mM;the Kolliphor® EL is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Kolliphor® HS 15 is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Pluronic® F-127 (Poloxamer 407) is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Pluronic® F-68 (Poloxamer 188) is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Tween® 20 (polysorbate 20) is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Tween® 80 (polysorbate 80) is present in the printable tip formulation at about 0% w / v to about 2% w / v;the Soluplus® is present in the printable tip formulation at about 0% w / v to about 10% w / v;the P124 is present in the printable tip formulation at about 0% w / v to about 2% w / v;the CHAPS is present in the printable tip formulation at about 0% w / v to about 2% w / v;the NaCl is present in the printable tip formulation at about 0% w / v to about 2% w / v;the CaCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v;the ZnCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v;the MgCl2 is present in the printable tip formulation at about 0% w / v to about 2% w / v; and / orthe Urea is present in the printable tip formulation at about 0% w / v to about 2% w / v.

15. The microneedle of any one of the claims 5-14, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 180 mg / mL.

16. The microneedle of claim 15, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is selected from the group consisting of semaglutide; dulaglutide; exenatide; liraglutide; lixisenatide; tirzepatide; albiglutide; taspoglutide; pharmaceutically acceptable salts thereof; derivatives thereof; and combinations thereof.

17. The microneedle of claim 16, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof.

18. The microneedle of any one of the preceding claims, further comprising an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof.

19. The microneedle of any one of the preceding claims, wherein: (i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%;(iii) the surfactant is present in the printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v);(iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (v) the dispensable formulation further comprises a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v);(vi) the dispensable formulation further comprises a fibroin protein present at a concentration of about 0.1% (w / v) to about 2% (w / v);(vii) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); (viii) the dispensable formulation further comprises a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); and / or(ix) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM.

20. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a proline amino acid, or a derivative thereof.

21. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof.

22. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a Polysorbate 80 surfactant, or a derivative thereof.

23. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof.

24. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a polyvinyl alcohol (PVA) 4-88 polymer, or a derivative thereof.

25. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a silk fibroin protein, or a derivative thereof.

26. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a NaCl salt.

27. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a sucrose sugar.

28. The microneedle of any one of the preceding claims, wherein the consolidated tip comprises a Tris-HCl buffer.

29. The microneedle of any one of the preceding claims, further comprising a microneedle base formed from a dispensable formulation, optionally wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 10% (w / v) to about 70% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 20% (w / v); (iii) a water-soluble excipient comprising a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); (iv) a water-soluble excipient comprising a surfactant present at a concentration of about 0.01% (w / v) to about 1% (w / v); (v) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and(vi) combinations thereof.

30. The microneedle of claim 29, wherein the microneedle base comprises:(i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; and(iii) a 1x TE buffer.

31. The microneedle of claim 29, wherein the microneedle base comprises:(i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a sucrose sugar; and(iv) a Tris buffer.

32. The microneedle of any one of the claims 29-31, wherein:the PVP K12 is present in the printable base formulation at about 0% w / v to about 90% w / v;the PVP K17 is present in the printable base formulation at about 0% w / v to about 90% w / v;the Kollidon® VA 64 is present in the printable base formulation at about 0% w / v to about 90% w / v;the Dextran is present in the printable base formulation at about 0% w / v to about 90% w / v;the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 40% w / v;the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Tris-HCl is present in the printable base formulation at about 0% w / v to about 40 mM% w / v;the MOPS is present in the printable base formulation at about 0 mM to about 50 mM;the Tris-EDTA is present in the printable base formulation at about 0X to about 2X;the Kolliphor EL is present in the printable base formulation at about 0% w / v to about 2% w / v;the Pluronic® F-68 (Poloxamer 188) is present in the printable base formulation at about 0% w / v to about 2% w / v;the Kolliphor® HS 15 is present in the printable base formulation at about 0% w / v to about 2% w / v;the F-127 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Tween® 20 (polysorbate 20) is present in the printable base formulation at about 0% w / v to about 2% w / v;the Triton-X-100 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Sucrose is present in the printable base formulation at about 0% w / v to about 60% w / v;the Trehalose is present in the printable base formulation at about 0% w / v to about 40% w / v;the Glycerol is present in the printable base formulation at about 0% w / v to about 8% w / v;the Carboxymethylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v;the Methyl Cellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; and / orthe Hydroxypropyl Methylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v.

33. The microneedle of any one of the preceding claims, wherein the active pharmaceutical ingredient (API) comprises at least one selected from the group consisting of a small molecule, a biological molecule, a nucleotide, an oligonucleotide, a nucleic acid, a DNA, an RNA, an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), an amino acid, a peptide, a polypeptide, a protein, a hormone, an antigen, a vaccine, a virus-like particle (VLP), a mimetic, an agonist, an antagonist, an inhibitor, a biologic, an antibody or antigen-binding fragment thereof, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof.

34. The microneedle of claim 33, wherein the active pharmaceutical ingredient (API) comprises an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), or combinations thereof.

35. A microarray patch (MAP), comprising a plurality of microneedles of any one of the preceding claims, optionally wherein each of the plurality of microneedles comprises a consolidated microneedle tip and a microneedle base, wherein the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation, andWherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin.

36. A microarray patch (MAP), comprising: a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) an active pharmaceutical ingredient (API); and(ii) a water-soluble excipient at a concentration of about 0.01% (w / v) to about 90% (w / v).

37. The microarray patch (MAP) of claim 36, wherein the dispensable formulation comprises an active pharmaceutical ingredient (API) at a concentration of greater than about 100 mg / mL.

38. The microarray patch (MAP) of claim 36 or 37, wherein the dispensable formulation comprises a water-soluble excipient at a concentration of about 0.01% (w / v) to about 30% (w / v).

39. The microarray patch (MAP) of any one of claims 36-37, wherein the dispensable formulation comprises a water-soluble excipient selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof.

40. The microarray patch (MAP) of any one of claims 36-38, wherein the dispensable formulation comprises a glucagon-like peptide-1 (GLP-1) receptor agonist.

41. A microarray patch (MAP), comprising:a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and(ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.

42. A microarray patch (MAP), comprising:a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and(ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.

43. The microarray patch (MAP) of any one of claims 40-42, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in the dispensable formulation at a concentration of about 150 mg / mL to about 300 mg / mL, or wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present at a concentration of about 180 mg / mL.

44. The microarray patch (MAP) of any one of claims 40-43, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof.

45. The microarray patch (MAP) of any one of claims 35-44, further comprising an additional active pharmaceutical ingredient (API), wherein the additional API is selected from the group consisting of (i) an antidiabetic agent, (ii) an anti-obesity agent, (iii) an anti-cardiovascular disease agent, and (iv) combinations thereof.

46. The microarray patch (MAP) of any one of claims 35-45, wherein:(i) the water-soluble excipient is present in the dispensable formulation at a concentration of about 0.01% (w / v) to about 10% (w / v); (ii) the amino acid is present in the dispensable formulation at a concentration of about 0.5% to about 5%;(iii) the surfactant is present in the printable tip formulation at a concentration of about 0.01% (w / v) to about 1% (w / v);(iv) the dispensable formulation further comprises a povidone polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v); (v) the dispensable formulation further comprises a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.5% (w / v) to about 5% (w / v);(vi) the dispensable formulation further comprises a fibroin protein present at a concentration of about 0.1% (w / v) to about 2% (w / v);(vii) the dispensable formulation further comprises a salt present at a concentration of about 0.5% (w / v) to about 5% (w / v); (viii) the dispensable formulation further comprises a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); and / or(ix) the dispensable formulation further comprises a buffer present at a concentration of about 50 mM to about 150 mM.

47. The microarray patch (MAP) of any one of claims 35-46, wherein the consolidated tip comprises a proline amino acid, or a derivative thereof.

48. The microarray patch (MAP) of any one of claims 35-47, wherein the consolidated tip comprises a polyoxyl 35 castor oil surfactant, or a derivative thereof.

49. The microarray patch (MAP) of any one of claims 35-48, wherein the consolidated tip comprises a Polysorbate 80 surfactant, or a derivative thereof.

50. The microarray patch (MAP) of any one of claims 35-49, wherein the consolidated tip comprises a povidone K 17 (PVP K17) polymer, or a derivative thereof.

51. The microarray patch (MAP) of any one of claims 35-50, wherein the consolidated tip comprises a polyvinyl alcohol (PVA) 4-88 polymer, or a derivative thereof.

52. The microarray patch (MAP) of any one of claims 35-51, wherein the consolidated tip comprises a silk fibroin protein, or a derivative thereof.

53. The microarray patch (MAP) of any one of claims 35-52, wherein the consolidated tip comprises a NaCl salt.

54. The microarray patch (MAP) of any one of claims 35-53, wherein the consolidated tip comprises a sucrose sugar.

55. The microarray patch (MAP) of any one of claims 35-54, wherein the consolidated tip comprises a Tris-HCl buffer.

56. The microarray patch (MAP) of any one of claims 35-55, further comprising a microneedle base formed from a dispensable formulation, optionally wherein the dispensable formulation comprises at least one selected from the group consisting of (i) a water-soluble excipient comprising a povidone polymer present at a concentration of about 10% (w / v) to about 70% (w / v); (ii) a water-soluble excipient comprising a polyvinyl alcohol (PVA) polymer present at a concentration of about 0.1% (w / v) to about 20% (w / v); (iii) a water-soluble excipient comprising a sugar present at a concentration of about 10% (w / v) to about 30% (w / v); (iv) a water-soluble excipient comprising a surfactant present at a concentration of about 0.01% (w / v) to about 1% (w / v); (v) a water-soluble excipient comprising a buffer present at a concentration of about 5 mM to about 25 mM (w / v); and(vi) combinations thereof.

57. The microneedle of microarray patch (MAP) of claim 56, wherein the microneedle base comprises:(i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; and(iii) a 1x TE buffer.

58. The microneedle of microarray patch (MAP) of claim 56, wherein the microneedle base comprises:(i) a povidone K 17 (PVP K17) polymer, or a derivative thereof; (ii) a PVA 4-88 polymer, or a derivative thereof; (iii) a sucrose sugar; and(iv) a Tris buffer.

59. The microarray patch (MAP) of any one of claims 56-60, wherein:the PVP K12 is present in the printable base formulation at about 0% w / v to about 90% w / v;the PVP K17 is present in the printable base formulation at about 0% w / v to about 90% w / v;the Kollidon® VA 64 is present in the printable base formulation at about 0% w / v to about 90% w / v;the Dextran is present in the printable base formulation at about 0% w / v to about 90% w / v;the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 40% w / v;the PVA 4-88 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Tris-HCl is present in the printable base formulation at about 0% w / v to about 40 mM% w / v;the MOPS is present in the printable base formulation at about 0 mM to about 50 mM;the Tris-EDTA is present in the printable base formulation at about 0X to about 2X;the Kolliphor EL is present in the printable base formulation at about 0% w / v to about 2% w / v;the Pluronic® F-68 (Poloxamer 188) is present in the printable base formulation at about 0% w / v to about 2% w / v;the Kolliphor® HS 15 is present in the printable base formulation at about 0% w / v to about 2% w / v;the F-127 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Tween® 20 (polysorbate 20) is present in the printable base formulation at about 0% w / v to about 2% w / v;the Triton-X-100 is present in the printable base formulation at about 0% w / v to about 2% w / v;the Sucrose is present in the printable base formulation at about 0% w / v to about 60% w / v;the Trehalose is present in the printable base formulation at about 0% w / v to about 40% w / v;the Glycerol is present in the printable base formulation at about 0% w / v to about 8% w / v;the Carboxymethylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v;the Methyl Cellulose is present in the printable base formulation at about 0% w / v to about 8% w / v; and / orthe Hydroxypropyl Methylcellulose is present in the printable base formulation at about 0% w / v to about 8% w / v.

60. The microarray patch (MAP) of any one of claims 35-59, wherein the active pharmaceutical ingredient (API) comprises at least one selected from the group consisting of a small molecule, a biological molecule, a nucleotide, an oligonucleotide, a nucleic acid, a DNA, an RNA, an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), an amino acid, a peptide, a polypeptide, a protein, a hormone, an antigen, a vaccine, a virus-like particle (VLP), a mimetic, an agonist, an antagonist, an inhibitor, a biologic, an antibody or antigen-binding fragment thereof, pharmaceutically acceptable salts thereof, derivatives thereof, and combinations thereof.

61. The microarray patch (MAP) of any one of claims 35-55, wherein the active pharmaceutical ingredient (API) comprises an mRNA, a mRNA-loaded lipid nanoparticle (mRNA-LNP), or combinations thereof.

62. A microarray patch (MAP), comprising:a plurality of microneedles, wherein each of the plurality of microneedles comprises a three-dimensional (3D) printed structure selected from the group consisting of a consolidated microneedle tip, a microneedle base, and combinations thereof,wherein the consolidated microneedle tip is formed from a printable tip formulation comprising:(i) an active pharmaceutical ingredient (API); (ii) a water-soluble povidone polymer, or a water-soluble polyvinyl alcohol (PVA) polymer, present at a concentration of about 0.5% (w / v) to about 5% (w / v); and(iii) a water-soluble excipient present at a concentration of about 0.01% (w / v) to about 30% (w / v), wherein the water-soluble excipient is selected from the group consisting of a polymer, a sugar, a sugar alcohol, an amino acid, an antioxidant, a buffer, a surfactant, a salt, and combinations thereof.

63. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation further comprises at least one selected from the group consisting of a polymer comprising Povidone K 17 (PVP K17),an amino acid comprising proline,a surfactant comprising Kolliphor® EL, a salt comprising NaCl, a sugar comprising sucrose, a buffer comprising Tris-HCl, and combinations thereof.

64. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) receptor agonist.

65. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is selected from the group consisting of selected from the group consisting of Semaglutide; Dulaglutide; Exenatide; Liraglutide;Lixisenatide; Tirzepatide; Albiglutide; Taspoglutide; pharmaceutically acceptable salts thereof; derivatives thereof; and combinations thereof..

66. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist comprises Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof.

67. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation comprises about 100 mg / mL to about 300 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 0.1% w / v to about 2% w / v PVP K17, about 0.1% w / v to about 6% w / v Proline, about 0.01% w / v to about 0.5% w / v Kolliphor EL, about 50 mM to about 250 mM Tris-HCl buffer, andoptionally about 0.1% w / v to about 2% w / v NaCl.

68. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation comprises about 180 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 1% w / v PVP K17, about 0.75% w / v Proline, about 0.1% w / v Kolliphor EL, about 0.9% w / v NaCl, and about 100 mM Tris-HCl buffer.

69. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation comprises about 180 mg / mL of the glucagon-like peptide-1 (GLP-1) agonist, about 1% w / v PVP K17, about 3% w / v Proline, about 0.1% w / v Kolliphor EL, andabout 100 mM Tris-HCl buffer.

70. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, which comprises about 0.1 mg to about 30 mg of the glucagon-like peptide-1 (GLP-1) receptor agonist.

71. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, which comprises about 0.25 mg to about 2.4 mg of Semaglutide, a pharmaceutically acceptable salt thereof, or a derivative thereof.

72. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the glucagon-like peptide-1 (GLP-1) receptor agonist is present in an amount of about 1 µg to about 20 µg per consolidated microneedle tip.

73. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein Semaglutide (Ozempic®, Rybelsus®, Wegovy®), a pharmaceutically acceptable salt thereof, or a derivative thereof, is present in an amount of at least about 2 µg per consolidated microneedle tip.

73. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the active pharmaceutical ingredient (API) comprises a lipid nanoparticle–mRNA (LNP–mRNA) formulation.

74. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation comprises about 0.1% w / v to about 2% w / v PVA 4-88, about 3% w / v to about 7% w / v PVA PVP K17,about 8% w / v to about 12% w / v sucrose, andabout 1X TE buffer.

75. The microneedle, or the microarray patch (MAP) of any one of the preceding claims, wherein the printable tip formulation comprises about 1% w / v PVA 4-88, about 5% w / v PVA PVP K17,about 10% w / v sucrose, andabout 1X TE buffer.

76. The microarray patch (MAP) of any one of claims 35-75, which is configured for deployment onto the skin of a subject by using an applicator, wherein the MAP and the applicator are independently configured to function as a system to provide a consistent dose delivery of the active pharmaceutical ingredient (API), optionally wherein the active pharmaceutical ingredient (API) comprises a glucagon-like peptide-1 (GLP-1) receptor agonist.

77. The microarray patch (MAP) of claim 76, wherein the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation, wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin.

78. The microarray patch (MAP) of claim 77 or 78, wherein:(i) each of the plurality of microneedles is characterized by a needle strength of at least about 0.1 N, at least about 0.2 N, at least about 0.3 N, at least about 0.4 N, and / or at least about 0.5 N yield load to minimize deformation and to maximize delivery depth of the consolidated microneedle tip during deployment, optionally wherein each of the plurality of microneedles is characterized by a needle strength of about 0.1 N to about 0.5 yield load;(ii) each of the plurality of microneedles is characterized by a tip strength and / or a failure force of at least about 0.1 N, at least about 0.2 N, at least about 0.3 N, at least about 0.4 N, and / or at least about 0.5 N per microneedle; (iii) each of the plurality of microneedles comprises about 0.001 µg to about 20 µg of the glucagon-like peptide-1 (GLP-1) receptor agonist per consolidated microneedle tip;(iv) each of the plurality of microneedles is characterized by a primary needle height (also referred to as “a pre-deployment needle height”) of about 700 µm to about 1,250 µm;(v) the consolidated microneedle tip is characterized by a tip length of about 200 µm to about 500 µm;(vi) the consolidated microneedle tip is formed from about 10 nL to about 50 nL of the dispensable formulation; (vii) the consolidated microneedle tip is characterized by a substantially flat meniscus; (viii) no more than about 20% of the plurality of microneedles comprises a defect; and / or(ix) no more than about 10% of the plurality of microneedles comprises a consolidated microneedle tip characterized by a tip length greater than about 400 µm.

79. The microarray patch (MAP) of any one of claims 35-78, wherein the microarray patch (MAP) comprises a microneedle array attached to a backing by an adhesive, wherein the microneedle array comprises a plurality of microneedles arranged in an array configuration, wherein each of the plurality of microneedles independently comprises the consolidated microneedle tip and the base, optionally wherein the adhesive is selected from the group consisting of an acrylic adhesive; an acrylate adhesive; a tackified adhesive, optionally a tackified acrylic adhesive and / or a tackified acrylate adhesive; a pressure sensitive adhesive; a synthetic rubber adhesive, optionally a pressure sensitive synthetic rubber adhesive; and combinations thereof.

80. The microarray patch (MAP) of any one of claims 35-79, wherein the microarray patch (MAP) comprises a microneedle array characterized by an array size of about 50 to about 1,000 microneedles, optionally wherein the microneedle array is characterized by an array configuration that enables microneedle insertion and deployment of the consolidated microneedle tip to a consistent delivery depth of at least about 400 µm below the skin surface.

81. The microarray patch (MAP) of any one of claims 35-80, wherein the MAP and the applicator are independently configured to provide an in vitro recovery of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist; andan ex vivo dose delivery efficiency of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, wherein less than about 30% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, is not delivered upon deployment.

81. A method of treating a disease or a condition, comprising deploying onto the skin of a subject the microneedle, or the microarray patch (MAP) of any one of the preceding claims.

82. A method of treating at least one condition selected from the group consisting of type 2 diabetes, overweight, obesity, cardiovascular disease, and combinations, comprising deploying onto the skin of a subject a microarray patch (MAP), comprising:a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip formed from a dispensable formulation, wherein the dispensable formulation comprises:(i) a glucagon-like peptide-1 (GLP-1) receptor agonist at a concentration of greater than about 100 mg / mL; and(ii) a water-soluble excipient selected from the group consisting of an amino acid, a surfactant, and combinations thereof.

83. The method of claims 81 or 82, wherein the microneedle or the microarray patch (MAP) sustains the release of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist.

84. The method of any one of claims 81-83, wherein the microneedle or the microarray patch (MAP) is configured for daily, weekly, or monthly administration, optionally wherein the microneedle or the microarray patch (MAP) is configured for once daily, once weekly, or once monthly administration, optionally wherein the microneedle or the microarray patch (MAP) is configured for multiple daily, multiple weekly, or multiple monthly administrations.

85. A high-throughput screening method for selecting a dispensable formulation suitable for microarray patch (MAP) manufacturing, comprising: providing a model air-dried film system comprising:(i) a printable tip formulation comprising an active pharmaceutical ingredient (API) formulation and a water-soluble excipient, and / or(ii) a printable base formulation comprising a water-soluble excipient,wherein the model air-dried film system was generated using a predefined printability parameter, optionally wherein the predefined printability parameter is selected from the group consisting of temperature, humidity, viscosity, solid content, dispense volume, dispense velocity, and combinations thereof.

86. A method of claim 85, wherein the dispensable formulation suitable for microarray patch (MAP) manufacturing is selected when the fluid properties of the dispensable formulation enable microarray patch (MAP) a manufacturing process, such that a microarray patch (MAP) generated using the predefined printability parameter is characterized by a morphology substantially free of defects, optionally wherein no more than about 0% to about 30% of the microneedles in the microarray patch (MAP) comprise a defect, and / or no more than about 0% to about 30% of the microneedles in the microarray patch (MAP) comprise a consolidated tip length of greater than 400 μm.

87. A method of claim 85 or 86, wherein the dispensable formulation suitable for microarray patch (MAP) manufacturing is selected when the fluid properties of the dispensable formulation enables (i) formation of a consolidated microneedle tip and / or a microneedle base configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment of without deformation, wherein the applicator is configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin; (ii) an in vitro recovery of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist; and / or(iii) an ex vivo dose delivery efficiency of at least about 70% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, wherein less than about 30% of the active pharmaceutical ingredient (API), optionally a glucagon-like peptide-1 (GLP-1) receptor agonist, is not delivered upon deployment.

88. A method of manufacturing a microarray patch (MAP), comprising:(i) providing:(a) a microarray mold comprising a plurality of cavities which are characterized by a predefined criteria selected from the group consisting of:a microneedle height,a microneedle spacing,a microneedle base size,a microneedle tip size, an array size, and combinations thereof;(b) at least one print solution selected from the group consisting of a printable tip formulation, a printable base formulation, and a combination thereof, and(c) an active pharmaceutical ingredient (API), wherein the API is independently present or absent in the at least one print solution;(ii) printing a plurality of microneedles by independently filling at least one cavity of the plurality of cavities with a predefined dispense volume of the print solution, thereby forming a plurality of printed microneedles;(iii) applying a backing to a surface of the plurality of microneedles; and(iv) demolding the plurality of microneedles, thereby generating a microarray patch (MAP).

89. A microarray patch (MAP), comprising a plurality of microneedles according to any one of claims 1-34 or generated according to claim 88.

90. A microarray patch (MAP) system, comprising:(i) a microarray patch (MAP) according to claim 89, wherein the MAP comprises a plurality of microneedles, wherein each of the plurality of microneedles comprises a consolidated microneedle tip and a microneedle base, wherein the consolidated microneedle tip and the microneedle base are independently configured to withstand and propagate an impact energy applied by an applicator to each of the plurality of microneedles during deployment without deformation; and(ii) an applicator configured to apply substantially the same amount of impact energy to each of the plurality of microneedles to achieve deployment of at least about 70% of the consolidate tips in the MAP to a delivery depth of at least about 400 µm below the surface of the subject’s skin.

Images